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ABSTRACT 
 B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia 
in the western world. CLL is often diagnosed in the asymptomatic (early-stage) stages. However, 
approximately 50% of these patients will progress to advanced, symptomatic disease and require 
therapy. Current treatment options are limited due to progressive drug resistance and severe 
drug-induced toxicities which are often too toxic for the elderly or those with co-morbidities. 
Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic 
CLL to symptomatic CLL or enhance the effects of actively used chemo-therapeutic drugs in 
patients who require therapy would be clinically beneficial. 
In our studies, we evaluated the use of omega-3 (n-3) fatty acids as therapeutic options 
for CLL utilizing both a clinical supplementation model (FWA #00002704) as well as a cell 
culture model. The primary objective of the initial study was to determine whether consumption 
of n-3 could suppress activation of nuclear factor kappa B (NF B) in lymphocytes from patients 
diagnosed with early stage CLL. The primary objective of the follow-up study was to evaluate 
whether n-3 eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) could enhance the 
chemo-sensitivity of CLL-derived cell lines EHEB and MEC-2 and pro-lymphocytic leukemia-
derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine or fludarabine in vitro.  
Our initial study indicated that consumption of an EPA + DHA containing n-3 
supplement 1) suppressed activation of NF B in lymphocytes from patients diagnosed with early 
stage CLL,  2) increased molar concentrations of n-3 in the plasma, 3) increased the chemo-
sensitivity of lymphocytes to doxorubicin in an in vitro assay and 4) decreased the expression of 
32 genes in lymphocytes. Targeting the NF B pathway is proposed as a therapy for CLL. 
Suppression of NF B activation by n-3 may slow the progression of the disease to symptomatic 
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disease where therapy is required. However, a definitive clinical trial will be needed to determine 
if n-3 can slow the progression of CLL.  
The aim of the second study was to expanding upon the chemo-sensitization capabilities 
of n-3. In these trials, cell-cycle analyses, Annexin-V assays, assays for malondialdehyde (a 
measure of lipid peroxidation) and DCF fluorescence assays (a measure of reactive oxygen 
species (ROS) generation) were performed to explore potential mechanism(s) through which 
enhanced chemo-sensitivity was achieved. 
Results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines 
EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and 
with drug treatment increased cell death and induced G2/M arrest in a cell-type specific manner; 
3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid peroxidation in 
MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 increased 
generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS 
generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA. 
N-3 are a promising therapeutic intervention for the treatment of CLL with the capacity 
to potentially slow the progression of the disease and enhance the chemo-sensitivity of malignant 
cells to chemo-therapeutic drugs and warrants further investigation. Slowing the progression of 
the disease would be clinically beneficial. Enhanced chemo-sensitivity would be expected to 
increase drug efficacy and potential reductions in drug dosage and drug-induced toxicities.  
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CHAPTER 1: INTRODUCTION 
CHRONIC LYMPHOCYTIC LEUKEMIA 
EPIDEMIOLOGY, CHARACTERIZATION 
 
B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia 
in the western world (Gaidano, Foa, & Dalla-Favera, 2012) and accounts for 30% of all mature 
B-cell malignancies (Linet et al., 2007). CLL involves progression toward malignant disease 
with most cases of CLL being preceded by monoclonal B-cell lymphocytosis (MBL), an indolent 
B-cell expansion defined by less than 5 x 10
3 
MBL/µL in the peripheral blood (Gaidano et al., 
2012). The incidence of CLL in the United States is approximately 100,000 individuals with an 
estimated 15,000 new diagnoses per year (Shanafelt & Call, 2004). CLL is typically diagnosed in 
the asymptomatic stages incidentally during a complete blood cell count (CBC) for unrelated 
indications (Shanafelt & Call, 2004). However, approximately 50% of these patients experience 
rapid progressive disease, require therapy and have a significantly shortened lifespan (Shanafelt 
& Call, 2004). It is approximated that 4,500 individuals will die of CLL or CLL-related 
complications in the United States per year (Lanasa, 2010; Shanafelt & Call, 2004). The life 
expectancy of an individual with CLL is highly variable with a medium survival from diagnosis 
varying between 18 months to >10 years (Eichhorst, Dreyling, Robak, Montserrat, & Hallek, 
2011; Gaidano et al., 2012; Shanafelt & Call, 2004), a trait largely attributed to the marked 
clinical heterogeneity of the disease. 
CLL is considered to be a disease of the elderly with a median age range of 60-68 years 
(Shanafelt & Call, 2004). According to the NCI SEER (Surveillance Epidemiology and End 
Results) study, which enrolled 20,000 CLL and small lymphocytic lymphoma (SLL) patients in 
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the United States from 1987 to 2004, the incidence of CLL increased with age and showed a 70-
90% higher propensity in males than females when adjusting for age (Linet et al., 2007). 
Compared to Caucasians, the incidence in African-Americans and Asian/Pacific Islanders was 
found to be 25-28% and 69-80% lower, respectively (Linet et al., 2007). While the exact origin 
of CLL remains unknown, immunogenetic studies and gene expression profiling analyses have 
provided insight into the putative CLL progenitor and suggest that the origin of CLL is derived 
from antigen-experienced B cells (including both memory B cells and marginal zone B-
cells)(Gaidano et al., 2012).  
Historically, CLL is viewed as a tumor caused by the accumulation of long-lived but 
mainly indolent lymphocytes (Gaidano et al., 2012). However, studies have shown that a small 
fraction of CLL cells have proliferative capacity resulting in approximately 2% new CLLs being 
produced per day (Messmer et al., 2005). While lymphocytes in the peripheral blood are in a 
predominantly resting, non-proliferative state, specific structures known as proliferation centers 
(bone marrow and lymph nodes) replenish the CLL population and aid to the accumulation of 
CLL cells (Gaidano et al., 2012).  
Although designated as a single entity, CLL is characterized by biological, clinical and 
cytogenetic heterogeneity with a characteristic immunophenotype of IgM
weak
, CD5+, CD19+, 
CD20
weak
, CD22
weak
, CD79a+, CD23+, CD43+, CD11c
weak
, CD10
negative
, and cyclin D1 negative 
(Linet et al., 2007).  
CLASSIFICATION AND STAGING 
Chronic lymphocytic leukemia has been recognized as a distinct clinical entity for nearly 
100 years (Linet et al., 2007). However, disease classification systems did not systematically 
distinguish „chronic‟ from „acute‟ forms of leukemia until the late 1960s with the adoption of the 
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International Classification of Disease (ICD) (Linet et al., 2007). The absence of standardized 
disease definitions, staging schemes and markers of behavior hampered clinical trials and 
epidemiological studies until the mid-1970s (Linet et al., 2007). It was during this time that 
proposals for staging systems by Rai et al. and Binet et al. (1977) were accepted. Clinical trial 
guidelines from the International Workshop of CLL, Binet et al. and Cheson et al. were 
subsequently implemented in the 1980s and 1990s. The staging system and clinical trial 
guidelines were instrumental to advances in the treatment and understanding of CLL biology 
(Linet et al., 2007; Shanafelt & Call, 2004). The improved knowledge of normal B- and T-cell 
differentiation and genetic changes led to the revised European and American Lymphoma 
classification in the mid-1990s, followed by the World Health Organization (WHO) 
classification of all hematopoietic and lymphoproliferative disorders and set the basis for modern 
classification and staging of CLL (Linet et al., 2007).  
Before the advent of automated instruments for performing blood cell counts, CLL was 
typically diagnosed when patients exhibited symptoms such as lymphadenopathy, cytopenias, 
frequent infections, and abnormal morphology of peripheral blood lymphocytes (Shanafelt & 
Call, 2004). At this point in time, CLL was thought to be an indolent disease of the elderly 
(Shanafelt & Call, 2004). Clinical management of CLL was predominately mediated by 
“watchful waiting” and most clinicians often counseled patients that they would likely die of 
causes unrelated to CLL before they would require therapy (Shanafelt & Call, 2004). The 
infectious complications associated with CLL, increased risk of autoimmune disorders, and 
increased risk of secondary malignancies were less defined and clinically underappreciated with 
treatment being reserved for patients with advanced-stage disease (Shanafelt & Call, 2004). 
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Nearly all of these paradigms have changed with the advent of automated instruments, 
immunophenotyping, flow cytometry, and cytogenetic evaluations (Shanafelt & Call, 2004).  
Currently, CLL should be considered anytime a patient presents an absolute lymphocyte 
count (ALC) > 5 x 10
9
/L without clear etiology over a duration of at least 3 months (Eichhorst et 
al., 2011; Shanafelt & Call, 2004). Furthermore, according to the WHO classification, SLL and 
CLL are considered the same entity. SLL requires the presence of lymphadenopathy and/or 
splenomegaly, with the number of B-lymphocytes in the peripheral blood not exceeding 5 x 
10
9
/L and must be excluded during the diagnosis of CLL (Eichhorst et al., 2011). Similarly, 
reactive causes of lymphocytosis and leukemic phase of other lymphoproliferative disorders, 
particularly mantle cell lymphoma, must be excluded before diagnosis of CLL (Eichhorst et al., 
2011; Shanafelt & Call, 2004). Diagnostic criteria for CLL are described in Table 1.1.  
Upon diagnosis of CLL, patients staging is determined according to the clinical “staging” 
criteria outline by Rai et al.(Rai & Jain, 2011) which separates patients into different prognostic 
“risk” groups based on the presence of lymphadenopathy, splenomegaly, hepatomegaly, and 
cytopenias (Shanafelt & Call, 2004). The three stage system categorizes patients as having low 
risk (original Rai stage 0), intermediate risk (Rai stage I-II), or high risk (Rai stage III-IV) 
disease (Shanafelt & Call, 2004). Staging criteria are described in Table 1.2. Additional 
cytogenetic and phenotypic tests are performed to assist with predicting diagnosis and guide 
treatment (Shanafelt & Call, 2004) (outlined in next section). 
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Table 1. 1. Diagnostic Criteria for CLL 
Diagnostic Criteria Typical Method of Testing 
1. ALC, >5.0 x 109/L Automated blood counter 
2. Clonal B-cell proliferation Exclusively  or  light chain use on flow 
cytometry 
Immunophenotype consistent with CLL:  
CD5+, CD19+, CD20
dim
, dim surface 
immunoglobulin 
3. Rule out leukemic phase of other 
lymphoproliferative disorders 
(especially mantle cell lymphoma) 
Mantle cell lymphoma: 
Flow cytometry*: CD23
dim or absent
, CD5+, bright       
CD20+ 
FISH**: t(11:14) 
Cyclin D1 positive 
Nodal marginal zone lymphoma: 
Flow cytometry*: CD5-, bright CD20+ 
Hairy cell lymphoma: 
Flow cytometry*: CD5-, bright CD11c/CD22+, 
CD19+, bright CD20+, CD103+ 
TRAP positive 
Lymphoplasmacytic lymphoma: 
Flow cytometry*: CD5+/-, CD19+, CD20+ 
SPEP-associated monoclonal protein (>2.5g/dL) 
Follicular lymphoma (leukemic phase): 
Flow Cytometry*: CD5-, CD19+, CD20+, 
CD10+/- 
FISH**: t(14:18) 
 
Material obtained  from (Shanafelt & Call, 2004)  
Table 1.1 Diagnostic Criteria for Chronic Lymphocytic Leukemia. Abbrev: ALC- absolute lymphocyte 
count; CLL- chronic lymphocytic leukemia; FISH- fluorescence in situ hybridization; SPEP- serum protein 
electrophoresis; TRAP- tartrate-resistance acid phosphatase; *Flow cytometric results must be correlated with 
careful pathologic assessment of morphologic features; **FISH- translocation of indicated chromosome. 
Material was obtained from (Shanafelt & Call, 2004).  
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Table 1. 2. Rai Staging Criteria 
  Physical Examination    
Rai 
Stage 
ALC 
>5.0 x 10
9
/L 
Enlarged 
nodes 
Enlarged 
liver/spleen 
Hemoglobin 
<10.5 g/dL 
Platelets 
<100 x 10
9
/L 
Median 
Survival 
(months)
* 
0 + - - - - 150 
I + + - - - 101 
II + +/- + - - 71 
III + +/- +/- + - 19 
IV + +/- +/- +/- + 19 
Material obtained  from (Shanafelt & Call, 2004) 
 
SYMPTOMS, RISK ASSESSMENT, PROGNOSTICS 
Clinical manifestations associated with CLL often include fever, night sweats, weight 
loss defined as >10% of body weight, fatigue, frequent infections, splenomegaly, hepatomegaly, 
lymphadenopathy, autoimmune complications and cytopenias (Shanafelt & Call, 2004). 
Given the heterogeneity of CLL, various prognostic indicators have been established to 
aid in predicting prognosis and guiding treatment. The staging criteria outlined by Rai et al. (Rai 
& Jain, 2011) provided a useful tool for grouping patients into low-, intermediate- or high-risk 
groups and has been shown to correlate with prognosis of disease (Table 1.2). The lymphocyte 
doubling time (LDT) also provided insight into the kinetics of CLL. The LDT is a clinical 
measurement that addresses the kinetics of cell growth by calculating the number of months the 
ALC takes to double. Since patients with advanced disease (Rai stages III and IV) typically 
Table 1.2. Rai Staging Criteria. Abbrev: ALC- absolute lymphocyte count; +: present, -: absent; +/-: may be 
present or absent; *: according to original series by Rai et al. Material was obtained from (Shanafelt & Call, 
2004).  
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require therapy, the prognostic utility of LDT is most important for patients with early stage 
disease (Rai stages 0, I and II) (Shanafelt & Call, 2004). Studies have found that patients with 
CLL exhibiting a LDT of less than 12 months had shortened survival time as compared to those 
patients with a LDT greater than 12 months (Montserrat, Sanchez-Bisono, Vinolas, & Rozman, 
1986). While historically clinical stage and LDT have been the most accurate and widely used 
prognostic tools for counseling patients with CLL, both are imprecise. Clinical staging can 
underappreciate the prognosis of patients due to marked heterogeneity in the clinical progression 
of disease in patients at similar age (Shanafelt & Call, 2004). Similarly, the LDT can be 
confounded by factors that cause fluctuations in the ALC (Shanafelt & Call, 2004). As such, 
other diagnostic tools such as flow cytometry, gene expression profiling, chromosomal analysis 
and fluorescence in situ hybridization (FISH) have been established to aid in risk assessment and 
prognosis of CLL.  
Extensive molecular investigations of the B-Cell Receptor (BCR) indicated that 60-65% 
of CLL harbor somatic hypermutations in the immunoglobulin heavy variable chain (IgVH) 
genes. In 1999, Damle et al. (Damle et al., 1999) and Hamblin et al. (Hamblin, Davis, Gardiner, 
Oscier, & Stevenson, 1999) reported the prognostic significance of somatic mutations in the 
IgVH genes in CLL. When patients with early stage CLL were stratified as IgVH-mutated or 
IgVH-nonmutated, significant differences in survival times were observed (Damle et al., 1999; 
Hamblin et al., 1999). Median survival time for early-stage patients with nonmutated IgVH 
genes was less than 95 months (8 years) whereas early-stage patients with a mutated IgVH had a 
median survival time greater than 293 months (24 years) (Damle et al., 1999; Hamblin et al., 
1999). Whereas tests for IgVH mutational status are not typically performed in the United States 
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(Shanafelt & Call, 2004), its utilization as a prognostic marker is beneficial for patients with 
CLL.  
Phenotypic evaluations of CLL cells have indicated the presence of surface protein 
marker CD38 in subsets of CLL. Numerous reports have substantiated the prognostic 
significance of CD38 expression (Del Poeta et al., 2001; Lekovic et al., 2011; Shanafelt & Call, 
2004). Del Poeta et al. reported an 8-year survival of 92% for patients who were CD38 negative 
but only 50% for patients who were CD38 positive (Del Poeta et al., 2001). However, the 
consistency of CD38 expression on CLL cells has been controversial because many groups 
reported changes in the CD38 status in as many as 10-25% of patients with CLL (Shanafelt & 
Call, 2004). Despite the controversy of CD38 expression, it appears to be correlated with poor 
prognosis (Lekovic et al., 2011).  
Gene expression profiles have also aided to the identification of prognostic markers for 
CLL. Gene expression profile analyses (GEPA) have identified a restricted set of genes that 
helped discriminate between mutated- and unmutated-IgVH clones in patients with CLL 
(Shanafelt & Call, 2004). Of particular interest was the tyrosine kinase gene, zeta-associated 
protein 70 (ZAP-70). Under normal conditions, ZAP-70 is involved with T-cell signaling; 
however, it has been shown to be differentially expressed by patients with unmutated IgVH CLL 
clones (Shanafelt & Call, 2004). Subsequent studies have shown that ZAP-70 positive CLL cells 
correctly predict the mutational status (unmutated) in approximately 78-90% of patients (Crespo 
et al., 2003; Wiestner et al., 2003). More importantly, ZAP-70 expression was also a prognostic 
marker for time to treatment (TT) and overall survival (OS) (Crespo et al., 2003). Crespo et al. 
reported that patients who had at least 20% ZAP-70-positive CLL cells had more rapid 
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progression and poorer survival than those with less than 20% ZAP-70-positive CLL cells 
(Crespo et al., 2003).  
Similarly, GEPA have identified other markers thought to aid in prognosis including 
notch homolog 1 (NOTCH1), splicing factor 3B subunit 1 (SF3B1) and baculoviral IAP repeat-
containing protein 3 (BIRC3) (Gaidano et al., 2012). Descriptions of these genes and their 
influence on prognosis are provided in Table 1.3.  
 
 
Chromosomal analysis and the development of FISH aided the detection of chromosomal 
abnormalities and provided numerous prognostic markers for CLL (Shanafelt & Call, 2004). 
Studies have demonstrated that over 80% of all CLL patients have chromosomal abnormalities 
(Rodriguez-Vicente, Diaz, & Hernandez-Rivas, 2013). Descriptions of the most common 
chromosomal abnormalities and their influence on prognosis are illustrated in Table 1.4. 
Table 1. 3. GEPA Identified Prognostic Markers for Chronic Lymphocytic 
Leukemia 
Gene Description Frequency Prognostic 
Indication 
NOTCH1 (Notch Homolog 
1) 
Encodes a ligand-activated 
transcription factor that regulates 
several downstream pathways involved 
in cell growth. Mutations in NOTCH1 
impair NOTCH1 degradation leading to 
increased intensity and duration of 
NOTCH1 activity. 
10% Poor Prognosis 
SF3B1 (Splicing Factor 3B 
Subunit 1) 
Critical component of splicesome. 
Thought to control cell cycle 
progression and apoptosis.  
5-10% Associated with 
shortened survival 
time. 
BIRC3 (Baculoviral IAP 
Repeat-containing Protein 3) 
Negative regulator of MAP3K14. 
Mutations in BIRC3 disrupts 
proteosomal degradation of MAP3K14 
and leads to constitutive activation of 
non-cannonical NF B.  
4% Poor Prognosis 
Material obtained from (Gaidano et al., 2012) 
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In summary, CLL, although designated as a single entity, is a highly variable disease. While 
clinical staging remains the foundation for determining the prognosis of patients, it fails to 
recognize a substantial subset of patients who are likely to experience rapid progression to 
advanced stage disease. The use of LDT and identification of various prognostic markers 
outlined above have aided the identification of patients with early-stage CLL who are at risk of 
early progression. All of these tools are vital for guiding clinical treatment of CLL and 
identifying at risk patients who may benefit from shorter follow-up intervals.  
TREATMENT 
Currently, no curative therapy exists for CLL with the exception of allogeneic 
transplantation (Dreger, 2009). Historically, the goal of treatment was to alleviate symptoms and 
prolong survival (Shanafelt & Call, 2004). Additionally, chemotherapy for all (non-selected) 
Table 1. 4. Prognosis by FISH Results for Patients with CLL 
Chromosomal Abnormality Description Frequency Median Survival 
(years) 
None - - 9.0 
Del13q14 Contains the DLEU-1/2 genes 
which encode for miR-15a and 
miR-16a. MiR-15a/16a 
regulates a variety of genes 
including anti-apoptotic Bcl-2 
gene, cyclins CCND1/3 and 
CDK6.  
50-60% 11.0 
Trisomy 12 positive Thought to alter dosage of one 
or more proto-oncogenes. 
15% 9.0 
Del11q22-23 Affects the ATM gene. 
Deficiency in ATM causes 
genomic instability. 
unknown 6.6 
Del17p13 Disrupts the TP53 tumor 
suppressor gene. 
5-10% 2.5 
Table 1.4. Prognosis by FISH Results for Patients with CLL. Del13q14: deletion of chromosomal region 
13q14; Del11q22-23: deletion of chromosomal region 11q22-23; Del17p13: deletion of chromosomal region 
17p13; DLEU-1/2: deleted in leukemia-1/2; miR: microRNA; Bcl-2: B-cell lymphoma 2; CCND1/3: cyclins; 
CDK6: cyclin-dependent kinase 6; ATM: ataxia telangiectasia; TP53: tumor suppressor protein p53. Data 
obtained from (Gaidano et al., 2012). 
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patients has been found to be ineffective for patients with early-stage disease. Treatment of 
early-stage CLL has been associated with severe toxicity and no increase in survival (Shanafelt 
& Call, 2004). As such, treatment for early-stage CLL is not recommended outside of clinical 
trials (Shanafelt & Call, 2004). Watchful waiting with active support care measures remains the 
standard of care for early-stage (asymptomatic) patients (Shanafelt & Call, 2004).  
However, approximately 50% of patients with early-stage CLL will progress to 
aggressive symptomatic disease and require therapy (Shanafelt & Call, 2004). Criteria for 
treatment, according to the National Cancer Institute, are outlined in Table 1.5. Treatment 
options are largely dependent on the performance status of the patient (ECOG-Eastern 
Cooperative Oncology Group), prior treatment, duration of remission, co-morbidities, and 
adverse effects associated with prior treatment (Shanafelt & Call, 2004). Current therapies for 
CLL include alkylating agents, purine analogues, monoclonal antibodies, combinatorial 
treatments, and allogeneic transplantation (Shanafelt & Call, 2004). Descriptions of the various 
treatment options and their mechanism(s) of action are in Table 1.6.  
Although numerous treatment options exist for the treatment of CLL, most of them are 
undermined due to progressive drug resistance and the severe toxicities associated with 
treatments which are often too toxic for the elderly and those with co-morbidities. Similarly, 
certain prognostic indicators, such as del17p13, have been shown to contribute to 
chemorefractoriness further limiting the application of certain drugs (Gaidano et al., 2012). 
Given the age group of individuals diagnosed with CLL, a non-toxic therapeutic intervention that 
could 1) have cytotoxic effects against malignant cells, 2) increase the sensitivity of CLL cells to 
chemotherapy or 3) reduce anti-cancer drug-induced toxicities would be highly desirable and 
clinically beneficial. Increased chemo-sensitivity would be expected to increase drug efficacy, 
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and potentially reduce drug dosage resulting in reduced drug-induced toxicities. Similarly, a 
reduction in drug-induced toxicities would allow for potential increases in the number of 
chemotherapy cycles an individual can receive, thereby, increasing the likelihood of achieving a 
response.  
 
 
 
 
 
 
Table 1. 5. Clinical Treatment of CLL Criteria 
Indication for Treatment Exception 
Worsening Anemia (hemoglobin, <10.5g/dL), 
Thrombocytopenia (platelets, <100 x 10
9
/L) due 
to marrow failure 
Rule out autoimmune hemolytic anemia, 
pure red blood cell aplasia, or ITP as etiology 
of cytopenias 
>50% increase in ALC in <2 months or 
anticipated doubling lymphocyte doubling time 
of <6 months 
Exclude acute infection or transient reactive 
etiology as cause of increase in ALC 
Progressive or massive splenomegaly (>6 cm 
below costal margin) 
Consider Richter transformation if rapid 
enlargement 
Progressive or massive lymphadenopathy (>10 
cm in longest dimension) 
Consider Richter transformation if rapid 
enlargement 
Constitutional Symptoms: 
Weight loss >10% body weight in < 6 months 
Fever >38
o
C for > 2 weeks without infection 
Night sweats without evidence of infection 
Extreme Fatigue (unable to work or perform 
usual activities) 
Autoimmune anemia or ITP poorly responsive to 
other therapies 
Exclude infection as the etiology of 
constitutional symptoms 
Material obtained from (Shanafelt & Call, 2004) 
Table 1.5. Clinical Treatment of CLL Criteria. Abbrev. ALC: absolute lymphocyte count; ITP: Idiopathic 
thrombocytopenic purpura. Material was obtained from  (Shanafelt & Call, 2004).  
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Table 1. 6. Treatment Regimes for Chronic Lymphocytic Leukemia 
Type Therapies Mechanism of Action 
Allogeneic 
Transplantation 
Transplantation The anti-leukemic principle of 
allogeneic transplantation is thought 
to be through the immune-mediated 
anti-host activities conferred with 
the graft (graft-versus-leukemia 
effect (GVL)). Only curative 
therapy. Limited in use due to 
compatibility issues and chronic 
graft-versus-host complications.  
Alkylating Agents Chlorambucil 
Cyclosphosphamide 
Bendamustine (Bifunctional) 
Irreversible DNA cross-linking 
ultimately leading to cell death. 
Purine Nucleoside 
Analogs 
Fludarabine* 
Cladrine 
Pentostatin 
Bendamustine (Bifunctional) 
Purine analog, inhibits DNA 
synthesis by inhibiting DNA 
polymerase, DNA primase, DNA 
ligase and accessory protein that 
synthesizes an RNA primer 
ultimately leading to cell death. 
Immunotherapies Rituximab (Anti-CD20) 
Alemtuzumab (Anti-CD52) 
Exert cytotoxic effects by inducing 
complement-mediated cytotoxicity 
and antibody-dependent cell-
mediated cytotoxicity. 
Combinatorial 
Therapies  
CHOP, CAP, FCR**, OFAR 
CFAR 
Multi-factorial.  
 
  
Table 1.6. Treatment Regimes for Chronic Lymphocytic Leukemia. CHOP: cyclophosphamide, 
doxorubicin, vincristine, prednisone; CAP: cyclophosphamide, doxorubicin, prednisone; FCR: fludarabine, 
cyclophosphamide, rituximab; OFAR: oxaliplatin, fludarabine, alemtuzumab, rituximab; CFAR: 
cyclophosphamide, fludarabine, alemtuzumab, rituximab. *: Standard of Care as Monotherapy; **: Standard of 
Care 
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NUCLEAR FACTOR KAPPA B 
BACKGROUND 
 Nuclear factor kappa B (NF B) is a multi-protein complex transcriptional regulator that 
is made up of different protein dimers (Karin et al., 2002). The NF B family of transcription 
factors is composed of homo- and hetero-dimers derived from five distinct subunits: Rel A (p65), 
c-Rel, RelB, p50 (NF B1) and p52 (NF B2) (Lawrence, 2009; F. Li & Sethi, 2010). All family 
members share a highly conserved Rel homology domain and interactions with inhibitors of 
kappa B (I Bs), the intracellular inhibitors of NF B (F. Li & Sethi, 2010). NF B proteins bind 
B sites as either as homo- or hetero-dimers, and can exert both positive and negative effects on 
target gene transcription (Hayden & Ghosh, 2012). NF B proteins are characterized by the 
presence of an N-terminal Rel homology domain (RHD) which comes into contact with DNA 
and supports dimerization of NF B subunits (Hayden & Ghosh, 2012). Only Rel A, c-Rel, and 
RelB possess C-terminal transactivation domains (TADs) that confer the ability to initiate 
transcription (Hayden & Ghosh, 2012). Despite p50 and p52 lacking TADs, they can positively 
regulate transcription through heterodimerization with TAD-containing NF B subunits or 
through interaction with non-Rel proteins that have transactivating capability (Hayden & Ghosh, 
2012). Inversely, p50 and p52 homodimers can negatively regulate transcription by competing 
with TAD-containing dimers for binding B sites. Similarly, p50 and p52 dimers may also 
constitutively occupy some B sites thereby enforcing an activation threshold for certain NF B 
target genes (Hayden & Ghosh, 2012).  
 A hallmark of the NF B pathway is its regulation by I B proteins. I B proteins  I Bα, 
I Bß, I B , I B Bcl-3 (B-cell lymphoma 3) and I Bns and the precursor proteins p100 
(NF B2) and p105 (NF B1) are defined by the presence of multiple ankyrin repeats (Hayden & 
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Ghosh, 2012). Activation of NF B is achieved through phosphorylation of I Bs on conserved 
serine residues inducing polyubiquitination of the nuclear export signal, which, under normal 
conditions keeps a steady-state cytoplasmic localization of NF B dimers, thus preventing DNA 
binding (Hayden & Ghosh, 2012). Proteosomal degradation of I B from the NF B complex 
allows NF B dimers to accumulate in the nucleus and bind DNA B sites (Hayden & Ghosh, 
2012). The degenerative nature of the B site sequence, ability of individual NF B subunits to 
form homo- or hetero-dimers, heterotypic interactions with other transcription factors, and the 
regulation of transcriptional activity by post-translational modifications (PTMs) targeting NF B 
subunits allow for both positive and negative regulation of transcription of a wide variety of 
target genes (Hayden & Ghosh, 2012). The termination of transcription response depends on 
both resynthesis of typical I B proteins and removal of active NF B dimers from the DNA 
(Hayden & Ghosh, 2012).  
Collectively, the regulation and activity of NF B are intricate in nature and can be 
influenced by a variety of factors. The following sections are to explore the signaling pathways 
which lead to NF B activation, its physiological role and its implications in cancer.  
ACTIVATION OF NF B 
NF B is activated by many divergent stimuli, including pro-inflammatory cytokines (e.g. 
tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1)), T- and B-cell mitogens, bacteria, 
lipopolysaccharide (LPS), viruses, viral proteins, double-stranded RNA, physical and chemical 
stresses and cellular stresses such as ionizing radiation and chemo-therapeutic agents (F. Li & 
Sethi, 2010). Activation of NF B can be broadly classified into two types of pathways: canonical 
and non-canonical (Hayden & Ghosh, 2012; F. Li & Sethi, 2010).   
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The canonical pathway is triggered by microbial products and pro-inflammatory 
cytokines such as TNF-α and IL-1 (Hayden & Ghosh, 2012; F. Li & Sethi, 2010). Upon 
recognition of ligand, cytokine receptors such as TNF receptor (TNFR), IL-1 receptor (IL-1R) or 
toll-like receptor 4 (TLR4) trigger signaling cascades that culminate in activation of inhibitor of 
I B kinase-ß (IKKß) .IKKß exists in a complex with IKKα and the regulatory protein NEMO 
(IKK ) (Hayden & Ghosh, 2012; Karin et al., 2002).  Activation of IKKß phosphorylates I B 
proteins such as IkBα resulting in IkBα‟s polyubiquitination and proteosomal degradation, 
thereby allowing the NF B complex to translocate into the nucleus and bind B sites (Figure 
1.1) (Hayden & Ghosh, 2012; Karin et al., 2002). It should also be noted that IKKα and IKKß 
can mediate cross-talk with additional signaling pathways, including p53, MAP kinase (MAPK) 
and IFN regulatory factor (IRF) pathways, and directly regulate aspects of transcriptional 
responses (Hayden & Ghosh, 2012).  
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Figure 1. 1. Canonical NF B Pathway. 
Upstream ligand activated cytokine receptors, such as TNFR and IL-1R, activate the IKKß subunit of the 
NEMO/IKKα/IKKß complex. Activated IKKß phosphorylates the I B proteins (bound to the NF B heterodimers). 
Phosphorylation of I B leads to polyubiquitination of I B and ubiquitin-dependent degradation of I B by the 26s 
proteasome, resulting in the nuclear translocation of RelA/p50 (or c-Rel/p50) heterodimers and subsequent binding to B 
sites and transcriptional activation of target genes. Figure is redrawn from (Karin, Cao, Greten, & Li, 2002; Lawrence, 
2009).  
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The non-canonical, or alternative, pathway is triggered by specific members of the TNF 
cytokine family, such as CD40 ligand, receptor activator of NF B ligand (RANKL) and B-cell 
activating factor (BAFF) (Hayden & Ghosh, 2012; Sun, 2011). In contrast to the canonical 
pathway, the non-canonical pathway depends on IKKα and is independent of NEMO (Hayden & 
Ghosh, 2012; Lawrence, 2009). These cytokines (CD40L/BAFF/RANKL) activate NF B-
inducing kinase (NIK)  which, in turn, activates IKKα (Lawrence, 2009). Activation of IKKα 
leads to phosphorylation of p100 and the generation of p52/RelB complexes and regulates genes 
involved in lympho-organogenesis and B-cell activation (Figure 1.2) (Hagemann, Biswas, 
Lawrence, Sica, & Lewis, 2009; Hayden & Ghosh, 2012).  
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Figure 1. 2. Non-canonical NF B Pathway. 
Upstream activation by TNF cytokine family members, such as CD40L and BAFF, activates the kinase, NIK. NIK in turn 
activates IKKα which phosphorylates the p100 subunit of the p100/RelB complexs. Phosphorylation of p100 leads to its 
polyubiquitination and triggering the ubiquitin-dependent degradation of the carboxyl terminal half of p100, releasing its 
amino acid half, the p52 polypeptide, which together with its heterodimer partner, RelB, translocates into the nucleus to 
activate transcription. Figure is redrawn from (Karin et al., 2002; Lawrence, 2009).  
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Although various stimuli can activate NF B, most are mediated through either the 
canonical or non-canonical (alternative) pathways to regulate a wide variety of genes. Although 
each NF B dimer is likely to have distinct regulatory functions, many of the target genes are 
conserved to several, if not all NF B proteins (Karin et al., 2002). These genes fall into four 
major categories: immunoregulatory and inflammatory genes, anti-apoptotic genes, genes that 
positively regulate cell proliferation, and genes that encode for negative regulators of NF B 
(Karin et al., 2002). Collectively, the transcriptional programs regulated by NF B are essential 
for the development and maintenance of immune systems, skeletal systems, and epithelium 
(Hayden & Ghosh, 2012). In these settings, the NF B pathways contributes to control of cell 
survival, differentiation and proliferation (Hayden & Ghosh, 2012). While NF B aids in various 
processes necessary for normal functioning cells, the same processes can be performed in a 
variety of diseases in which aberrant activation of NF B has been associated, including cancer 
(Hayden & Ghosh, 2012). In this context, the initiation of tumorigenesis requires six essential 
alterations to normal cell physiology: self-sufficiency in growth signals, insensitivity to contact 
inhibition, evasion of apoptosis, immortalization, sustained angiogenesis and tissue invasion and 
metastasis (Karin et al., 2002). NF B is known to induce several of these cellular alterations 
(Karin et al., 2002). Thus, the likelihood that NF B is involved in cancer is high, a notion which 
will be explored in the following section.  
NF B AND CANCER 
Increased constitutively active NF B has been observed in various solid tumors as well 
as hematological malignancies (Braun et al., 2006; Darnell, 2002; Ditsworth & Zong, 2004). 
Several mechanisms have indicated how NF B transcription factors bypass their normal modes 
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of regulation. For example, the avian REV-T oncovirus produces a constitutively active v-Rel 
oncoprotein which can induce constitutive NF B activation and causes rapidly progressing 
lymphomas and leukemias (Gilmore, 1999). Chromosomal abnormalities can also disrupt genes 
which encode NF B and I B proteins, thereby uncoupling NF B factors from their regulators 
and causing constitutive NF B activation. Finally, autocrine and paracrine production of pro-
inflammatory cytokines, oncogenic activation of upstream signaling molecules can persistently 
stimulate IKK activity leading to constitutive NF B activation (Karin et al., 2002). Together, 
constitutively active NF B activation can promote various aspects of tumorigenesis including 
promoting cancer-cell proliferation, inhibition of apoptosis and increasing tumor‟s angiogenic 
and metastatic potential (Karin et al., 2002). 
NF B can contribute to cell-proliferation by activating genes such as IL-2, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and CD40L which encode for various growth 
factors that stimulate the proliferation of lymphoid and myeloid cells. The continuous production 
of these cytokines can induce a chronic stimulation of cell proliferation through an autocrine or 
paracrine fashion. Additionally, NF B has also been shown to stimulate production of cyclin D1, 
thereby promoting cell-cycle progression (Guttridge, Albanese, Reuther, Pestell, & Baldwin, 
1999; Hinz et al., 1999).  
NF B can also inhibit apoptosis by promoting transcription of anti-apoptotic genes 
(Karin et al., 2002). These factors include inhibitors of apoptosis (cIAPs), caspase-8/FADD 
(FAS-associated death domain)-like IL-1ß converting enzyme (FLICE) inhibitory protein (c-
FLIP) and members of the Bcl-2 family (Karin & Lin, 2002). Furthermore, NF B can also 
attenuate the apoptotic response of genotoxic anti-cancer therapies and ionizing radiation thereby 
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contributing to chemo-resistance (F. Li & Sethi, 2010; C. Y. Wang, Cusack, Liu, & Baldwin, 
1999; C. Y. Wang, Mayo, & Baldwin, 1996).  
In addition to the ability of NF B to promote cell proliferation and inhibit apoptosis, 
NF B can also increase angiogenesis and metastatic potential. This is achieved by NF B-
targeted transcription of various chemokines, such as IL-8, which increase the migratory and 
invasive capacity (Guo et al., 2011; Kim, Choi, Park, & Kim, 2012) and by transcription of the 
stimulator of angiogenesis- vascular endothelial growth factor (VEGF) (Huang, Robinson, 
Deguzman, Bucana, & Fidler, 2000; Tanaka et al., 2012). NF B has also been shown to induce 
transcription of several metalloproteinases- proteolytic enzymes that promote tumor invasion of 
surrounding tissues (J. Li et al., 2012; Qin et al., 2012).  
Consistent with the notions that NF B can promote oncogenesis, various studies have 
demonstrated that NF B activation is positively associated with disease progression. Studies by 
Tang et al. found that high levels of immunohistochemical expression of NF B p65 were 
detected in lung cancers (X. Tang et al., 2006). Interestingly, the NF B p65 expression in lung 
adenocarcinomas was significantly higher in advanced TNM (tumor, lymph nodes, metastasis) 
stages (III-IV) than in earlier stages (I-II), suggesting that NF B is associated with disease 
progression (X. Tang et al., 2006). These findings are further supported by Zhang et al. who 
found that expression of NF B/Rel A was higher in non-small cell lung cancer (NSCLC) tissue 
as compared to normal adjacent tissue and normal lung tissue (Zhang et al., 2007). Additionally, 
there was a positive correlation between NF B activation (nuclear translocation of Rel A) and 
tumor clinicopathological features such as tumor grade and TNM staging, supporting the 
findings by Tang et al (Zhang et al., 2007). Zhang et al. also demonstrated that nuclear Rel A 
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binding and cytoplasmic phosphorylated-inhibitor of kappa-B-alpha (pI B-α) were positively 
associated with poor prognosis (Zhang et al., 2007).  
Although the involvement of NF B activation in various malignancies has been 
evaluated, the activation of NF B in CLL remains of primary interest in this dissertation. 
Targeting NF B activation has also come into light as a promising candidate for intervention for 
the treatment of CLL. (F. Li & Sethi, 2010). Increased constitutive activation of NF B has been 
observed in primary CLL cells (Hewamana, Alghazal, et al., 2008; Hewamana, Lin, et al., 2008; 
Hewamana et al., 2009). It has also been found that increased binding of Rel A, a subunit of 
NF B which contains the transactivation domain, was positively correlated with white blood cell 
count, a measure of tumor burden, and lymphocyte doubling time, a measure of tumor kinetics 
(Hewamana, Alghazal, et al., 2008). Furthermore, it has been shown that Rel A DNA binding 
was strongly associated with Binet staging, predictive of time to initial treatment and subsequent 
treatment, and predictive of overall survival (Hewamana et al., 2009). Rel A DNA binding has 
also been shown to be negatively correlated with induction of spontaneous apoptosis in vitro 
suggesting that NF B is an important mediator of survival (Hewamana, Alghazal, et al., 2008). 
This is supported by the fact that inhibition of NF B activation, through the use of an 
irreversible-IKK inhibitor (LC-1), induced dose-responsive increases in apoptosis (Hewamana, 
Lin, et al., 2008). The addition of LC-1 was also able to overcome the cytoprotective effects of 
CD40L and IL-4, upstream agonists of NF B activation, providing further support of the 
importance of NF B in CLL (Hewamana, Lin, et al., 2008). Additionally, studies by Pepper et 
al. indicated that the cytotoxic effects of aspirin and its analogues were mediated by both COX-2 
inhibition as well as inhibition of Rel A DNA (Pepper et al., 2011). It is also important to note 
that in the studies by Hewamana et al., inhibition of NF B activation by LC-1 exhibited strong 
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synergy with fludarabine, a commonly used first-line treatment in CLL (Riches, Ramsay, & 
Gribben, 2011; Silber et al., 1994), in both good prognostic CLL patients who were fludarabine-
sensitive and poor prognostic CLL patients who displayed chemorefractoriness toward 
fludarabine (Hewamana, Lin, et al., 2008). Given the ability of NF B to promote survival of 
CLL cells in vitro and aid in various biological processes such as proliferation, migration, 
inhibition of apoptosis and chemo-resistance, therapeutic interventions which target NF B 
would be of considerable interest and clinically relevant.  
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OMEGA-3 FATTY ACIDS 
BACKGROUND 
Omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) are essential fatty 
acids (EFAs). These fats are referred to as essential because humans, like all mammals, are 
unable to synthesize them and thereby must obtain them from the diet. The n-6 EFA is 
represented by linoleic acid (LA; 18:2n-6) and n-3 EFA is represented by alpha-linolenic acid 
(ALA; 18:3n-3) (Figure 1.1). LA is primarily found in seeds of most plants, whereas, ALA is 
primarily found in green leafy vegetables, flax seed, and walnuts (Simopoulos, 2008). The 
distinction of these two essential fatty acids (FAs) is based on the location of the first double 
bond from the methyl (omega) end of the FA molecule located between carbon 6-7 (n-6) or 3-4 
(n-3) (Figure 1.1) (Simopoulos, 1991, 2000, 2002, 2008).  
Both EFAs are capable of being metabolized in humans to their longer chain 20-carbon 
and 22-carbon derivatives. LA is metabolized to 20-carbon arachidonic acid (AA; 20:3n-6) and 
ALA is metabolized to the 20-carbon eicosapaentaenoic acid (EPA; 20:5n-3) and 22-carbon 
docosahexaenoic acid (DHA; 22:6n-3). This is achieved by increasing the carbon chain length 
and degree of unsaturation through addition of extra carbons to the carboxyl end of the fatty acid 
chain (Figure 1.1) and then desaturating a bond. While AA can be metabolized from its pre-
cursor, LA, it can also be obtain from meats of animals that consume LA and then store AA in 
their meat. Similarly, EPA and DHA can be obtained from fish or fish oils (Simopoulos, 1991, 
2000, 2002, 2008).  
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EFAs are important components of cellular membranes and are selectively found 
amongst lipid classes. ALA and LA are mostly found in triglycerides, cholesterol esters with a 
relatively small abundance found in phospholipids. AA and EPA are found in triglycerides, 
cholesterol esters and phospholipids. Unlike the other n-3 FAs, DHA is predominantly found in 
phospholipids (Simopoulos, 2008). Furthermore, n-6 and n-3 FA compete with each other for 
incorporation into the cell and are substrates for the same metabolizing enzymes (reviewed in the 
following section). As such, consumption of n-3 such as EPA or DHA can partially displace n-6, 
especially AA, in the membranes of cells (Simopoulos, 1991, 2000, 2002, 2008).  
Currently, the western diet is heavily favored toward the n-6 FA with little to no n-3 FA 
intake. The average ratio of n-6 to n-3 in the western diet is 15-20 to 1 (Simopoulos, 2008) 
whereas the ideal ratio of n-6 to n-3 is 4-1:1 (Patterson, Wall, Fitzgerald, Ross, & Stanton, 2012). 
Furthermore, mammalians lack the ability to convert n-6 to n-3 as they lack the necessary 
converting enzyme, omega-3 desaturase (Simopoulos, 2008). This is an important consideration; 
Figure 1. 3. Chemical Structures of Omega-3 and Omega-6 Fatty Acids. 
Picture modified from the European Food Information Council. Abbrev. X:Y- X denotes number of carbon atoms; Y 
denotes number of unsaturations; n-3: omega-3; n-6: omega-6. Picture modified from the European Food 
Information Council.  
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both n-6 and n-3 are integral parts of cellular membranes and are structurally similar. Yet these 
two classes of EFA are not interconvertible, and are metabolically and functionally distinct, often 
having important opposing physiological functions (Simopoulos, 2008). As such, this imbalance 
toward n-6 can lead to increased risk of various diseases. In support of this notion, various 
studies have illustrated that a high intake of n-6 and a high n-6/n-3 ratio can promote 
pathogenesis of many diseases including cardiovascular, autoimmune, cancer, and inflammatory 
disease (Simopoulos, 2008). Inversely, consumption of n-3 has been shown to have beneficial 
health effects and often has suppressive effects on pathogenesis (Simopoulos, 2008).  
Beneficial health effects of n-3, particularly EPA and DHA, were described first in 
Greenland Eskimos who consumed high quantities of fish and displayed lower rates of coronary 
heart disease, asthma, type 1 diabetes mellitus, and multiple sclerosis (Simopoulos, 2008) than 
populations that consumed less fish. Since then, beneficial effects of n-3 have been extended to 
include cancer, inflammatory bowel disease, rheumatoid arthritis and psoriasis (Simopoulos, 
2008).  
The application of n-3 as potential therapeutic options for CLL is of great interest and the 
principle focus of this thesis. The metabolism of PUFAs and their physiological role in humans 
as well as their implications on CLL will be discussed in the following sections.   
METABOLISM 
As introduced above, both LA and ALA are able to be metabolized to their longer 20-
carbon and 22-carbon derivatives. This is achieved through a series of elongation and 
desaturation reactions mediated by specific elongase and desaturase enzymes illustrated in 
Figure 1.2 with delta-6 desaturase being the rate limiting enzyme (Patterson et al., 2012; 
Simopoulos, 2008). Since both n-3 and n-6 FA utilize the same enzymes their conversion to their 
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longer derivatives can be influenced if there is a high intake of one type of EFA. For instance, a 
high intake of ALA can interfere with the elongation and desaturation of LA. This concept has 
been demonstrated in human studies which illustrated that a constant consumption of ALA with 
a decreasing consumption of LA led to increases in EPA in the plasma phospholipids (Liou, 
King, Zibrik, & Innis, 2007). Additionally, the elongation and desaturation of n-3 and n-6 FA 
can also be hindered by the present of trans-fats, which inhibit the delta-6 desaturase (Patterson 
et al., 2012; Simopoulos, 2008). As such, the propensity of PUFAs to undergo elongations and 
desaturations is largely dependent on the type of fat intake of the individual.  
The elongation and desaturation of LA and ALA is an important process as the 
bioactivity of these EFAs is thought to be predominately mediated through their longer chain 
metabolites. Of the various n-6 and n-3 derivatives, AA and EPA are especially important as 
these FAs are precursors for eicosanoid production (Haeggstrom, Rinaldo-Matthis, Wheelock, & 
Wetterholm, 2010; Serhan & Petasis, 2011). Eicosanoids are biologically active, 20-carbon lipids 
which are important mediators of acute inflammation, and have been implicated in several 
specific diseases such as thrombosis, cancer, atherosclerosis, asthma and rhinitis (Haeggstrom et 
al., 2010; Patterson et al., 2012). These AA-derived and EPA-derived eicosanoids are produced 
by three major pathways: the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 
(CYP) pathways (Haeggstrom et al., 2010; Luo & Wang, 2011; Patterson et al., 2012). 
Collectively, eicosanoids consist of prostaglandins (PGs), thromboxanes (TXs), leukotrienes 
(LTs), hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EET), 
epoxyeicosatetraenoic acids (EETeTrs) and hydroxyeicosapentaenoic acids (HEPE)  (Arnold, 
Konkel, Fischer, & Schunck, 2010; Luo & Wang, 2011; Patterson et al., 2012). The synthesis of 
the various eicosanoids is illustrated in Figure 1.3.  
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Linoleic Acid (LA: 18:2n-6) Alpha-Linolenic Acid (ALA: 18:3n-3)
Delta-6-Desaturase
Gamma-Linolenic Acid (GLA: 18:3n-6) Stearidonic Acid (SA: 18:4n-3)
Elongase
Dihomogamma-Linolenic Acid (DGLA: 20:3n-6) Eicosatetraenoic Acid (EA: 20:4n-3)
Delta-5-Desaturase
Arachidonic Acid (AA: 20:4n-6) Eicosapentaenoic Acid (EPA: 20:5n-3)
Elongase
(22:4n-6 Intermediate) Docosapentaenoic Acid (DPA: 22:5n-3)
Delta-4-Desaturase
Docosapentaenoic Acid (DPA:22:5n-6) Docosahexaenoic Acid (DHA: 22:6n-3)
Figure 1. 4. Metabolism of Linoleic Acid and Alpha-Linolenic Acid to their longer-chain derivatives. 
Abbrev. X:Y- X denotes number of carbon atoms; Y denotes number of unsaturations; n-3: omega 3; n-6: omega 6.  
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Whereas PUFA are able to undergo enzymatic metabolism, they are also able to undergo 
non-enzymatic degradation. Non-enzymatic degradation of PUFA is mediated by various 
reactive oxygen and nitrogen species (ROS/RNS) which oxidize lipids, collectively referred to as 
lipid peroxidation, and yield a diverse array of products (Niki, 2009). The degree of lipid 
peroxidation is dependent on the number of unsaturations possessed by the FA molecule. As 
such, the higher the degree of unsaturation the FA molecule possesses the greater the amount of 
lipid peroxidation that can ensue (Niki, 2009).  
Lipid peroxidation can be mediated by free radical-mediated oxidation or free radical-
independent non-enzymatic oxidation (Niki, 2009). Free radical-mediated lipid peroxidation is 
achieved by a chain mechanism in which one initiating free radical can oxidize many molecules 
of lipids (Niki, 2009). The type of free radical which oxidizes the lipid molecules is dependent 
on the condition of the cell (Niki, 2009). Free radical-independent non-enzymatic oxidation is 
mediated by singlet oxygen and ozone (Niki, 2009). Singlet oxygen oxidizes unsaturated lipids 
mainly by the ene-reaction to give hydroperoxide with concomitant double-bond migration, with 
minor side reactions such as 1,4 addition to give 1,4-endoperoxide and 1,2 addition to give 
dioxetane, which readily decomposes to yield carbonyl compounds (Niki, 2009).   
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Membrane Phospholipid
Eicosapentaenoic Acid
Phospholipase-A2
Cyclo-Oxygenase-1
(COX-1: Constitutively Active)
Cyclo-Oxygenase-2
(COX-2: Inducible)
PGH3
Tissue-Specific Isomerases
(PGE Synthase, TXA Synthase, PGI
Synthase)
PGE3 TXA3 PGI3 PGD3 PGF3a
Biological Effect
5-Lipoxygenase
LTA Synthase
5-series Leukotrienes (LTs)
Biological Effect
5-HEPE
Cyt. P450
EETeTrs
19- and 20-HEPEs
Biological Effect
Membrane Phospholipid
Arachidonic Acid
Phospholipase-A2
Cyclo-Oxygenase-1
(COX-1: Constitutively Active)
Cyclo-Oxygenase-2
(COX-2: Inducible)
PGH2
Tissue-Specific Isomerases
(PGE Synthase, TXA Synthase, PGI
Synthase)
PGE2 TXA2 PGI2 PGD2 PGF2a
Biological Effect
5-Lipoxygenase
LTA Synthase
4-series Leukotrienes (LTs)
Biological Effect
5-HETE
Cyt. P450
16- to 20-HETE
5,6-EET
8,9-EET
11,12-EET
14,15-EET
Biological Effect
Figure 1. 5. Schematic of Eicosanoid Production. 
Within a cell, AA and EPA is released from the membrane phospholipids by the enzyme phospholipase-A2 (PLA2) 
where after they will be metabolized by the cyclo-oxygenase enzymes (COX-1, a constitutive enzyme, or COX-2, an 
inducible enzyme), 5-lipoxygenase (LOX) or cytochrome p450 (CYP). AA COX-derived eicosanoid PGH2 is 
subsequently metabolized by a series of specific prostaglandin synthase enzymes leading to the production of the 2-series 
prostaglandins: PGE2, PGI2, PGD2, and PGF2α and thromboxanes A2 and B2. AA LOX-derived eicosanoid 5-
hydroperoxyeicosatetraenoic acid (5-HPETE) is subsequently metabolized by Leukotriene Synthase to produce the 4-
series of leukotrienes: LTA4, LTB4, LTC4, LTD4 and LTE4. Metabolism of AA by CYP produces the 16- to 20-HETEs 
and 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids (EETs). In contrast, EPA can also act as a substrate for COX, 
LOX and CYP enzymes and give rise to an entirely different set of eicosanoids. These are the 3-series prostaglandins and 
thromboxanes and the 5-series leukotrienes and epoxyeicosatetraenoic acids (EETeTrs) and 19- and 20-
hydroxyeicosapentaenoic acids (HEPE). 
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Collectively, PUFA are substrates for a variety of enzymatic and non-enzymatic 
reactions. The type of PUFA, degree of unsaturation and intake all influence the rate and type of 
by-products that are produced aiding to the complexity of PUFA metabolism and the versatility 
of their actions.  
MECHANISMS OF ACTION 
The mechanisms through which PUFA exert their actions are diverse and multifaceted, a 
trait aided by the diversity of their by-products. However, one of the most prominent roles of 
PUFA is their involvement with inflammation.  
Inflammation is an important physiological host defense mechanism that protects the host 
from infection and other insults. Inflammation initiates pathogen killing and tissue repair 
processes as well as restoration of homeostasis at an infected or damaged site (Niki, 2009). 
Under normal conditions, inflammation is tightly regulated to prevent excessive damage to the 
host. Regulation is often mediated through negative feedback mechanisms such as anti-
inflammatory cytokines, inhibition of pro-inflammatory cascades, shedding of receptors for 
inflammatory mediators and through activation of regulatory cells (Niki, 2009). As such, 
controlled, regulated inflammatory responses are essential to remain healthy and maintain body 
homeostasis. However, a loss of tolerance and/or regulation of inflammatory processes can lead 
to excessive, irreparable damage to the host tissue leading to various pathologies, including 
cancer (Niki, 2009).  
Eicosanoids are key mediators and regulators of inflammation (Calder, 2009; 
Haeggstrom et al., 2010; Serhan & Petasis, 2011). As previously mentioned, the eicosanoids 
produced by AA are comprised of the 2-series PGs and TXs and the 4-series LTs. PGE2 and the 
4-series LTs are particularly important as these eicosanoids modulate both the intensity and 
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duration of the inflammatory response (Calder, 2009). However, eicosanoid production is not 
solely derived from AA, but can also be derived from EPA. The eicosanoids produced from 
EPA, which includes the 3-series PGs/TXs and 5-series LTs, are functionally different from their 
AA-derived counterparts and often times have antagonistic actions on inflammation (Table 1.7) 
(Calder, 2009). 
Prostaglandins and thromboxanes, collectively referred to as prostanoids, exert their 
biological effects by binding to cell-surface prostanoid receptors belonging to the family of G-
protein-coupled rhodopsin receptors (GPCRs) or nuclear receptors such as the peroxisome 
proliferator-activated receptors (PPARs) (Cathcart, Lysaght, & Pidgeon, 2011; Ricciotti & 
FitzGerald, 2011).  The prostanoid receptor family is composed of 8 members: E prostanoid 
receptor (EP 1-4); D prostanoid receptor (DP1); F prostanoid receptor (FP); I prostanoid receptor 
(IP); and thromboxane receptor (TP) (Ricciotti & FitzGerald, 2011). These prostanoid receptors 
are coupled to a range of intracellular signaling pathways summarized in Table 1.8.   
Of particular interest are the EP receptors and PGE2 as PGE2 is one of the most abundant 
eicosanoids produced in the body (Ricciotti & FitzGerald, 2011). EP2 and EP4 activate adenylyl 
cyclase to generate cyclic adenosine monophosphate (cAMP) leading to activation of protein 
kinase A (PKA) (Alfranca et al., 2006; Ricciotti & FitzGerald, 2011). PKA can, in turn, inhibit 
glycogen synthase kinase 3 alpha (GSK3α), thereby promoting transcription of T-cell factor 
(Tcf)-dependent genes such as COX-2. Additionally, EP4 specifically activates the 
phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt) pathway which, in some cell types, 
augments extracellular signal-regulated kinase (ERK) activity and mediates expression of early 
growth response protein 1 (EGR-1) and subsequent transcription of genes such as prostaglandin 
E synthase-1 (mPGES-1) (Alfranca et al., 2006). PGE2 has also been shown to activate nuclear 
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factor kappa B (NF B), a key mediator of the inflammatory processes(Ditsworth & Zong, 2004), 
and hypoxia inducible factor-1 alpha (HIF-1α) (Alfranca et al., 2006). Additionally, PGE2 has 
been shown to transactivate the epidermal growth factor receptor (EGFR) via activation of  
proto-oncogene tyrosine-protein kinase Src (c-Src), which activates EGFR directly or indirectly 
by inducing metalloproteinase activity that releases membrane bound transforming growth 
factor-alpha (TGFα) (Buchanan, Wang, Bargiacchi, & DuBois, 2003; Pai et al., 2002). 
Collectively, the bioactivity of PGE2 is diverse and cell-type specific. However, PGE2 is 
typically associated with promotion of increased states of inflammation and has been implicated 
in various tumorigenic processes (Reader, Holt, & Fulton, 2011).    
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Table 1. 7. Pro-inflammatory Effects of N-6 Fatty Acid-derived Eicosanoids 
and Anti-inflammatory Effects of N-3 Fatty Acid-derived Eicosanoids 
Pro-inflammatory effects of the n-6 fatty-acid-derived eicosanoids 
 Arachidonic Acid (n-6) 
Derived Eicosanoids 
Physiological Effect Organ or Cells 
Prostaglandins PGD2 Bronchoconstriction 
Pro-inflammatory 
Pro-arrhythmic 
Bronchi 
Activation of Eosinophils 
Vessels 
PGE2 Induces Fever 
Causes Pain 
Increases Production of 
IL-6 
Nociceptor Sensory 
Neurons 
PGF2 Bronchoconstriction 
Pro-arrhythmic 
Bronchi 
Vessels 
PGI2 Causes Pain Nociceptor Sensory 
Neurons 
Thromboxanes TXA2/TXB2 Pro-aggregation 
Vasoconstriction 
Bronchoconstriction 
Platelets 
Vessels 
Bronchi 
Leukotrienes LTA4/LTB4/LTC4/LTD4/LTE4 Pro-inflammatory 
Chemotaxis 
Release of ROS 
Leukocytes 
Leukocytes 
Granulocytes 
Anti-inflammatory effects of the n-3 fatty-acid-derived eicosanoids 
 Eicosapentaenoic Acid and 
Docosahexaenoic Aicd (n-3) 
Derived Eicosanoids 
Physiological Effect Organ or Cells 
Prostaglandins PGD3/PGE3/PGF3/PGI3 Anti-arrhythmic Vessels 
Thromboxanes TXA3/TXB3 Anti-aggregation Platelets 
Leukotrienes LTA5/LTB5/LTC5/LTD5/LTE5 Anti-inflammatory Leukocytes 
Resolvins RVE1 Anti-aggregation 
Anti-inflammatory 
Platelets 
Dendritic Cells 
RVD Anti-inflammatory Dendritic Cells 
Neuroprotectin NPD1 Anti-inflammatory 
Anti-apoptotic 
Decreases Oxidative 
Stress 
Retina (photoreceptor cells) 
and Brain 
Material obtained from (Calder, 2009).  
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Table 1. 8. Signal Transduction of AA-derived Prostanoids 
Class Subtype G-Protein Coupled Second Messenger(s) 
PGE2 EP1 
EP2 
EP3 
EP4 
Gq 
Gs 
Gi, G12, GRho 
Gs 
  IP3 
  cAMP 
  cAMP,    Ca
2+
 
  cAMP 
PGD2 DP 
CRTH2 
Gs 
Gi 
  cAMP 
  cAMP,    Ca
2+
 
PGF2α FPA, FPB Gq, GRho   IP3 
PGI2 IP-IP 
IP-TPα 
Gs, Gq, Gi 
Gs 
  IP3 ,          cAMP 
  cAMP 
TxA2 TPα, TPß Gq, Gs (α), Gi (ß), Gh, 
G12/13 
  IP3 ,          cAMP 
  Ca
2+ 
Material obtained from (Alfranca et al., 2006).  
 
Whereas eicosanoids are primary mediators of inflammation, products of lipid 
peroxidation can also contribute to an inflammatory state. While the mechanisms, dynamics and 
products of lipid peroxidation are still under investigation, it has been shown that lipid 
peroxidation induces: 1) disturbances of fine structures, 2) alterations in integrity, fluidity and 
permeability of cell membranes leading to functional loss, 3) modifies low-density lipoproteins 
to pro-atherogenic and pro-inflammatory forms, and 4) can generate potentially toxic products 
(Greenberg et al., 2008; Niki, 2009). Despite the potential mutagenic and genotoxic effects that 
lipid peroxides can elicit, it has also become evident that lipid peroxidation products exert 
various biological functions in vivo such as regulation of gene expression, signaling messengers, 
activators of receptors and nuclear transcription factors, and inducers of adaptive responses 
(Niki, 2009). Recent studies have provided evidence that many products of lipid peroxidation 
Table 1.8. Signal Transduction of AA-derived Prostanoids. Abrrev.: PGE2: prostaglandin E2; 
EP:prostaglandin E2 receptor; IP3: inositol triphosphate; cAMP: cyclic adenosine monophosphate; PGD2: 
prostaglandin D2; DP: prostaglandin D2 receptor; CRTH2: chemoattractant receptor-homologous molecule 
expressed on Th2 cells; PGF2α: prostaglandin F2α; FP: prostaglandin F receptor; PGI2: prostacyclin 2; IP: 
prostacyclin receptor; TP: thromboxane receptor; TxA2: thromboxane A2. Data obtained from  (Alfranca, 
Iniguez, Fresno, & Redondo, 2006). 
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exert opposite dual effects, depending on conditions, such as cytotoxic or cytoprotective effects, 
pro- and anti-atherogenic effects, pro- and anti-apoptotic effects and pro- and anti-inflammatory 
effects (Parthasarathy, Santanam, Ramachandran, & Meilhac, 2000; Zmijewski et al., 2005). 
Thus, the contribution of lipid peroxides to a pro-inflammatory state is complex and context 
dependent.  
The mechanisms of action exerted by n-6 and n-3 are diverse and multi-faceted. 
Typically, n-6 FAs are considered to be pro-inflammatory; whereas n-3 FAs are considered to be 
anti-inflammatory. States of chronic inflammation are an underlying cause for various 
pathologies including cancer (Balkwill & Coussens, 2004; Clevers, 2004). A diet rich in n-6 will 
shift the balance toward a pro-inflammatory and pro-thrombotic state and can, thereby, promote 
tumor promotion and progression. Inversely, the addition of n-3 can antagonize the pro-
inflammatory effects of n-6 thereby providing a potential therapy for the treatment of cancer, the 
focal point of this thesis.  
OMEGA-3 FATTY ACIDS AND CANCER 
Recently, numerous studies have supported the notion that AA and its metabolites have a 
significant role in tumor promotion (Hyde & Missailidis, 2009). Although the role of AA and its 
metabolites on tumor promotion is intricate and multi-faceted, much attention has been placed on 
COX-2 and PGE2. It is clear that overexpression of COX-2 is implicated in various forms of 
human cancers including lung (Krysan et al., 2004), breast (Barnes, Haywood, Flint, Knox, & 
Bundred, 2006), colorectal (Chan, Ogino, & Fuchs, 2007), prostate (Lee, Pan, Cheng, Chi, & 
Liu, 2001), head and neck (D. W. Tang et al., 2003), and chronic lymphocytic leukemia (Ryan et 
al., 2006; Secchiero et al., 2005). In conjunction, AA-COX derived eicosanoid, PGE2, is the most 
abundantly formed prostaglandin (Ricciotti & FitzGerald, 2011) and has been implicated in 
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various aspects of tumorigenesis via induction of cell proliferation, anti-apoptosis, angiogenesis, 
invasion, and metastasis (Greenhough et al., 2009). In addition, PGE2 has also been linked to 
upregulation of B-cell CLL/lymphoma 2 (Bcl-2), an anti-apoptotic protein, and induction of 
NF B (D. Wang & Dubois, 2010). 
Nuclear factor kappa B belongs to a family of transcription factors that play a pivotal role 
in inflammatory and stress responses as well as in tumor cell resistance to apoptosis (Balkwill & 
Coussens, 2004; Darnell, 2002). NF B controls various cytokines (e.g. IL-1, IL-2, IL-6, IL-12, 
TNF-α), chemokines (e.g. IL-8, MIP-1α, MCP1), adhesion molecules (e.g. ICAM, VCAM and 
E-selectin) and inducible effector enzymes such as inducible nitric oxide synthase (iNOS) and 
COX-2 (Schmitz & Ecker, 2008). Several studies have demonstrated that NF B can promote 
oncogenesis by virtue of its ability to regulate the expression of a wide array of genes that 
modulate apoptosis, proliferation, inflammation, tumor metastasis, and angiogenesis (Clevers, 
2004). Increased constitutively active NF B has been observed in various solid tumors as well as 
hematological malignancies (Braun et al., 2006; Darnell, 2002; Ditsworth & Zong, 2004). 
Activation of NF B has been linked to aggressive tumor growth and resistance to both 
chemotherapy and radiotherapy (F. Li & Sethi, 2010). NF B regulates COX-2 (Schmitz & 
Ecker, 2008). COX-2 increases production of PGE2 (Calder, 2009). PGE2 in turn can stimulate 
various pathways associated with tumorigenesis including activation of NF B (Ditsworth & 
Zong, 2004; D. Wang & Dubois, 2010). Thus, the relationship between NF B, COX-2 and PGE2 
is inherently intertwined and potentially self-propagating.  
N-3 and n-6 compete with each other for incorporation and metabolism. The effects of n-
3 derived metabolites are antagonistic of n-6 derived metabolites. Given the involvement of AA 
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and its metabolites in tumor promotion, the use of n-3, particularly EPA and DHA, as therapeutic 
options for various malignancies presents a promising avenue of research.  
Consistent with this thought, n-3 fatty acids have consistently been shown to slow the 
growth and increase the chemo-sensitivity of various malignancies in vitro and in animal models 
(Das & Madhavi, 2011; Das, Madhavi, Sravan Kumar, Padma, & Sangeetha, 1998; Dekoj et al., 
2007; Hardman, Avula, Fernandes, & Cameron, 2001). However, the capacity of n-3 to translate 
into clinical benefit is of primary interest. Clinical studies utilizing n-3 in breast and lung cancer 
have demonstrated promising results. Studies by Bougnoux et al. indicated that response to 
therapy was positively correlated with n-3 levels in breast adipose tissue in patients with 
localized breast carcinoma given a therapy of mitoxantrone, vindesine, cyclophosphamide, and 
5-fluorouracil (Bougnoux et al., 1999). Notably, increased DHA especially stood out as a 
positive predictor of chemo-sensitivity (Bougnoux et al., 1999). In line with these observations, 
studies by Bougnoux et al. also illustrated that supplementation with 1.8 g/daily of DHA 
improved the efficacy of anthracycline-based therapy against the progression of visceral 
metastases (Bougnoux et al., 2009).  In this study, significant increases in time to progression 
and median overall survival were achieved in patients with the highest plasma DHA levels as 
compared to the lowest plasma DHA levels ( 8.7 months versus 3.5 months and 34 months 
versus 22 months; respectively)  (Bougnoux et al., 2009). Importantly, it was also found that 
supplementation with DHA did not induce any additional adverse effects. It should be noted that 
this was a small study (n= 25) and the relationship between DHA content and metastatic cancer 
outcome subsequent to chemotherapy does not ensure a causality (Bougnoux et al., 2009). 
Similarly, studies by Murphy et al. indicated that supplementation with fish oil increased the 
first-line chemotherapy efficacy in patients with advanced non-small cell lung cancer (NSCLC) 
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(Murphy et al., 2011b). In this study, patients with clinical diagnosis of stage IIIB or IV NSCLC 
who were chemotherapy-naïve were either supplemented with fish oil (2.5g of EPA + DHA/day; 
n=15) or no fish oil (standard of care group (SOC); n=31) in conjunction with first-line platinum-
based doublet chemotherapy of palliative intent consisting of either carboplatin with vinorelbine 
or carboplatin with gemcitabine (Murphy et al., 2011b). Primary endpoints of this study were 
response rates, defined as complete response plus partial response, and clinical benefit, defined 
as the sum of complete response, partial response and stable disease divided by the number of 
patients (Murphy et al., 2011b). Collectively, results from Murphy et al. illustrated that patients 
in the fish oil group had increased response rates and greater clinical benefit compared to the 
SOC group (60.0% versus 25.8%, p-value: 0.008 and 80.0% versus 41.9%, p-value: 0.02, 
respectively) (Murphy et al., 2011b). It should also be noted that patients in the fish oil group had 
greater 1-year survival rates as compared to the SOC group (60.0% versus 38.7%), although this 
was not statistically significant (Murphy et al., 2011b). Furthermore, patients in the fish oil group 
did not display any additional toxicities associated with treatment as compared to the SOC 
group. Inversely, as compared to the SOC group, patients in the fish oil received a significantly 
higher number of chemotherapy cycles (number of chemotherapy cycles received ± SD: 3.9 ± 
0.9 versus 3.0 ± 1.4, p-value: 0.02) and longer, almost significant, time on chemotherapy (time 
on chemotherapy (days) ± SD: 78.9 ± 23.5 versus 60.3 ± 31.1, p-value: 0.05) (Murphy et al., 
2011b).  
N-3 may also be able to reduce the side effects of treatments. In support of this notion, 
Ghoreishi et al. illustrated that a daily dose of 630 mg n-3 partially prevented paclitaxel induced 
peripheral neuropathy (PIPN), a dose-limiting side effect of paclitaxel therapy (Ghoreishi et al., 
2012). Additionally, Heller et al. indicated that the addition of 0.2g/kg/daily fish oil increased 
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liver and pancreas function while reducing weight loss in patients recovering from major elective 
abdominal surgery (Heller et al., 2004). Studies by van der Meij et al. indicated that patients with 
stage III NSCLC who consumed oral n-3 supplements (2.02g EPA + 0.92g DHA) during 
multimodality treatment had significantly greater quality of life parameters, physical and 
cognitive function, global health status and social function, and higher physical activity as 
compared to the placebo group (van der Meij et al., 2012). Similarly, Murphy et al. also found 
that patients with NSCLC who consumed fish oil (2.2g of EPA/day) retained weight and either 
gained or maintained muscle mass as compared to the non-intervention group during first-line 
therapy (Murphy et al., 2011a).  
Collectively, these findings highlight the application of n-3 at both the basic research 
level as well as in a clinical setting. However, the primary purpose of this research was to 
evaluate the potential of n-3 as therapeutic interventions for the treatment of CLL. Although 
limited, in vitro and in vivo studies on B-leukemic cells have provided insight into the 
application of n-3 as potential therapeutic options for the treatment of B-cell malignancies (such 
as CLL). Studies by Cha et al. indicated that supplementation of mice bearing L1210 B-leukemia 
with a DHA containing diet, as compared to a chow diet, in combination with arabinosylcytosine 
(AraC) chemotherapy displayed improved survival (Cha, Meckling, & Stewart, 2002). In this 
study, compared to the chow diet, the 1.5% DHA-containing diet (average intake of 1.8 g of 
DHA/kg/day) prolonged the life span (33 ± 3.4 days, p: <0.01) of L1210-bearing mice following 
AraC treatment with no incidence of death due to drug toxicity(Cha et al., 2002). However, it 
should be noted that a high intake of DHA (4.5 g of DHA/kg/day) in combination with AraC did 
not shown benefit. Inversely, the high DHA-containing diet was associated with a shorter 
survival time (26.5 ± 2.0 days), increased circulating tumor cell burden, and lowered red blood 
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cell concentrations (Cha et al., 2002). Studies by Guffy et al. illustrated that in vitro treatment of 
L1210 lymphoblastic leukemia cells with DHA increased the sensitivity of cells to the anti-
cancer drug Adriamycin in a dose-responsive manner as compared to cells treated with oleic acid 
(Guffy, North, & Burns, 1984). Additionally, increased DHA content indicate dose-responsive 
decreases in viability at a fixed concentration of Adriamycin (Guffy et al., 1984). Petersen et al. 
indicated that treatment of L1210 cells with DHA increased the sensitivity of cells to the 
thioether lipid BM 41.400 as compared to cells treated with oleic acid (Petersen, Kelley, Modest, 
& Burns, 1992).  Whereas the use of n-3 has actively been explored in various malignancies, 
including B-cell malignancies, it has not been demonstrated whether or not n-3 can provide 
benefit to patients diagnosed with CLL in clinical settings. 
It should be reminded that CLL is the most common form of adult leukemia in the 
western world (Riches et al., 2011). CLL is primarily a disease of the elderly with two thirds of 
patients being 65 years of age at the time of diagnosis (Riches et al., 2011). CLL is often initially 
diagnosed in the asymptomatic stages where watchful waiting is the primary course of treatment 
(Riches et al., 2011). However, approximately 50% of these patients will progress to advanced, 
symptomatic stages (Shanafelt & Call, 2004).  Progression to symptomatic stages is associated 
with shortened survival and need for therapy (Shanafelt & Call, 2004). Despite the success of 
current treatment options, such as FCR (fludarabine, cyclophosphamide and rituximab), many 
patients develop drug resistance and disease relapse (Riches et al., 2011; Shanafelt & Call, 2004; 
Silber et al., 1994).  Additionally, clinical treatment of CLL in patients who require aggressive 
treatment is limited due to significant side-effect profiles which are often too toxic for the elderly 
or those with co-morbidities (Riches et al., 2011). As such, clinical treatment of CLL is often 
hindered by progressive drug resistance and drug-induced toxicities (Riches et al., 2011). 
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Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic 
CLL to symptomatic CLL or enhance the effects of actively used chemotherapeutic drugs in 
patients who require therapy would be clinically beneficial. Thus, the application of n-3 as a 
novel therapeutic option for CLL is of considerable interest. In the following chapters, the 
application of n-3 fatty acids, particularly EPA and DHA, as therapeutic options for CLL will be 
explored through both in vitro studies as well as clinical studies with the aim of providing 
scientific insight into the potential use of n-3 as therapeutic options for the treatment of CLL.  
  
44 
 
REFERENCES 
 
Alfranca, A., Iniguez, M. A., Fresno, M., & Redondo, J. M. (2006). Prostanoid signal 
transduction and gene expression in the endothelium: role in cardiovascular diseases. 
Cardiovasc Res, 70(3), 446-456. doi: 10.1016/j.cardiores.2005.12.020 
Arnold, C., Konkel, A., Fischer, R., & Schunck, W. H. (2010). Cytochrome P450-dependent 
metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol 
Rep, 62(3), 536-547.  
Balkwill, F., & Coussens, L. M. (2004). Cancer: an inflammatory link. Nature, 431(7007), 405-
406. doi: 10.1038/431405a 
Barnes, N., Haywood, P., Flint, P., Knox, W. F., & Bundred, N. J. (2006). Survivin expression in 
in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J 
Cancer, 94(2), 253-258. doi: 10.1038/sj.bjc.6602932 
Bougnoux, P., Germain, E., Chajes, V., Hubert, B., Lhuillery, C., Le Floch, O., . . . Calais, G. 
(1999). Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid 
level in locally advanced breast carcinoma. Br J Cancer, 79(11-12), 1765-1769. doi: 
10.1038/sj.bjc.6690281 
Bougnoux, P., Hajjaji, N., Ferrasson, M. N., Giraudeau, B., Couet, C., & Le Floch, O. (2009). 
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic 
acid: a phase II trial. Br J Cancer, 101(12), 1978-1985. doi: 10.1038/sj.bjc.6605441 
Braun, T., Carvalho, G., Fabre, C., Grosjean, J., Fenaux, P., & Kroemer, G. (2006). Targeting 
NF-kappaB in hematologic malignancies. Cell Death Differ, 13(5), 748-758. doi: 
10.1038/sj.cdd.4401874 
45 
 
Buchanan, F. G., Wang, D., Bargiacchi, F., & DuBois, R. N. (2003). Prostaglandin E2 regulates 
cell migration via the intracellular activation of the epidermal growth factor receptor. J 
Biol Chem, 278(37), 35451-35457. doi: 10.1074/jbc.M302474200 
Calder, P. C. (2009). Polyunsaturated fatty acids and inflammatory processes: New twists in an 
old tale. Biochimie, 91(6), 791-795. doi: 10.1016/j.biochi.2009.01.008 
Cathcart, M. C., Lysaght, J., & Pidgeon, G. P. (2011). Eicosanoid signalling pathways in the 
development and progression of colorectal cancer: novel approaches for 
prevention/intervention. Cancer Metastasis Rev, 30(3-4), 363-385. doi: 10.1007/s10555-
011-9324-x 
Cha, M. C., Meckling, K. A., & Stewart, C. (2002). Dietary docosahexaenoic acid levels 
influence the outcome of arabinosylcytosine chemotherapy in L1210 leukemic mice. Nutr 
Cancer, 44(2), 176-181. doi: 10.1207/s15327914nc4402_09 
Chan, A. T., Ogino, S., & Fuchs, C. S. (2007). Aspirin and the risk of colorectal cancer in 
relation to the expression of COX-2. N Engl J Med, 356(21), 2131-2142. doi: 
10.1056/NEJMoa067208 
Clevers, H. (2004). At the crossroads of inflammation and cancer. Cell, 118(6), 671-674. doi: 
10.1016/j.cell.2004.09.005 
Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., . . . Montserrat, E. 
(2003). ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations 
in chronic lymphocytic leukemia. N Engl J Med, 348(18), 1764-1775. doi: 
10.1056/NEJMoa023143 
46 
 
Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., . . . Chiorazzi, N. (1999). 
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic 
lymphocytic leukemia. Blood, 94(6), 1840-1847.  
Darnell, J. E., Jr. (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer, 
2(10), 740-749. doi: 10.1038/nrc906 
Das, U. N., & Madhavi, N. (2011). Effect of polyunsaturated fatty acids on drug-sensitive and 
resistant tumor cells in vitro. Lipids Health Dis, 10, 159. doi: 10.1186/1476-511X-10-159 
1476-511X-10-159 [pii] 
Das, U. N., Madhavi, N., Sravan Kumar, G., Padma, M., & Sangeetha, P. (1998). Can tumour 
cell drug resistance be reversed by essential fatty acids and their metabolites? 
Prostaglandins Leukot Essent Fatty Acids, 58(1), 39-54.  
Dekoj, T., Lee, S., Desai, S., Trevino, J., Babcock, T. A., Helton, W. S., & Espat, N. J. (2007). 
G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model. J 
Surg Res, 139(1), 106-112. doi: S0022-4804(06)00559-2 [pii] 
10.1016/j.jss.2006.10.024 
Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A. M., Capelli, G., . . . 
Amadori, S. (2001). Clinical significance of CD38 expression in chronic lymphocytic 
leukemia. Blood, 98(9), 2633-2639.  
Ditsworth, D., & Zong, W. X. (2004). NF-kappaB: key mediator of inflammation-associated 
cancer. Cancer Biol Ther, 3(12), 1214-1216.  
Dreger, P. (2009). Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc 
Hematol Educ Program, 602-609. doi: 10.1182/asheducation-2009.1.602 
47 
 
Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E., & Hallek, M. (2011). Chronic 
lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol, 22 Suppl 6, vi50-54. doi: 10.1093/annonc/mdr377 
Gaidano, G., Foa, R., & Dalla-Favera, R. (2012). Molecular pathogenesis of chronic lymphocytic 
leukemia. J Clin Invest, 122(10), 3432-3438. doi: 10.1172/JCI64101 
64101 [pii] 
Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., . . . Darabi, 
M. (2012). Omega-3 fatty acids are protective against paclitaxel-induced peripheral 
neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer, 12, 355. 
doi: 10.1186/1471-2407-12-355 
Gilmore, T. D. (1999). Multiple mutations contribute to the oncogenicity of the retroviral 
oncoprotein v-Rel. Oncogene, 18(49), 6925-6937. doi: 10.1038/sj.onc.1203222 
Greenberg, M. E., Li, X. M., Gugiu, B. G., Gu, X., Qin, J., Salomon, R. G., & Hazen, S. L. 
(2008). The lipid whisker model of the structure of oxidized cell membranes. J Biol 
Chem, 283(4), 2385-2396. doi: 10.1074/jbc.M707348200 
Greenhough, A., Smartt, H. J., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & 
Kaidi, A. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and 
adaptation to the tumour microenvironment. Carcinogenesis, 30(3), 377-386. doi: 
10.1093/carcin/bgp014 
Guffy, M. M., North, J. A., & Burns, C. P. (1984). Effect of cellular fatty acid alteration on 
adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res, 44(5), 1863-
1866.  
48 
 
Guo, D. L., Zhou, H., Wu, Y., Zhou, F., Zhang, X. M., Xu, G. Y., & Wen, H. P. (2011). [Role of 
NF-kappaB in factor VIIa-induced proliferation and migration of colon cancer cell line 
SW620 cells]. Zhonghua Zhong Liu Za Zhi, 33(9), 649-653.  
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S., Jr. (1999). NF-
kappaB controls cell growth and differentiation through transcriptional regulation of 
cyclin D1. Mol Cell Biol, 19(8), 5785-5799.  
Haeggstrom, J. Z., Rinaldo-Matthis, A., Wheelock, C. E., & Wetterholm, A. (2010). Advances in 
eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun, 
396(1), 135-139. doi: 10.1016/j.bbrc.2010.03.140 
Hagemann, T., Biswas, S. K., Lawrence, T., Sica, A., & Lewis, C. E. (2009). Regulation of 
macrophage function in tumors: the multifaceted role of NF-kappaB. Blood, 113(14), 
3139-3146. doi: 10.1182/blood-2008-12-172825 
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999). Unmutated Ig 
V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. 
Blood, 94(6), 1848-1854.  
Hardman, W. E., Avula, C. P., Fernandes, G., & Cameron, I. L. (2001). Three percent dietary 
fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast 
cancer xenografts. Clin Cancer Res, 7(7), 2041-2049.  
Hayden, M. S., & Ghosh, S. (2012). NF-kappaB, the first quarter-century: remarkable progress 
and outstanding questions. Genes Dev, 26(3), 203-234. doi: 10.1101/gad.183434.111 
Heller, A. R., Rossel, T., Gottschlich, B., Tiebel, O., Menschikowski, M., Litz, R. J., . . . Koch, 
T. (2004). Omega-3 fatty acids improve liver and pancreas function in postoperative 
cancer patients. Int J Cancer, 111(4), 611-616. doi: 10.1002/ijc.20291 
49 
 
Hewamana, S., Alghazal, S., Lin, T. T., Clement, M., Jenkins, C., Guzman, M. L., . . . Pepper, C. 
(2008). The NF-kappaB subunit Rel A is associated with in vitro survival and clinical 
disease progression in chronic lymphocytic leukemia and represents a promising 
therapeutic target. Blood, 111(9), 4681-4689. doi: 10.1182/blood-2007-11-125278 
Hewamana, S., Lin, T. T., Jenkins, C., Burnett, A. K., Jordan, C. T., Fegan, C., . . . Pepper, C. 
(2008). The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic 
subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. 
Clin Cancer Res, 14(24), 8102-8111. doi: 10.1158/1078-0432.ccr-08-1673 
Hewamana, S., Lin, T. T., Rowntree, C., Karunanithi, K., Pratt, G., Hills, R., . . . Pepper, C. 
(2009). Rel a is an independent biomarker of clinical outcome in chronic lymphocytic 
leukemia. J Clin Oncol, 27(5), 763-769. doi: 10.1200/jco.2008.19.1114 
Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., & Strauss, M. (1999). NF-
kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-
phase transition. Mol Cell Biol, 19(4), 2690-2698.  
Huang, S., Robinson, J. B., Deguzman, A., Bucana, C. D., & Fidler, I. J. (2000). Blockade of 
nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human 
ovarian cancer cells by suppressing expression of vascular endothelial growth factor and 
interleukin 8. Cancer Res, 60(19), 5334-5339.  
Hyde, C. A., & Missailidis, S. (2009). Inhibition of arachidonic acid metabolism and its 
implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol, 9(6), 
701-715. doi: 10.1016/j.intimp.2009.02.003 
Karin, M., Cao, Y., Greten, F. R., & Li, Z. W. (2002). NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer, 2(4), 301-310. doi: 10.1038/nrc780 
50 
 
Karin, M., & Lin, A. (2002). NF-kappaB at the crossroads of life and death. Nat Immunol, 3(3), 
221-227. doi: 10.1038/ni0302-221 
Kim, H., Choi, J. A., Park, G. S., & Kim, J. H. (2012). BLT2 up-regulates interleukin-8 
production and promotes the invasiveness of breast cancer cells. PLoS One, 7(11), 
e49186. doi: 10.1371/journal.pone.0049186 
Krysan, K., Dohadwala, M., Luo, J., Lin, Y., Zhu, L., Heuze-Vourc'h, N., . . . Dubinett, S. 
(2004). Cyclooxygenase-2-dependent expression of survivin in non-small cell lung 
cancer. Chest, 125(5 Suppl), 140S.  
Lanasa, M. C. (2010). Novel insights into the biology of CLL. Hematology Am Soc Hematol 
Educ Program, 2010, 70-76. doi: 10.1182/asheducation-2010.1.70 
Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb 
Perspect Biol, 1(6), a001651. doi: 10.1101/cshperspect.a001651 
Lee, L. M., Pan, C. C., Cheng, C. J., Chi, C. W., & Liu, T. Y. (2001). Expression of 
cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. 
Anticancer Res, 21(2B), 1291-1294.  
Lekovic, D., Mihaljevic, B., Kraguljac-Kurtovic, N., Peruncic-Jovanovic, M., Bogdanovic, A., 
Colovic, M., & Gotic, M. (2011). [Prognostic significance of new biological markers in 
chronic lymphocytic leukaemia]. Srp Arh Celok Lek, 139(11-12), 753-758.  
Li, F., & Sethi, G. (2010). Targeting transcription factor NF-kappaB to overcome 
chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta, 1805(2), 
167-180. doi: 10.1016/j.bbcan.2010.01.002 
Li, J., Lau, G., Chen, L., Yuan, Y. F., Huang, J., Luk, J. M., . . . Guan, X. Y. (2012). Interleukin 
23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix 
51 
 
metalloproteinase 9 expression. PLoS One, 7(9), e46264. doi: 
10.1371/journal.pone.0046264 
Linet, M. S., Schubauer-Berigan, M. K., Weisenburger, D. D., Richardson, D. B., Landgren, O., 
Blair, A., . . . Dores, G. M. (2007). Chronic lymphocytic leukaemia: an overview of 
aetiology in light of recent developments in classification and pathogenesis. Br J 
Haematol, 139(5), 672-686. doi: 10.1111/j.1365-2141.2007.06847.x 
Liou, Y. A., King, D. J., Zibrik, D., & Innis, S. M. (2007). Decreasing linoleic acid with constant 
alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma 
phospholipids in healthy men. J Nutr, 137(4), 945-952.  
Luo, P., & Wang, M. H. (2011). Eicosanoids, beta-cell function, and diabetes. Prostaglandins 
Other Lipid Mediat, 95(1-4), 1-10. doi: 10.1016/j.prostaglandins.2011.06.001 
Messmer, B. T., Messmer, D., Allen, S. L., Kolitz, J. E., Kudalkar, P., Cesar, D., . . . Chiorazzi, 
N. (2005). In vivo measurements document the dynamic cellular kinetics of chronic 
lymphocytic leukemia B cells. J Clin Invest, 115(3), 755-764. doi: 10.1172/jci23409 
Montserrat, E., Sanchez-Bisono, J., Vinolas, N., & Rozman, C. (1986). Lymphocyte doubling 
time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J 
Haematol, 62(3), 567-575.  
Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., Reiman, T., & Mazurak, V. C. 
(2011a). Nutritional intervention with fish oil provides a benefit over standard of care for 
weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving 
chemotherapy. Cancer, 117(8), 1775-1782. doi: 10.1002/cncr.25709 
Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., Reiman, T., & Mazurak, V. C. 
(2011b). Supplementation with fish oil increases first-line chemotherapy efficacy in 
52 
 
patients with advanced nonsmall cell lung cancer. Cancer, 117(16), 3774-3780. doi: 
10.1002/cncr.25933 
Niki, E. (2009). Lipid peroxidation: physiological levels and dual biological effects. Free Radic 
Biol Med, 47(5), 469-484. doi: 10.1016/j.freeradbiomed.2009.05.032 
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002). 
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon 
cancer growth and gastrointestinal hypertrophy. Nat Med, 8(3), 289-293. doi: 
10.1038/nm0302-289 
Parthasarathy, S., Santanam, N., Ramachandran, S., & Meilhac, O. (2000). Potential role of 
oxidized lipids and lipoproteins in antioxidant defense. Free Radic Res, 33(3), 197-215.  
Patterson, E., Wall, R., Fitzgerald, G. F., Ross, R. P., & Stanton, C. (2012). Health implications 
of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab, 2012, 539426. doi: 
10.1155/2012/539426 
Pepper, C., Mahdi, J. G., Buggins, A. G., Hewamana, S., Walsby, E., Mahdi, E., . . . Fegan, C. 
(2011). Two novel aspirin analogues show selective cytotoxicity in primary chronic 
lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. 
Cell Prolif, 44(4), 380-390. doi: 10.1111/j.1365-2184.2011.00760.x 
Petersen, E. S., Kelley, E. E., Modest, E. J., & Burns, C. P. (1992). Membrane lipid modification 
and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res, 
52(22), 6263-6269.  
Qin, J., Wang, Y., Bai, Y., Yang, K., Mao, Q., Lin, Y., . . . Xie, L. (2012). Epigallocatechin-3-
gallate inhibits bladder cancer cell invasion via suppression of NF-kappaBmediated 
53 
 
matrix metalloproteinase-9 expression. Mol Med Rep, 6(5), 1040-1044. doi: 
10.3892/mmr.2012.1054 
Rai, K. R., & Jain, P. (2011). Advances in the clinical staging of chronic lymphocytic leukemia. 
Clin Chem, 57(12), 1771-1772. doi: 10.1373/clinchem.2010.159004 
Reader, J., Holt, D., & Fulton, A. (2011). Prostaglandin E2 EP receptors as therapeutic targets in 
breast cancer. Cancer Metastasis Rev, 30(3-4), 449-463. doi: 10.1007/s10555-011-9303-
2 
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arterioscler Thromb 
Vasc Biol, 31(5), 986-1000. doi: 10.1161/atvbaha.110.207449 
Riches, J. C., Ramsay, A. G., & Gribben, J. G. (2011). Chronic lymphocytic leukemia: an update 
on biology and treatment. Curr Oncol Rep, 13(5), 379-385. doi: 10.1007/s11912-011-
0188-6 
Rodriguez-Vicente, A. E., Diaz, M. G., & Hernandez-Rivas, J. M. (2013). Chronic lymphocytic 
leukemia: a clinical and molecular heterogenous disease. Cancer Genet, 206(3), 49-62. 
doi: 10.1016/j.cancergen.2013.01.003 
Ryan, E. P., Pollock, S. J., Kaur, K., Felgar, R. E., Bernstein, S. H., Chiorazzi, N., & Phipps, R. 
P. (2006). Constitutive and activation-inducible cyclooxygenase-2 expression enhances 
survival of chronic lymphocytic leukemia B cells. Clin Immunol, 120(1), 76-90. doi: 
10.1016/j.clim.2005.12.012 
Schmitz, G., & Ecker, J. (2008). The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res, 
47(2), 147-155. doi: 10.1016/j.plipres.2007.12.004 
Secchiero, P., Barbarotto, E., Gonelli, A., Tiribelli, M., Zerbinati, C., Celeghini, C., . . . Zauli, G. 
(2005). Potential pathogenetic implications of cyclooxygenase-2 overexpression in B 
54 
 
chronic lymphoid leukemia cells. Am J Pathol, 167(6), 1599-1607. doi: 10.1016/s0002-
9440(10)61244-8 
Serhan, C. N., & Petasis, N. A. (2011). Resolvins and protectins in inflammation resolution. 
Chem Rev, 111(10), 5922-5943. doi: 10.1021/cr100396c 
Shanafelt, T. D., & Call, T. G. (2004). Current approach to diagnosis and management of chronic 
lymphocytic leukemia. Mayo Clin Proc, 79(3), 388-398. doi: 10.4065/79.3.388 
Silber, R., Degar, B., Costin, D., Newcomb, E. W., Mani, M., Rosenberg, C. R., . . . Potmesil, M. 
(1994). Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic 
leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood, 84(10), 3440-
3446.  
Simopoulos, A. P. (1991). Omega-3 fatty acids in health and disease and in growth and 
development. Am J Clin Nutr, 54(3), 438-463.  
Simopoulos, A. P. (2000). Human requirement for N-3 polyunsaturated fatty acids. Poult Sci, 
79(7), 961-970.  
Simopoulos, A. P. (2002). The importance of the ratio of omega-6/omega-3 essential fatty acids. 
Biomed Pharmacother, 56(8), 365-379.  
Simopoulos, A. P. (2008). The importance of the omega-6/omega-3 fatty acid ratio in 
cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood), 233(6), 
674-688. doi: 10.3181/0711-mr-311 
Sun, S. C. (2011). Non-canonical NF-kappaB signaling pathway. Cell Res, 21(1), 71-85. doi: 
10.1038/cr.2010.177 
Tanaka, T., Nakayama, H., Yoshitake, Y., Irie, A., Nagata, M., Kawahara, K., . . . Shinohara, M. 
(2012). Selective inhibition of nuclear factor-kappaB by nuclear factor-kappaB essential 
55 
 
modulator-binding domain peptide suppresses the metastasis of highly metastatic oral 
squamous cell carcinoma. Cancer Sci, 103(3), 455-463. doi: 10.1111/j.1349-
7006.2011.02174.x 
Tang, D. W., Lin, S. C., Chang, K. W., Chi, C. W., Chang, C. S., & Liu, T. Y. (2003). Elevated 
expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for 
COX-2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med, 
32(9), 522-529.  
Tang, X., Liu, D., Shishodia, S., Ozburn, N., Behrens, C., Lee, J. J., . . . Wistuba, II. (2006). 
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and 
preneoplastic lesions. Cancer, 107(11), 2637-2646. doi: 10.1002/cncr.22315 
van der Meij, B. S., Langius, J. A., Spreeuwenberg, M. D., Slootmaker, S. M., Paul, M. A., Smit, 
E. F., & van Leeuwen, P. A. (2012). Oral nutritional supplements containing n-3 
polyunsaturated fatty acids affect quality of life and functional status in lung cancer 
patients during multimodality treatment: an RCT. Eur J Clin Nutr, 66(3), 399-404. doi: 
10.1038/ejcn.2011.214 
Wang, C. Y., Cusack, J. C., Jr., Liu, R., & Baldwin, A. S., Jr. (1999). Control of inducible 
chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition 
of NF-kappaB. Nat Med, 5(4), 412-417. doi: 10.1038/7410 
Wang, C. Y., Mayo, M. W., & Baldwin, A. S., Jr. (1996). TNF- and cancer therapy-induced 
apoptosis: potentiation by inhibition of NF-kappaB. Science, 274(5288), 784-787.  
Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nat Rev Cancer, 10(3), 181-193. 
doi: 10.1038/nrc2809 
56 
 
Wiestner, A., Rosenwald, A., Barry, T. S., Wright, G., Davis, R. E., Henrickson, S. E., . . . 
Staudt, L. M. (2003). ZAP-70 expression identifies a chronic lymphocytic leukemia 
subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct 
gene expression profile. Blood, 101(12), 4944-4951. doi: 10.1182/blood-2002-10-3306 
Zhang, D., Jin, X., Wang, F., Wang, S., Deng, C., Gao, Z., & Guo, C. (2007). Combined 
prognostic value of both RelA and IkappaB-alpha expression in human non-small cell 
lung cancer. Ann Surg Oncol, 14(12), 3581-3592. doi: 10.1245/s10434-007-9560-z 
Zmijewski, J. W., Landar, A., Watanabe, N., Dickinson, D. A., Noguchi, N., & Darley-Usmar, 
V. M. (2005). Cell signalling by oxidized lipids and the role of reactive oxygen species in 
the endothelium. Biochem Soc Trans, 33(Pt 6), 1385-1389. doi: 10.1042/bst20051385 
 
  
57 
 
CHAPTER 2: INHIBITION OF NUCLEAR FACTOR 
KAPPA B ACTIVATION IN EARLY-STAGE CHRONIC 
LYMPHOCYTIC LEUKEMIA BY OMEGA-3 FATTY 
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ABSTRACT 
 
Targeting the nuclear factor kappa B (NF B) pathway is proposed as a therapy for 
chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) 
supplement would suppress NF B activation in lymphocytes of Rai Stage 0-1 CLL patients. The 
initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day. After n-3 consumption: (1) 
plasma n-3 increased; (2) NF B activation was suppressed in lymphocytes; (3) in vitro 
sensitivity of lymphocytes to doxorubicin was increased; and (4) expression of 32 genes in 
lymphocytes was significantly decreased.  
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INTRODUCTION 
 
Chronic lymphocytic leukemia is a B-cell leukemia. During the early stages (Rai Stage 0- 
1) of CLL patients, no therapy is required (Robak, 2007). However, about 50% of these patients 
will progress to more advanced stages (Shanafelt & Call, 2004). Progression to later stages (Rai 
Stage 2-4) disease is associated with shortened survival and the need for chemotherapy 
(Shanafelt & Call, 2004). Therefore, early identification of progression potential and a 
therapeutic intervention that could prevent or delay disease progression without undesirable side 
effects would be clinically beneficial.  
Nuclear factor kappa B (NF B) belongs to a family of transcription factors that plays a 
key role in inflammatory and stress responses as well as in tumor cell resistance to apoptosis 
(Balkwill & Coussens, 2004; Darnell, 2002).
 
Several studies suggest that NF B family members 
are involved in cancer development (Clevers, 2004; Munzert et al., 2002). NF B can promote 
oncogenesis by virtue of its capacity to regulate the expression of a large number of genes that 
modulate apoptosis, proliferation, inflammation, tumor metastasis and angiogenesis (Clevers, 
2004).
 
Increased, constitutive activity of NF B is observed in various solid tumors and in 
hematological malignancies (Cilloni, Martinelli, Messa, Baccarani, & Saglio, 2007; Darnell, 
2002; Ditsworth & Zong, 2004). 
There is increasing evidence that NF B may play a key role in controlling apoptosis and 
disease progression in hematologic malignancies (Cilloni et al., 2007). Previous studies have 
demonstrated that CLL cells have elevated NF B DNA-binding activity compared to normal B 
cells (Braun et al., 2006; Endo et al., 2007) and that inhibition of NF B activation in vitro 
resulted in apoptosis of the malignant cells (Braun et al., 2006; Endo et al., 2007). NF B is 
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currently considered an important target for the development of novel drugs for the treatment of 
hematological malignancies, especially CLL, and of solid tumors (Braun et al., 2006; Cilloni et 
al., 2007; Cilloni et al., 2006; Darnell, 2002; Hewamana et al., 2008; Hewamana et al., 2009).
 
Omega-3 and omega-6 polyunsaturated fatty acids are essential fatty acids which must be 
obtained from diet. The ratio of omega-3 to omega-6 in the average western diet is heavily 
weighted in favor of omega-6 (Simopoulos, 2000, 2002). Long chain omega-3 fatty acids 
(eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)) are primarily found in fish oils 
(Simopoulos, 1991). However, the 18 carbon n-3 FA, alpha linolenic acid (ALA), is also found 
in plant derived foods, especially canola or flax oil and walnuts. Omega-3 fatty acids have 
consistently been shown in vitro and in vivo to slow growth of cancer of various types and to 
increase the efficacy of chemotherapy (Bougnoux et al., 1999; Hardman, 2002). The omega-6 
fatty acid, linoleic acid (LA), is found in corn and soybean oils. The elongated, desaturated 
product of LA, arachidonic acid (AA), is found in the meat of animals that consumed corn or 
soybeans and can be synthesized by humans. Growing evidence supports the notion that AA and 
its metabolites have a significant role in tumor promotion (Hyde & Missailidis, 2009).  
Our preliminary work and that of others (Narayanan, Narayanan, & Reddy, 2005; Ross, 
Maingay, Fearon, Sangster, & Powell, 2003)
 
indicates that supplementation with omega-3 fatty 
acids (n-3) inhibits NF B activity of many cancer types in vitro and in mouse models. We did 
not know if this inhibitory effect would translate to humans. The primary objective of this study 
was to determine if consumption of an n-3 supplement would suppress the activation of NF B in 
the lymphocytes of patients with early stage (Rai Stage 0-1) CLL. We hypothesized that dietary 
omega-3 supplementation would decrease the activation of NF B in malignant lymphocytes 
from patients with CLL in early stages.  In this pilot study, we assayed NF B activity in 
61 
 
lymphocytes from patients with early stage (Rai Stage 0-1) CLL before and after up to 12 
months of oral omega-3 supplementation. Secondary objectives were to evaluate the effects of n-
3 supplementation on 1) fatty acid composition of lymphocytes, 2) concentration of fatty acids in 
the plasma before and after consumption of n-3, 3) the in vitro sensitivity of the patients‟ 
lymphocytes to doxorubicin and 4) changes in lymphocyte gene expression. 
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METHODS 
IRB and informed consent 
The Marshall University Institutional Review Board reviewed and approved the protocol 
for this study under a Federal Wide Assurance (FWA #00002704) with the Office of Human 
Research Protections. The trial was listed at www.clinicaltrials.gov/, number NCT00899353. 
The purpose of the study and possible risks and benefits were explained prior to obtaining signed 
informed consent from all research participants. Whenever possible, specimens were obtained at 
the same time as blood was being obtained for routine clinical tests.  
Subject Population 
Subjects participating in this pilot study had been diagnosed with chronic lymphocytic 
leukemia in the early stages (Rai stage 0-1) at the time of entry according to standard clinical 
practice, and did not require therapy. General eligibilities were that participants had to be older 
than 18 years of age with no maximum age limit, free of co-morbid conditions with a life 
expectancy of more than 12 months, patients who have taken omega-3 or other fish oil 
containing nutritional supplements prior to study accrual, discontinued their use for minimum of 
2 months before enrollment, and patients should have an ECOG (Eastern Cooperative Oncology 
Group) performance score of 0, 1 or 2.   
After obtaining informed consent, two 7 ml tubes of Ethylenediaminetetraacetic acid 
(EDTA)-anticoagulated blood were obtained (time 0) as a baseline and at each subsequent 
monthly visit. One month after the initial specimen, each patient started n-3 consumption with a 
dose of 3 capsules (2.4g of n-3) per day (1 capsule/meal). Dosage was increased to 6 capsules 
(4.8g of n-3) and then to 9 capsules (7.2g of n-3) per day (up to 3/meal) at monthly intervals A 
schematic of dosing scheme is provided in Appendix, Supplementary Figure 2.1). If a patient did 
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not want to consume the increased dosages, he/she was allowed to continue in the study at a 
lower dose. Results of fatty acid composition in lymphocytes and plasma, NF B activity, 
doxorubicin sensitivity, and mRNA expression of the lymphocytes up to consumption of 7.2 g 
per day for three months are reported. No placebo was used, rather after-consumption data were 
compared to baseline data.  
Normal participants 
Five normal healthy volunteers were recruited. These volunteers did not receive omega-3 
supplementation and served to establish normal values for NF B activation in lymphocytes. 
Description of omega 3 supplement 
The supplement was a commercially available (Res-Q 1250, N3 Oceanic, Palm, PA) fish 
oil concentrate prepared by molecular distillation. It was free from pollutants, PCB‟s, pesticides 
and mercury. Each capsule contained about 400mg of EPA, 300mg of DHA and 100-150 mg of 
other omega 3 fatty acids. Thus, consumption of 3, 6, or 9 capsules/day yielded 2.4 g, 4.8 g, or 
7.2 g/day of n-3, respectively. These amounts are all below the maximum tolerated dose of 13.1 
g/day EPA + DHA reported by Burns et al. (Burns et al., 1999). Potential dose limiting events 
were diarrhea, stomach upset or dislike of taking the capsules.  
Platelet function 
Tests of platelet function were performed in the clinical laboratory at Cabell Huntington 
Hospital. For these tests, anticoagulated fresh, whole blood is rapidly passed through a small 
hole in a membrane coated with either collagen and adenosine diphosphate (ADP) 
(Collagen/ADP) or collagen and epinephrine (Collagen/EPI). Platelets adhere to and gradually 
block the small hole in the center of each membrane. The time, in seconds, for blood to close the 
hole is the Closure Time (CT).  
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Molecular Testing 
 Tests for cytogenetic alterations were performed using standard tests (culture and 
banding) at Cabell Huntington Hospital. Interphase fluorescence in situ hybridization (FISH) was 
performed using a multiprobe panel (Vysis, Abbot Molecular, Abbott Park, IL, USA.) targeting 
five prognosis related CLL anomalies according to routine techniques at the Laboratory 
Corporation of America. 
Lymphocyte Isolation 
EDTA anticoagulated blood specimens (7 ml x 2) were placed on ice until retrieved by 
research laboratory personnel (within 2 hours of collection). The sample was centrifuged at 400 
x g for 10 minutes and about 2 ml of plasma was removed, divided to 0.5 ml aliquots and stored 
at -80°C for future assay. The buffy coat, some plasma and adjacent red blood cells were 
removed. A Ficoll-Paque (GE Healthcare, Piscataway, NJ) gradient was used to isolate 
lymphocytes, according to manufacturer‟s protocol. Following Ficoll-Paque separation, greater 
than 95% of cells were lymphocytes (Silber et al., 1994). Since there was not 100% lymphocyte 
isolation, samples were referred to as WBCs. WBCs were washed twice with a glucose 
containing balanced salt solution, counted and divided into appropriate aliquots for NF B 
activity assay, doxorubicin sensitivity, mRNA assay and for gas chromatography analysis.  
White and red blood cell fatty acid composition 
The fatty acid compositions of WBCs or RBCs were assessed using gas chromatography 
of samples collected prior to initiation of the omega 3 supplement (baseline, time 0) and after 
consumption of each dose of the supplement for 1 month. The assay was performed as 
previously published (Witte, Salazar, Ballester, & Hardman, 2010). 
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Plasma Fatty Acid Concentrations 
The concentrations of 10 analyzed fatty acids in plasma were assessed using gas 
chromatography, according to our routine techniques, prior to initiation of the omega-3 
supplement (baseline, time 0) and after consumption of each dose of the supplement for 1 month. 
Two hundred forty microliters to 400 µL of plasma was added to distilled water with 0.1% BHT 
for a final volume of 700 µL to prevent fatty acid oxidation. One hundred microliters of 1mM 
nervonic acid was added to each sample. Nervonic acid served as the internal standard as 
previously published (Shantha & Ackman, 1990). Lipids were extracted with 
chloroform/methanol, then methylated. Methylated lipids were separated and identified using gas 
chromatography as previously published (Witte et al., 2010). Fatty acid methyl ester standards 
(Nu-Chek-Prep, Elysian, MN) were used for peak identification. Respective fatty acids were 
corrected for FID response and carbon response as previously described by others (Huang Yieru, 
1990; William, 1989) and initial plasma volume used (see Equation 1). We were especially 
interested in total omega 6 fatty acids, LA, gamma linolenic acid (GLA), 20:3n-6, and AA, and 
total omega-3 fatty acids, ALA, EPA, docosapentaenoic acid (DPA) and DHA. 
 
Protein extraction 
Protein extraction from lymphocytes was performed using Thermo Scientific Mammalian 
Protein Extraction Reagent (M-PER) according to manufacturer‟s protocol. Total protein 
concentration was determined using Pierce Coomassie (Bradford) Protein Assay Kit protocol.  
Equation 1: [Fatty Acid] 
[Fatty Acid] = AUC of fatty acid x [Nervonic acid] x FID Response Factor x Carbon Response Factor x Final Volume of Fatty Acid 
  AUC of Nervonic Acid          Initial Volume of Fatty Acid 
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A standard curve was used to determine the protein concentration of each unknown 
sample.  
NF B Activity Assay 
NF B activities in patient specimens, positive and negative controls were evaluated using 
a Thermo Scientific Transcription Factor kit for NF B p50, according to manufacturer‟s 
protocol. The kit contains streptavidin-coated 96-well plates and an NF B biotinylated-
consensus sequence. Only the active form of NF B will bind to the DNA consensus sequence. 
Protein extracts containing 1-15µg of protein/well were added in triplicates to appropriate 
microplate wells. Luminescence resulting from a reaction with bound NF B was detected using 
a Berthold Centro LB960 Luminometer and analyzed with MikroWin 2000 ver. 1.08. NF B 
activity was normalized by luminescence units/µg of protein per well.  
Doxorubicin sensitivity assay 
About 5 x 10
5
 lymphocytes were diluted into 500 µl of RPMI/15% fetal bovine serum, 
100 units/mL penicillin, and 0.1 mg/mL streptomycin media. Cells were aliquoted in triplicates 
in microtubes and treated with 0, 0.5, 1, 1.5, 2, or 2.5 µM doxorubicin (DOX) for 20 hours at 
37°C. Lymphocytes were centrifuged at 600 x g for 10 minutes then DOX/media was removed. 
A standard colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay was used to determine remaining live cells compared to the untreated sample. MTT is a 
yellow tetrazolium dye that is reduced to a purple formazan dye in living cells by reductase 
enzymes. The relative number of viable cells can be assessed by spectrophotometric 
measurement of formazan production relative to control specimens.  
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mRNA extraction, microarray and statistical analyses 
 Expression profiling was performed on mRNA from 5 patients characterized with higher 
initial NF B activity and 4 patients with lower initial NF B activity. Remaining patients were 
not assayed due to limited samples or to insufficient n-3 consumption time points.  
About 1 million WBCs from each patient were homogenized in Tri-Reagent LS (Sigma) 
following the manufacturer‟s protocol to isolate mRNA. RNA concentration and purity was 
determined using a Nanodrop ND-1000 spectrophotometer. Total RNA quality was determined 
using an Agilent BioAnalyzer (Agilent, Santa Clara, CA).  All samples had RNA Integrity 
Numbers higher than 7. 
RNA expression profiles were obtained using a universal reference microarray design.  
Total RNA, 250 ng, was labeled using QuickAmp labeling kit (Agilent) and Cy3-CTP and Cy5-
CTP from Perkin Elmer (Waltham, MA) according to previously described methods  (Syed & 
Threadgill, 2006). The RNA samples isolated from patient‟s peripheral blood were labeled using 
Cy3-CTP and the universal human reference RNA was labeled with Cy5-CTP.  Following 
purification of labeled cRNA, 825 ng of Cy3- and Cy5-labeled samples were combined and 
hybridized for 17 hours at 65
o
C onto Whole Human Genome 4x44k microarrays (Agilent). 
Arrays were scanned and lowest-normalized data extracted to tab-delimited text files using 
Agilent Feature Extraction software (version 10.5.1.1).   
The log ratio of expression of the sample to that of universal reference RNA was 
computed, with values removed for control spots, spots identified as not well above background 
on both channels, and spots identified as non-uniform or saturated on either channel. Values 
from all arrays were compiled into a single table. Spots for which more than 50% of the samples 
had missing values were removed from further analysis. The Agilent array platform contains a 
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number of probes that are spotted multiple times on the array; for these probes the average across 
replicate spots was computed. Missing values were then imputed using the K nearest neighbor 
algorithm as implemented by the R/Bioconductor (www.r-project.org, www.bioconductor.org) 
impute.knn function in the "impute" package. A two-class Significance Analysis of Microarrays
 
(Tusher, Tibshirani, & Chu, 2001), using the SAM function in the R/Bioconductor package 
"siggenes", was performed between the baseline mRNA expressions and the mRNA expressions 
after consumption of highest amount of omega-3 on: 1) samples with higher initial NF B 
activity (patients 1 to 5, n= 5 patients) or 2) with lower initial NF B activity (patients 6 to 9, n= 
4 patients). A threshold delta value was chosen using the findDelta function from the same 
package to give a false discovery rate of 10%. The resulting list of probes was filtered for a 
minimum fold change of 1.5. For any genes represented by multiple probes in this list of 
significantly differentially expressed genes, the maximum fold change among those probes was 
reported. These analyses follow the method detailed in Tusher VG, et al. (Tusher et al., 2001). 
Microarray data are available in MIAME-complaint form at the NCBI GEO repository, 
accession number GSE29678. 
Statistical Analysis, other data 
SPSS (IBM SPSS Statistics) Version 14.0 was used for statistical analysis of other 
numeric data by Multiple Comparison using Games-Howell Post-Hoc Test. Correlation 
coefficients were calculated from least squares linear regression plots. Prism
©
 software 
(Graphpad, Inc., La Jolla, CA) was used for preparation of graphs. 
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RESULTS 
Subject characteristics 
Fifteen CLL and 5 normal participants were recruited for this pilot study. All available 
data from these patients is reported. Individual characteristics are indicated in Table 2.1.  
Graphic display of NF B data seemed to indicate 2 populations of patients. Thus, patient 
characteristics were analyzed on the basis of subjects which fell below the median NF B 
activation (< 21.4 x 10
5
 NF B luminescence units/µg of protein) or above the median NF B 
activation ( > 21.4 x 10
5
 NF B luminescence units/µg of protein ). Subject characteristics, with 
subjects divided into higher and lower initial NF B activation groups are shown in Table 2.2. 
There were no significant differences in mean age or gender of the groups. Data indicated that 
the „lower initial activation‟ patients had significantly lower absolute lymphocyte counts (Mean 
± SEM: 11.9 ± 3.2 x 10
3
 lymphocytes/µl vs 28.8 ± 4.0 x 10
3
 lymphocytes/µl; p: 0.009) and 
tended to be at lower Rai stage (stage 0, 84% vs 58%, not statistically different by Fisher exact 
test) than patients exhibiting „higher initial activation‟ of NF B at baseline.  
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Table 2. 1. Individual Patient Characteristics 
Patient Age/Gender RAI Stage 
(0-1) 
Time 
From 
Diagnosis 
to N-3 
Initiation 
(Months) 
Duration of N-
3 
Consumption 
(Months) 
Baseline 
ALC  
(10
3
/µL) 
ALC post n-3 
consumption 
(10
3
/µL) 
Fold 
Change 
in ALC 
T(14;19) Del.13q Trisomy 
12 
Del. 17p CD38 ß2M 
(mg/L) 
1 63/M 0 16 12 25.4 41.3
 
1.62 - - + - - 1.7 
2 70/F 0 8 12 30.5 52.1
 
1.71 + - - - - 1.4 
3 64/F 0 39 12 15.2 11.9 0.78 - + - - Unknown 1.6 
4 59/F 1 133
a 
12 26.3 25.2 0.96 - + - - - 2.1 
5 58/M 1 2 5 20.7 27.3 1.32 - Unknown - - + 1.3 
6 77/M 0 157 12 35.5 38.2 1.08 - + - - - unknown 
7 68/M 1 2 12 5.7 5.7 1.00 - + - - - 1.4 
8 65/F 0 5 12 20.3 18.9 0.92 - + - - - 3.5 
9 72/M 0 5 12 5.7 8.5 1.49 - - + - - 1.8 
10 63/F 0 28 12 7.5 7.9 1.05 - - - Unknown - 1.9 
11 72/F 0 35 12 8.5 9.9 1.16 - - - - - 1.8 
12 62/F Unknown 79 8 Unknown 2.5 N/A - Unknown - - unknown Unknown 
13 63/M 1 61 8 48.1 49.7 1.03 - - - - - 1.5 
14 82/F 0 11 5 7.9 9.6 1.22 - - - - - 2.4 
15 73/M 0 14 1 23.6 Unknown N/A - - + - + 3.8 
Table 2.1. Individual Patient Characteristics. Individual patient‟s age, gender, staging, time from diagnosis to n-3 initiation, duration of n-3 consumption, 
absolute lymphocyte counts (ALC) before and after n-3 consumption, fold change in ALC as compared to baseline, cytogenetics and phenotype is shown. 
Prognostics were done on samples at diagnosis of CLL. Tests for IGVH status were not performed at this institution. Prognosis - translocation between 
chromosome 14 and chromosome 19 [ t(14;19)]; and deletion of long arm of chromosome 13 (Del.13q), are associated with good prognosis; trisomy 12 is 
associated with intermediate prognosis; deletion of short arm of chromosome 17 (Del.17p), CD38 positive, and high levels of ß2-microglublin (ß2M mg/L) > 
2 are associated with poor prognosis; 
a
 patient referral, exact time of diagnosis unknown. 
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Table 2. 2. Patient Lymphocyte Count, Cytogenetics, Phenotype and NF B 
Activity 
 Total Population Baseline 
NF B 
Activity > 
Median 
Baseline NF B 
Activity < 
Median 
P-value 
Patients (n) 15 7 6  
Age  
( Mean ± SEM ) 
66; 63 - 82 
(median; range) 
64.9 ± 2.5 69.2 ± 1.6 0.192 
Rai Stage (Stage 0/1) 11/4 4/3 5/1  
Absolute Lymphocyte Count 
(10
3
/µl)  
( Mean ± SEM ) 
 
20.07; 5.7 – 48.1 
(median; range) 
 
28.8 ± 4.0 
 
11.9 ± 3.2 
 
0.009 
# with T (14;19) 1 1 0  
# with Del. 13q 5 3 2  
# with Trisomy 12 
 
3 1 2  
# CD38 +/- 2/10 1/5 1/5  
ß2M mg/L 
 ( Mean± SEM ) 
1.8; 1.3 - 3.8 
(median; range) 
1.60 ± 0.12 2.37 ± 0.41 0.134 
NF B Activity  
( Mean ± SEM ) 
 
21.4 x 10
5
;  
0.945 x 10
5
 – 231 x 105 
(median; range) 
 
127. x 10
5  
± 27.7 x 10
5
 
 
7.75 x 10
5
  
± 2.67 x 10
5
 
 
0.005 
Table 2.2. Patient Characteristics and NF B Activity. Median and Range of patient‟s age, staging, median 
and range of absolute lymphocyte counts, cytogenetics, phenotype and median and range of NF B activity for 
all patients are shown. Mean ± SEM patient age, staging, mean ± SEM absolute lymphocyte count, cytogenetics, 
phenotype and mean ± SEM NF B activity on the basis of whether patients fell above or below the median 
initial NF B activity are shown. NF B values were done on entry into the study and after n-3 consumption. 
NF B activity is presented in NF B luminescence units/µg protein. Subjects were divided into two groups based 
on whether initial NF B activation fell below or above the median (21.4 x 10
5
 NF B luminescence units/ µg 
protein) NF B activation in lymphocytes from all but 2 patients. Three (3) patients were excluded as baseline 
NF B Activity was not determined.  
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Omega-3 fatty acid supplementation did not have detrimental effects on 
platelet function 
Consumption of omega 3 fatty acids is known to slightly slow blood clotting. To assess 
the impact of omega 3 fatty acids on platelet function, standard clinical tests, collagen/ADP and 
collagen/EPI (epinephrine), were performed at baseline and after 6 months of omega-3 
consumption (dosage up to 7.2 g of n-3/day).  
There was no difference between either collagen/ADP or collagen/EPI times at baseline 
and after omega-3 consumption. Omega-3 consumption slightly increased collagen/EPI time but 
this increase was neither statistically nor clinically significant and remained within normal 
parameters (Appendix, Supplementary Figure 2.1).  
Omega-3 consumption had minimal side effects 
Known side effects associated with omega-3 consumption are diarrhea, nausea, fishy 
odors, bloating and slowed blood coagulation. Side effects experienced by participants were 
most commonly associated with mild diarrhea (grade 1 and 2, n=4 and 1, respectively) or nausea 
(n=2). As a result of associated side effects, patients 3, 4, 8, 10 and 14 reduced intakes to 4.8, 
2.4, 4.8, 2.4, and 4.8 g of n-3/day, respectively.  
Omega-3 fatty acid fraction in RBCs and WBCs increased upon fish oil 
consumption 
 The content of fatty acids in tissue membranes is generally indicative of consumption of 
those fats and can be used as a measure of compliance with the supplement. There was a 
statistically significant reduction of AA and there were significant increases in EPA, DPA, and 
DHA in red blood cells following omega-3 consumption (data not shown, previously published
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(Witte et al., 2010)). Differences in the levels of omega-6 and omega-3 fatty acids in white blood 
cells showed a trend similar to that of red cells but were not mathematically significant.  
 
Consumption of n-3 increased n-3 fatty acid content in plasma 
Mean ± SEM baseline (prior to n-3 supplementation) plasma concentrations of 10 fatty 
acids analyzed from 6 patients with early-stage CLL are shown in Table 2.3. Mean baseline 
[µM] of analyzed fatty acids were in agreement with previously published results
 
(Harper, 
Edwards, DeFilippis, & Jacobson, 2006). Only 6 patients were analyzed as these were the only 
patients who consumed all three proposed doses of n-3 (2.4g, 4.8g and 7.2 g of n-3/day).  
Mean ± SEM fatty acid plasma concentrations of 10 fatty acids analyzed from 6 subjects 
at baseline (0 g supplement), 2.4, 4.8, and 7.2 g of n-3 consumption per day and discontinued n-3 
consumption (n=2) are shown in Figure 2.1 and Table 2.3. Graphs are provided for visual 
comparison (Fig. 2.1) and Table 2.3 provides means ± SEM molar concentrations for use in 
future comparisons. 
Figure 2.1A shows the mean [µM] ± SEM of stearic acid (SA) and oleic acid (OA) with 
increasing n-3 consumption and discontinued n-3 consumption. Plasma OA was significantly 
decreased following consumption of 2.4 g of n-3 per day (p-value: 0.033 (Table 2.3)). No 
differences were observed in SA during the course of n-3 consumption.  
Figure 2.1B shows the mean [µM] ± SEM of n-6 fatty acids: LA, GLA, homogamma 
linolenic acid (HLA) and AA following increasing doses of n-3 or discontinued consumption of 
n-3. Compared to baseline, there were significant decreases in LA at 2.4 g, and GLA at 4.8 and 
7.2 g of n-3 per day (p-value: 0.007, 0.037, and 0.03, respectively (Table 2.3)). Dose-responsive 
reductions in AA were observed at 4.8 g and 7.2 g of n-3 per day (p-value: 0.045 and 0.005, 
respectively) compared to baseline (Table 2.3). 
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Figure 2.1C shows the mean [µM] ± SEM of n-3 fatty acids: ALA, EPA, DPA and DHA 
following increasing doses of n-3 consumption and discontinued consumption of n-3. DPA was 
significantly increased at 7.2 g of n-3 per day (p-value: 0.042) compared to baseline (Table 2.3). 
There were dose-responsive increases in EPA and DHA at 2.4 g, 4.8 g and 7.2 g of n-3 per day 
(p-value: all <0.001) compared to baseline (Table 2.3).  Interestingly, significantly higher plasma 
levels of DHA remained 3 months after discontinuation of n-3 consumption (p-value: <0.001) 
compared to baseline (Table 2.3).  
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Table 2. 3. Plasma Concentrations of 10 Fatty Acids Analyzed from Subjects Before and 
Following N-3 Consumption. 
Fatty acid Baseline  
0 g of n-3 
per day 
[µM] ± SEM 
Following 
2.4 g of  
n-3 per day 
[µM] ± SEM 
P-values 
 
Following 
4.8 g of  
n-3 per day 
[µM] ± SEM] 
P-values 7.2 g of  
n-3 per day 
[µM] ± SEM 
P-values 3 Months Off 
supplement 
0g of n-3 per 
day 
[µM] ± SEM 
P-
values 
SA 
(18:0)
b 
967.6 ± 55.10 717.0 ±  62.14 0.051 862.3 ± 55.35 0.666 819.6 ± 68.23 0.462 798.4 ± 35.85 0.138 
OA
 
(18:1n-9) 
3142.2 ± 
203.36 
2209.0 ± 205.72 *0.033 2491.4 ± 
257.87 
0.310 2358.8 ± 
249.98 
0.144 2690.4 ± 
130.98 
0.383 
LA 
(18:2n-6) 
3411.7 ± 
212.53 
2359.3 ± 146.28 *0.007 2840.8 ± 
163.76 
0.252 2726.6 ± 
177.10 
0.137 3305.1 ± 
329.59 
0.998 
GLA 
(18:3n-6) 
64.4 ± 8.09 40.7 ± 4.39 0.129 34.9 ± 3.67 *0.037 32.8 ± 4.88 *0.030 45.0 ± 4.72 0.292 
ALA 
(18:3n-3) 
104.0 ± 22.51 52.4 ± 8.86 0.270 67.9 ± 11.44 0.620 76.8 ± 8.70 0.791 75.4 ± 2.72 0.719 
HLA 
(18:3n-6) 
139.2 ± 13.13 114.2 ± 13.77 0.685 110.0 ± 9.63 0.408 95.7 ± 11.43 0.131 154.8 ± 14.77 0.927 
AA 
(20:4n-6) 
825.4 ± 53.24 649.4 ± 58.01 0.212 629.9 ± 32.37 *0.045 536.8 ± 47.71 *0.005 711.0 ± 56.19 0.600 
EPA 
(20:5n-3) 
79.1 ± 7.17 154.0 ± 11.04 *<0.001 302.5 ± 14.95 *<0.001 352.0 ± 15.98 *<0.001 91.4 ± 12.55 
 
0.904 
DPA 
(22:5n-3) 
65.7 ± 7.17 69.0 ± 5.58 0.996 90.5 ± 5.72 0.093 93.3 ± 5.17 *0.042 71.4 ± 4.02 0.954 
DHA 
(22:6n-3) 
69.4 ± 9.41 138.3 ± 8.08 *<0.001 205.2 ± 13.34 *<0.001 202.2 ± 14.43 *<0.001 149.2 ± 6.54 *<0.001 
Table 2.3.  Plasma Concentrations of 10 Fatty Acids Analyzed from Subjects Before and Following N-3 
Consumption.  
Mean fatty acid plasma concentrations [µM] ± SEM over the course of n-3 supplementation (n=6) and 
discontinued n-3 consumption (n=2) from subjects are shown. Omega-3 supplementation was compared against 
baseline. Statistical significance was determined by Games-Howell Multiple Comparison Test. Abbreviations: 
SA: Stearic Acid; OA: Oleic Acid; LA: Linoleic Acid; GLA: Gamma-Linolenic Acid; HLA: Homogamma-
Linolenic Acid; AA: Arachidonic Acid; ALA: Alpha-Linolenic Acid; EPA: Eicosapentaenoic Acid; DPA: 
Docosapentaenoic Acid; DHA: Docosahexaenoic Acid.n-9: omega-9 fatty acid; n-6: omega-6 fatty acid; n-3: 
omega-3 fatty acid.* indicates significance, α = 0.05. b A:B; A denotes carbon number, B denotes number of 
unsaturations. 
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Figure 2.1. Human Plasma Concentrations of 10 Fatty Acids Analyzed Before and Following N-3 
Consumption. 
Mean fatty acid plasma concentrations [µM] ± SEM from subjects over the course of n-3 supplementation (n=6) 
and after discontinued n-3 consumption (n=2) are shown. Figure A illustrates mean [µM] ± SEM concentrations 
of SA and OA with increasing n-3 doses and discontinued n-3 consumption. Figure B illustrates mean [µM] ± 
SEM concentrations of omega 6 fatty acids LA, GLA, HLA and AA with increasing n-3 doses and discontinued 
n-3 consumption. Figure C illustrates mean [µM] ± SEM concentrations of n-3 fatty acids ALA, EPA, DPA and 
DHA with increasing n-3 doses and discontinued n-3 consumption. Statistical significance was determined by 
Games-Howell Multiple Comparison Test. Abbreviations: SA: Stearic Acid; OA: Oleic Acid; LA: Linoleic 
Acid; GLA: Gamma-Linolenic Acid; HLA: Homogamma-Linolenic Acid; AA: Arachidonic Acid; ALA: Alpha-
Linolenic Acid; EPA: Eicosapentaenoic Acid; DPA: Docosapentaenoic Acid; DHA: Docosahexaenoic 
Acid.(A:Bn-9): A denotes carbon number, B denotes number of unsaturations; n-9: omega-9 fatty acid; n-6: 
omega-6 fatty acid; n-3: omega-3 fatty acid. α= 0.05, * <0.05, ** <0.01 
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Omega-3 consumption reduced NF B activation 
Figure 2.2 shows the NF B activity ± SD of 15 early (Rai Stage 0-1) stage CLL patients 
during omega-3 intervention and the mean of 5 healthy controls. In the 7 patients with higher 
(greater than the median) baseline NF B activity (patients 1-6, 13), NF B activity was decreased 
by the n-3 in a dose responsive manner. Furthermore, 7.2 g of n-3/day returned NF B activity to 
levels comparable to that observed in control patients (mean ± SD: 87,138 ± 79,040 NF B 
luminescence units/ µg protein). Lower (less than the median) initial activation of NF B activity 
was observed in 6 patients (patients 7-10, 11, 15) at baseline and 7.2 g of n-3/day decreased 
NF B activity to near normal levels. Patients 12 and 14 could not be categorized as either higher 
initial NF B activity or lower initial NF B activity as baseline NF B activity was not 
determined. NF B activity increased in patients 1, 2, 6 and 8 by three months after they 
discontinued consumption of omega-3. It is interesting that 2.4 or 4.8 g of n-3 per day, taken for 
long terms (patient 3, 4 and 10) decreased to or maintained NF B activity at a near normal level.  
Figure 2.3A illustrates NF B activity (mean ± SEM) during n-3 consumption for all 15 
patients. The greatest apparent decrease in NF B activity was following 7.2g of n-3 per day 
compared to baseline NF B activity but across all patients this decrease was not quite significant 
(p: 0.079).  
Figure 2.3B illustrates mean NF B activity ± SEM during the course of n-3 consumption 
for patients (# 1-6, 13, n=7) with higher (> median) initial NF B activity. Compared to baseline, 
there were statistically significant decreases in NF B activity following consumption of 7.2g of 
n-3/day (p: 0.027) and at 3 months after n-3 was discontinued (p: 0.040).  
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Figure 2.3C illustrates mean NF B activity ± SEM during the course of n-3 for patients 
(# 7-10, 11, 15, n=5) with lower initial NF B activity. There was no significant change in NF B 
activity during consumption of n-3. This might be expected since these patients did not initially 
have NF B activity significantly different from normal levels. 
  
79 
 
  
C
on
tr
ol
0
5.0×10 6
1.0×10 7
1.5×10 7
2.0×10 7
2.5×10 7 Controls
87138 ± 79040
N
F
k
B
 l
u
m
in
e
s
c
e
n
c
e
 u
n
it
s
/
g
 p
ro
te
in
m
e
a
n
 ±
 S
D
0 2 5 8 11 15
0
5.0×10 6
1.0×10 7
1.5×10 7
2.0×10 7
2.5×10 7
0
4.8
7.2 7.2 7.2
0 off
Patient # 1
Month
-1 0 1 2 5 8 11 14
0
0
2.4
4.8
7.2
Patient # 2
7.2 7.2 0 off
0 1 2 5 8 11 14
0
2.4
4.8
4.8 4.8
Patient # 3
4.8
0 Off
0 2 3 6 9 12
0
2.4
4.8
2.4
2.4 2.4
Patient # 4
0 2 3 6
0 2.4
4.8
7.2
Patient # 5
-1 0 1 2 5 8 11 14
0 0
2.4 4.8
7.2 7.2 7.2 0 off
Patient # 6
0 2 6 9 15
0 2.4
7.2 7.2
Patient # 7
0 off
-1 0 1 2 5 8 11 14
0
0 2.4 4.8 7.2 7.2
4.8 0 off
Patient # 8
-2 0 1 2 5 10 14
0 0
2.4
4.8 7.2
Patient # 9
7.2 0 Off
-1 0 1 2 5 8 11 14
0
0
2.4 7.2 2.4
Patient # 10
2.4 2.4 0 off
Patient # 11
0 2 5 8 11
0 7.24.8 7.2 7.2
Patient # 12
1 2 8
2.4 4.8 7.2
Patient # 13
0 2 5 8
0
4.8
4.8 2.4
Patient # 14
6 10
4.8 ?
Patient # 15
0 1
0
2.4
Figure 2.2. Effects of Omega-3 Consumption on NF B Activity. 
The NF B activities of 15 patients diagnosed with CLL (Rai stage 0-1) before and after consumption of omega-
3 and of 5 normal control patients (mean + SD) are shown. NF B activity was normalized to NF B 
luminescence units/ µg protein. All Y-axis are the same as for the patient # 1. The X-axis shows the time each 
sample was collected beginning with month 0. The number above each column indicates the amount of n-3 
(grams) being consumed at each time point. All assays were performed in triplicate. Error bars that are not 
visible are so small they are concealed by the top of the column. 
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Figure 2.3. NF B Activity. 
NF B Activity across time is shown. Games-Howell test was performed to determine statistical significance. (A) 
Mean ± SEM NF B activity for all patients following n-3 consumption is shown. Across all patients, the 
decrease in NF B activity following consumption of 7.2 g of n-3/day compared to baseline was not quite 
significant (p: 0.079). (B) Mean ± SEM NF B activity for patients whose baseline NF B activity was above the 
median (>2.14 X 10
6) and called “Higher activation” is shown. NF B activity was significantly less than 
baseline after 7.2 g of n-3/day and after 3 months off supplement (p: 0.027 and 0.040; respectively). (C) Mean ± 
SEM NF B activity for patients whose baseline NF B activity was below the median (<2.14 X 10
6
) and called 
“Lower activation” is shown. NF B activity was not significantly different from the normal subjects and no 
significant changes were seen over the course of n-3 supplementation. All Y-axis are the same as for figure 
2.3A. The X-axis shows the n-3 consumption across time.  
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Omega-3 consumption increases in vitro chemo-sensitivity of lymphocytes to 
doxorubicin 
We evaluated the effects of omega-3 consumption on the chemo-sensitivity of malignant 
lymphocytes to doxorubicin, a therapeutic agent that has been used in treating CLL (Keating, 
2010). Figure 2.4 shows the in vitro sensitivity to doxorubicin for 12 patients over the course of 
omega-3 supplementation. Due to inadequate sample required for chemo-sensitivity assays and 
limited number of data points, data from patients 11, 12 and 13 are not shown. In vitro results 
demonstrate that consumption of omega-3 fatty acids increased the sensitivity (i.e. increased cell 
death at lower doses of doxorubicin) of malignant lymphocytes to doxorubicin in most patients. 
Discontinuing omega-3 consumption was associated with decreased sensitivity to doxorubicin, 
as observed in patients 4, 6, 7 and 8.  
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Figure 2.4. Chemo-sensitivity of Lymphocytes to Doxorubicin During Omega-3 Intervention. 
The chemo-sensitivity (fraction of cells [compared to No doxorubicin] alive after each dose of doxorubicin 
treatment) of malignant lymphocytes to doxorubicin of 12 patients on omega-3 supplementation are shown. 
Consumption of omega-3 increased sensitivity of lymphocytes of most patients with higher NF B activity (1, 3, 
4, 5) to doxorubicin in vitro. Discontinued omega-3 consumption decreased doxorubicin sensitivity of the 
lymphocytes in vitro as seen in patients 4, 6, 7 and 8. All Y-axis are the same as for patient # 1.  
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mRNA expression in lymphocytes 
 Since omega-3 altered activation of NF B, sensitivity to doxorubicin and potentially 
slowed cancer progression, there should be changes in gene expression in the patient 
lymphocytes following consumption of omega-3. Expression profiling of mRNA from 
lymphocytes collected at baseline and following consumption of the highest level of omega-3 
indicated: 
 1. In patients with lower initial NF B activation, consumption of omega-3 did not 
significantly change NF B activation and did not significantly change mRNA abundance of any 
genes (data not shown). 
 2. In patients with higher initial NF B activation, consumption of omega-3 significantly 
decreased NF B activation and significantly decreased mRNA abundance of 31 identified genes. 
Genes down-regulated by omega-3 are shown in Table 2.4. Only the sixteen genes with known 
function are illustrated.  Three of these genes are known to be NF B responsive genes. 
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Table 2. 4. Differential mRNA Expression in Lymphocytes in Patients with 
Higher Initial NF B Activation 
Number Gene Description Fold 
Change 
1 
JMJD1C jumonji domain 
containing 1C  [Homo 
sapiens ] 
 
Probable JmjC domain-containing histone demethylation protein 2C. Known target 
of NF B.  
 
0.2018486 
2 
RIF1 
 
Included in pluripotency of stem cells, response to double-strand breaks, and breast 
cancer development. Inhibition of RIF1 has been shown to sensitize cancer cells to 
camptothecin or staurosporine treatment. 
0.2184341 
3 
ZNF644 
 
Metal ion binding, regulation of transcription. Known target of NF B.  
 
0.2339526 
4 CHD9 
Chromatin remodeling transcriptional regulation of mesenchymal cells. 
 
0.2407181 
5 
TPR 
 
Directly binds Mad1 and Mad2. Important for the Mad1-Mad2-mediated spindle 
checkpoint. Translocated promotor region (to activated MET oncogene).  
0.2420173 
6 
OSBPL8 (Oxysterol 
binding protein-like 8) 
 
Encodes a member of the oxysterol-binding protein (OSBP) family, a group of 
intracellular lipid receptors. 
 
0.2487205 
7 
KIAA1109 
 
Thought to function in the regulation of epithelial growth differentiation and in 
tumor development. 
0.2579169 
8 
BRWD1 (Bromodomain 
and WD repeat domain 
containing 1) 
 
Thought to facilitate formation of heterotrimetric or multiprotein complexes. 
Involved in variety of processes, including cell cycle progression, signal 
transduction, apoptosis and gene regulation.  
0.2635655 
9 
MKL (myocardin-like 
protein 2) 
Encodes myocardin-related transcription factor B in a megakaryoblastic leukemia 
gene family, shown to be involved in cancer cell invasion and motility. 
0.2762535 
10 
PCM1 (Pericentriolar 
material 1) 
 
Chromosomal aberrations involving this gene are associated with papillary thyroid 
carcinomas and a variety of hematological malignancies. 
0.2854771 
11 
ITSN2 (Human Intersectin 
2) 
 
Thought to regulate formation of clathrin-coated vesicles and function in the 
induction of T cell receptor endocytosis. 
0.3021278 
12 
ASH1L 
 
Mammalian ASH1L is a histone methyltransferase that occupies the transcribed 
region of active genes. 
 
0.3140698 
13 
PKN2  (Protein kinase N2) 
 
Protein kinase C-related kinase-2 (PRK2) as an HDAC5-interacting protein. 
Evidence suggests that the unique phospho-acceptor cooperates with the 14-3-3 
target sites to impair HDAC nuclear import. 
 
0.3235345 
14 
SLC12A1 (Solute carrier 
family 12) 
 
This gene encodes a kidney-specific sodium-potassium-chloride cotransporter. 
 
0.3310252 
15 
CASC5 (Cancer 
susceptibility candidate 5) 
Involved in chromosomal translocations that subsequently form chimeric 
oncoproteins BCR-ABL, TEL-ABL and MLL-AF15q14 in human leukaemia. 
Interact with the tumor suppressor pRb protein.Expressed in various human tumour 
cell lines and primary tumours. 
 
0.3414733 
16 
PTGS2 (prostaglandin 
synthase 2, COX 2) 
Linked to promotion of a variety of cancers via increased production of 
inflammatory eicosanoid prostaglandin E2. Known target of NF B. 
0.4050415 
Table 2.4. Differential mRNA Expression in Lymphocytes in Patients with Higher Initial NF B 
Activation.  Differentially regulated genes were identified by SAM analysis (false discovery rate = 10%, fold 
difference at least 1.5). Shown are results of repeated analyses of mRNA from 5 patients at highest omega-3 
dose verses baseline (no omega 3 supplement). A fold change of less than 1 indicates that omega-3 consumption 
decreased expression of the gene to the indicated fraction compared to baseline expression of the gene. 
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DISCUSSION 
Chronic lymphocytic leukemia is a disease that usually occurs in older people and in 
early stages, CLL does not require treatment. If the time to progression could be extended or if 
therapy were more effective then clinical benefit would be realized. Evidence has suggested that 
NF B may play a key role in controlling apoptosis and disease progression in CLL (Braun et al., 
2006; Cilloni et al., 2007; Endo et al., 2007) . NF B is currently considered an important target 
for the treatment of hematological malignancies, especially CLL (Braun et al., 2006; Cilloni et 
al., 2007; Cilloni et al., 2006; Endo et al., 2007; Hewamana et al., 2009). In our animal studies 
with other types of cancers, we have shown that omega-3 suppressed the activation of NF B 
(Hardman, 2002) and increased the effectiveness of several chemotherapies including 
doxorubicin (Hardman, Avula, Fernandes, & Cameron, 2001; Hardman, Moyer, & Cameron, 
2000) . It was not known if this benefit would translate to humans. This pilot study was primarily 
designed to determine whether omega-3 would reduce NF B activation in the lymphocytes of 
patients with early (RAI stage 0-1) CLL. Secondary objectives were to 1) evaluate the safety of 
consuming an omega-3 supplement, 2) determine circulating fatty acid concentrations in the 
plasma, 3) determine if omega-3 could increase the sensitivity of patient‟s lymphocytes to 
doxorubicin in vitro and 4) whether omega-3 might modify gene expression in the tumor cells 
(lymphocytes) of humans. 
Our patient characteristics indicated a range of prognoses from good to poor based on 
differences in patient staging, cytogenetics, and phenotypes. For example, deletion of 13q14.3 is 
associated with good prognosis; trisomy 12 is associated with intermediate prognosis; CD38 
positive lymphocytes, high levels of ß2-microglublin (mg/L) > 2, and/or deletion of 17p13.1 are 
associated with poor prognosis (Doubek et al., 2011; Mougalian & O'Brien, 2011) . Mutation 
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status of the IgVH chain was not evaluated as this is not performed during routine clinical 
practice at this institution.  
Chronic lymphocytic leukemia cells have been demonstrated to have high NF B activity. 
Our results appeared to indicate two populations of patients, those with higher initial NF B 
activation (greater than the median) and those with lower initial NF B activation (lower than the 
median). Hewamana et al. indicated that increased WBC counts significantly correlated with 
increased Rel A, a subunit of NF B which contains the transcription activation domains, DNA 
binding
 
(Hewamana et al., 2008). Similarly, we found a positive correlation between WBC 
counts and NF B activation (r
2
: 0.309, p: 0.0476, Appendix, Supplementary Figure 2.2). Data on 
absolute lymphocyte counts indicated that the „lower initial activation‟ patients had significantly 
lower absolute lymphocyte counts than patients exhibiting „higher initial activation‟ of NF B at 
baseline. Patient staging indicated that 3 of 7 patients with higher initial NF B activity had a Rai 
Stage of 1 (remainder had Rai Stage 0), whereas only 1 of 6 patients with lower initial NF B 
activity had a Rai Stage of 1 (remainder had Rai Stage 0). The trend in patient staging, 
correlation between WBC count and NF B activation, statistical differences observed at baseline 
for absolute lymphocyte counts, and differences in initial NF B activity suggest that NF B 
activation may be related to progression of the disease. Further studies will be needed to 
determine if NF B activation correlates with progression of the disease and if suppressing NF B 
activation will slow further progression.  
Our results indicate that consumption of an n-3 supplement, predominantly composed of 
EPA and DHA, increased the amount of n-3 in the plasma of subjects. Although the subjects had 
early stage CLL (Rai Stages 0-1), we could not determine a reason, a priori, that would indicate 
that the fatty acid concentrations in their plasma should be different from that of persons without 
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CLL.  Interestingly, despite plasma concentrations of EPA and DHA being highest following 
consumption of 7.2 g of n-3/per day for a month of more, these concentration did not differ 
statistically from that following consumption of 4.8 g of n-3/day (Mean [µM] ± SEM: 352.0 ± 
15.98 vs 302.5 ± 14.95; p: 0.192 and 202.2 ± 14.43 vs 205.2 ± 13.34; p:1.00 , respectively (Table 
2.3)). This suggests that plasma concentrations of EPA and DHA reached a steady state and that 
a steady state plasma concentration of EPA or DHA can be achieved at a lower dose that is more 
easily consumed. This is an important consideration for future clinical trials. A lower dose of 
supplement would increase compliance rates and decrease side effects associated with n-3 
consumption. 
Discontinuation of n-3 consumption resulted in a reduction of EPA toward values 
observed at baseline. Although DHA displayed a similar tendency for reduction toward baseline 
values, levels of DHA 3 months after discontinuation n-3 consumption remained significantly 
higher than baseline values (Mean [µM] ± SEM: 149.2 ± 6.54 vs 69.4 ± 9.41;p: <0.001 (Table 
2.3)). This indicates that the retention time of DHA in the plasma of patients consuming n-3 is 
greater than EPA. It is important to note that plasma levels of AA decreased following n-3 
consumption and subsequently increased toward values observed at baseline after 
discontinuation of n-3. It is not known if this is due to changes in the diet or if the increase in AA 
is as a result of reduced bioavailability of n-3.   
These data demonstrate that in patients with early stage CLL, consumption of an omega-3 
fatty acid supplement had minimal side effects and strongly suppressed highly activated NF B. 
A dose of 7.2 g of n-3/day suppressed NF B activity to nearly normal levels in all patients. This 
biomarker would be expected to correlate with clinical benefit, perhaps extending the time to 
requiring therapy. A longer randomized trial will be needed to determine if our intervention 
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slows disease progression. In patients unable or unwilling to take 7.2 g of n-3 per day, over time 
either 4.8 g or 2.4 g of n-3 per day also suppressed NF B to nearly normal levels. This suggests 
that a maximum possible dose may not be required to achieve benefit from omega-3 but that a 
lower dose, with time, could provide benefit. This idea is further supported by the fact that 
plasma levels of n-3 after 7.2 g of n-3 per day did not differ statistically from 4.8 g of n-3 per day 
(Table 2.3).  
These data also demonstrate that patients with lower initial NF B activity did not have 
NF B activity decreased below baseline levels while being supplemented with omega-3. A 
normal level of NF B activation is needed for normal immune response and cellular responses to 
other stress. 
Based on our data, it can be concluded that consumption of omega-3 fatty acids 
decreased the activity of NF B, a key target for slowing cancer progression, and would 
potentially slow the progression of the disease. A larger randomized clinical trial will be needed 
to determine if consumption of omega-3 fatty acids can slow progression of the disease. 
Omega-3 fatty acids have consistently been shown to enhance the sensitivity of various 
cancers to doxorubicin in vitro and in vivo (Bougnoux et al., 1999; Hardman, 2002; Hardman et 
al., 2000). Doxorubicin is a previously used treatment option for CLL (Keating, 2010) and is an 
active drug in this disease as part of the CHOP (cyclophosphamide, doxorubicin, oncovin and 
prednisone) regimen (Leporrier et al., 2001). Although doxorubicin has been replaced as the 
standard by other drugs such as bendamustine and fludarabine, we wanted to test the chemo-
sensitivity of isolated lymphocytes to doxorubicin following inhibition of NF B activation as 
this system was already in place. Omega-3 consumption was shown to increase sensitivity of 
malignant lymphocytes to doxorubicin while discontinued consumption of omega-3 resulted in 
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decreased sensitivity to doxorubicin. Our data illustrates that increased sensitivity of malignant 
lymphocytes to doxorubicin following n-3 consumption was most profound in patients with 
higher initial NF B activity. Little effect on chemo-sensitivity following n-3 consumption was 
observed in patients with lower initial NF B activity. Increased sensitivity of malignant 
lymphocytes from patients with higher initial NF B activity to doxorubicin suggests that high 
NF B activity is associated with chemoresistance. Numerous preclinical studies have shown that 
increased NF B activity increases chemoresistance (Li & Sethi, 2010).  We are currently 
preparing to conduct an additional clinical study aimed to determine if n-3 can increase the 
sensitivity of lymphocytes from patients with CLL to anti-cancer drugs fludarabine, 
chlorambucil or vincristine in vitro and whether enhanced sensitivity is through the inhibition of 
NF B activation. Increasing the efficacy of the chemotherapeutic agent would be clinically 
beneficial if patients progress to requiring therapy. 
In patients with higher initial NF B activation, consumption of the omega-3 supplement 
significantly suppressed expression of 31 identified genes. In this small population, no genes had 
increased expression due to omega 3 consumption. The list of altered genes that have a known 
function is included in Table 2.4. Of these 31 genes, JMJD1C, ZNF644 and PTGS2 are known to 
be regulated by NF B. Functions of some of these genes of particular interest are discussed 
below. (Numbers in brackets refer to number in first column of Table 2.4.) 
Several chromatin conformation related proteins were identified including: JMJD1C [1] 
which contains histone demethylation protein 2C (Katoh & Katoh, 2007). CHD9 [4] is a 
chromatin remodeling protein
 
(Marom, Shur, Hager, & Benayahu, 2006; Shur, Socher, & 
Benayahu, 2006). ASH1L [12] is a histone methyl transferase (An, Yeo, Jeon, & Song, 2011) 
and PKN2 [13] impairs histone deacetylase import (Harrison et al., 2010). Chromatin remodeling 
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is being recognized as an important mechanism by which dietary components may alter gene 
expression and influence cancer growth or progression. 
Several down-regulatated genes were identified as important in cancer development. 
RIF1 [2] is an embryonic stem cell marker. Inhibition of RIF1 has been shown to sensitize 
cancer cells to some chemotherapies (Park et al., 2010). KIAA1109 [7] is thought to function in 
epithelial growth and differentiation and in tumor development
 
(Zhernakova et al., 2007). 
BRWD1 [8] is an Oct4 (stem cell marker) interacting protein, its family members are involved in 
cell cycle progression, signal transduction, apoptosis and gene regulation (Pardo et al., 2010). 
Chromosomal aberrations involving PCM1 [10] are associated with thyroid carcinomas and a 
variety of hematological malignancies (Hoeller, Walz, Reiter, Dirnhofer, & Tzankov, 2011). 
CASC5 (15q14) is involved in chromosomal translocations that form oncoproteins in human 
leukemias (Kuefer et al., 2003) and in increased cell proliferation of some cancers (Bogdanov & 
Takimoto, 2008; Takimoto et al., 2002). 
PTGS2 (prostaglandin synthase 2, COX-2 [16]), a known target of NF B, has been 
linked to promotion of a variety of cancers possibly via increasing the production of 
inflammation producing prostaglandin E2 (Hardman, 2002; Prueitt et al., 2007). Suppression of 
COX-2 activity has been proposed as a mechanism to reduce cancer growth and resistance to 
chemotherapy. 
In conclusion, omega-3 consumption increased circulating plasma levels of n-3 while 
decreasing n-6, suppressed NF B activation in patients with early stage (Rai Stage 0-1) CLL to 
near normal levels and increased chemo-sensitivity of malignant lymphocytes to doxorubicin in 
vitro. Suppression of NF B activity has been proposed as a drug development target to slow 
progression of cancers.  The mRNA expression of multiple genes related to cancer promotion or 
91 
 
cancer aggressiveness were reduced in malignant lymphocytes following consumption of omega 
-3. Much work should be done to validate that reduced mRNA correlates with decreased 
expression of the protein and the clinical relevance. Since omega-3 was safe to consume and did 
not have detrimental side effects, a definitive randomized clinical trial should be initiated to 
determine whether there is clinical benefit for consumption of omega-3 to slowing progression of 
chronic lymphocytic leukemia. In agreement with animal studies, in vitro doxorubicin sensitivity 
assays suggest that when used in combination with chemotherapeutics, omega-3 fatty acids may 
increase the efficacy of some chemotherapeutic drugs for patients who require therapy. Current 
studies are underway to determine if omega-3 can enhance the sensitivity of lymphocytes from 
patients with CLL to anti-cancer drugs fludarabine, chlorambucil or vincristine. Plasma 
concentrations of fatty acids analyzed following consumption of n-3 and discontinued 
consumption of n-3 provides insight into doses of n-3 which can be used in future clinical trials. 
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APPENDIX 
  
Baseline-Month 0
Blood Draws
Month #1: 3 capsules of n-3 per day
(2.4 g of n-3/day)
Blood Draws
Month #2:
6 capsules of n-3 per day
(4.8 g of n-3/day)
Blood Draws
Month #3:
9 capsules of n-3 per day
(7.2 g of n-3/day)
Blood Draws
Months #4-12:
Highest Tolerable Dose
Discontinue Consumption Post Month #12
Blood Draws
Month #15:
Follow-Up
0 g of n-3/day
Blood Draws
Supplementary Figure 2. 1. Omega-3 Dosing Schedule. 
Each capsule of omega-3 contained 400mg EPA, 300mg DHA and 100-150mg other omega-3. Thus, 
consumption of 3, 6, or 9 capsules/day yielded 2.4 g, 4.8 g, or 7.2 g/day of n-3, respectively 
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Supplementary Figure 2. 2. Effects of Omega-3 on Blood Coagulation. 
Blood coagulation times for collagen/ADP and collagen/EPI (ephinephrine) on omega-3 
intervention are shown. No difference was observed in collagen/ADP, a measure of platelet 
function, coagulation when omega-3 was introduced. A slight increase was observed in 
collagen/EPI, a measure of clotting time, when omega-3 was introduced but this increase was not 
statistically significant and was within normal parameters. 
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Supplementary Figure 2. 3. Correlation Between WBC Counts and NF B Activation. 
Correlation between WBC counts and NF B activation is shown. A significant positive 
correlation was found between WBC counts and  NF B activation. Correlation coefficients 
were calculated by least squares linear regression.  
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ABSTRACT 
B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the 
United States. Clinical treatment of CLL is often limited due to drug resistance and severe 
therapy-induced toxicities. We hypothesized that the omega-3 (n-3) fatty acids, eicosapentaenoic 
acid (EPA) and/or docosahexaenoic acid (DHA), would increase the sensitivity of malignant B-
lymphocytes to anti-cancer drugs doxorubicin, vincristine and/or fludarabine in vitro and that 
increased sensitivity is achieved by alterations in cell-cycle progression leading to growth 
inhibition and/or enhanced cell death. We further postulate that enhanced sensitivity is dependent 
on the formation of lipid peroxides and to the generation of reactive oxygen species (ROS). 
In the present study, B-CLL-derived leukemic cell lines EHEB and MEC-2 and the B-
Prolymphocytic leukemic-derived (PLL) cell line JVM-2 were tested for in vitro sensitivity 
against doxorubicin, vincristine or fludarabine in the presence or absence of vehicle, arachidonic 
acid (omega 6), EPA or DHA. Cell cycle analysis and Annexin-V assays were performed to 
determine cell cycle progression and % apoptotic cells, respectively. Assays for 
malondialdehyde, a measure of lipid peroxidation, and DCF fluorescence assays, a measure of 
intracellular ROS, were performed to determine if enhanced sensitivity of cells to the drugs by n-
3 was dependent on the formation of ROS. 
Our results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell 
lines EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone 
and with drug treatment increased cell death and induced G2/M arrest in a cell-type specific 
manner; 3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid 
peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 
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increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase 
in ROS generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA. 
N-3‟s are promising chemo-sensitizing agents for the treatment of CLL. Selective 
enhancement of chemo-sensitivity of EHEB, JVM-2 and MEC-2 to drugs by n-3 that is not 
dependent on increased lipid peroxidation and ROS generation indicates alternative mechanisms 
by which n-3 enhances chemo-sensitivity. 
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INTRODUCTION 
B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the 
United States (Riches, Ramsay, & Gribben, 2011). CLL is a disease of the elderly with two 
thirds of patients being over 65 years of age at time of diagnosis (Riches et al., 2011). CLL 
remains largely incurable outside of allogeneic transplantation (Riches et al., 2011). Despite the 
success of current treatments such as fludarabine, many patients develop drug resistance and 
disease relapse (Silber et al., 1994). As such, clinical treatment of CLL is often hindered by drug 
resistance and the non-selectivity of most drugs (Schriever & Huhn, 2003). Additionally, 
treatment options for CLL patients who require aggressive treatment are limited due to 
significant side-effect profiles which are often too toxic for the elderly or those with 
comorbidities (Riches et al., 2011). Given the age group of patients diagnosed with CLL, a 
therapeutic intervention that can increase the sensitivity of CLL cells to chemotherapy without 
causing additional adverse effects would be clinically beneficial. 
Omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) are essential fatty acids 
(FAs) which must be obtained from diet. Long chain omega-3 fatty acids (eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA)) are primarily found in fish oils (Simopoulos, 1991). 
The omega-6 fatty acid, arachidonic acid (AA), is primarily found in the meat of animals that 
consumed corn or soybeans. The ratio of omega-3 FAs to omega-6 FAs in the average western 
diet is heavily weighted in favor of omega-6 (Simopoulos, 2000, 2003). Omega-3 fatty acids 
have consistently been shown to enhance sensitivity of various solid tumor cells to chemotherapy 
in vitro (Germain, Chajes, Cognault, Lhuillery, & Bougnoux, 1998; Kinsella & Black, 1993) and 
in vivo (Borgeson, Pardini, Pardini, & Reitz, 1989; Hardman, Avula, Fernandes, & Cameron, 
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2001; Shao, Pardini, & Pardini, 1997). However, it has not been shown whether n-3 can enhance 
the sensitivity of CLL to anti-cancer drugs. 
Previous studies performed by our group have shown that consumption of an omega-3 
supplement, predominantly composed of EPA and DHA, increased the sensitivity of malignant B 
lymphocytes isolated from patients with early CLL (RAI stages 0, 1) to doxorubicin in an in 
vitro assay (Fahrmann et al., 2013). These findings prompted us to further evaluate the potential 
use of omega-3 as a chemo-sensitizing agent for the treatment of CLL. The primary objective of 
this study was to determine whether EPA and/or DHA could increase the sensitivity of malignant 
B-lymphocytes to doxorubicin, vincristine and/or fludarabine in vitro. Secondary objectives were 
to elucidate potential mechanism(s) by which n-3 enhance chemo-sensitivity. We hypothesized 
that EPA and/or DHA would increase the sensitivity of malignant B-lymphocytes to 
doxorubicin, vincristine and fludarabine in vitro and that enhanced sensitivity is mediated by 
alterations in cell cycle progression leading to enhanced growth inhibition and/or enhanced cell 
death. We further postulate that increased chemo-sensitivity is dependent, in part, on the 
formation of lipid peroxides, and the generation of reactive oxygen species (ROS). 
In this study we assayed for: 1) fatty acid lipid composition, 2) in vitro sensitivity of B-
CLL-derived cell lines EHEB, and MEC-2 and B-Prolymphocytic-derived (PLL) cell line JVM-2 
against doxorubicin, vincristine and fludarabine in the presence of vehicle (no added FA), AA, 
EPA or DHA, 3) % of apoptotic cells, 4) cell cycle distribution, 5) generation of intracellular 
reactive oxygen species (ROS), and 6) levels of lipid peroxidation. 
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METHODS 
Chemicals 
Ninety-five percent pure doxorubicin hydrochloride (Fisher Scientific), and 2-
fluoroadenine-9-β-D-arabinofuranoside (Sigma Aldrich) were dissolved in dimethyl sulfoxide 
(DMSO) to stock solutions and diluted to the working concentrations in cell type specific culture 
media. Vincristine sulfate salt (Sigma Aldrich) was dissolved in ddH2O to stock solutions and 
diluted to the working concentrations in cell type specific culture media. Vitamin E (α-
tocopherol) (Sigma Aldrich) was dissolved in ethanol to stock solutions and diluted to working 
concentrations in the cell type specific media. 
Cell Lines 
EHEB (B-CLL), JVM-2 and MEC-2 (B-Prolymphocytic Leukemia) were obtained from 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). Cells were grown in 1640 
RPMI (ATCC) (EHEB and JVM-2) or Iscove‟s Modified Dulbecco‟s Medium (HyClone, 
Thermo Scientific) (MEC-2) supplemented with 10% Fetal Bovine Serum (HyClone, Thermo 
Scientific), 100 units/mL penicillin and 0.1 mg/mL streptomycin. All cell lines were grown in 
humidified incubator at 37
0
C and 5% CO2. 
Fatty Acid Treatments 
Stock solutions of 100 mM eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) 
or arachidonic acid (AA) (Cayman Chemical) in ethanol were made and diluted to the working 
concentrations in cell type specific culture media. Fatty acid concentrations used represent the 
concentration of each fatty acid that alone did not induce significant cytotoxicity. One million 
five hundred thousand (1.5x10
6
) cells per well were seeded in a 6 well plate (Santa Cruz 
Biotechnology, Inc) and treated with vehicle (ethanol only), AA, EPA or DHA at the stated 
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concentration for 72 hours. Cells were treated for 72 hours with FA to allow adequate time for 
FA incorporation and to allow for any FA-dependent changes in cellular function. Chosen 
concentrations of FA are clinically achievable (Fahrmann et al., 2013). Post 72 hours, cells were 
counted with a hemocytometer and prepared for the assays below. 
Lipid Composition 
Fatty acid composition was assessed by gas chromatography according to our routine 
techniques (Witte, Salazar, Ballester, & Hardman, 2010). Post 72 hours, cells were washed twice 
with 1X PBS. Cells were subsequently homogenized in distilled water with 0.1% BHT to prevent 
fatty acid oxidation. Lipids were extracted with chloroform/methanol, and then methylated. 
Methylated lipids were separated and identified using gas chromatography as previously 
published (Witte et al., 2010). Fatty acid methyl ester standards (Nu-Chek-Prep, Elysian, MN) 
were used for peak identification. 
Sensitivity Trials 
Cell counts were performed and viability was determined by Trypan Blue Exclusion 
assay following 72 hour fatty acid treatments (FA). Approximately 1x10
5
 living cells/well were 
seeded in triplicate into a round bottom 96 well plate (CELLSTAR, Greiner Bio One 
International AG). Cells were subsequently treated with culture media containing DMSO, H2O 
(solvent controls), doxorubicin (0–7.5μM), vincristine (0-250nM) or fludarabine (0-50μM) 
without FA for 20 hours (doxorubicin) or 24 hours (vincristine, fludarabine). Cells were treated 
in the presence or absence of 50μM vitamin E alone and in combination with doxorubicin 
(1.5μM) after 72 hour FA pre-treatment for Vitamin E rescue trials. Cell viability was 
determined using colorimetric MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (CALBIOCHEM, EMD MILLIPORE) assay. Cell viability was assessed by measuring 
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the intensity of precipitate formed, relative to control specimens. Absorption was measured using 
a SpectraMax M2 (Molecular Devices, Sunnyvale, CA) spectrophotometer at 570 nm. All 
measurements obtained from the MTT assay following treatment with the anti-cancer drugs in 
the presence of vehicle, AA, EPA or DHA were compared to cells treated with the vehicle or FA 
alone. MTT assays were performed in technical and biological triplicate. 
Measurement of Apoptosis by Annexin-V/Propidium Iodide Duel Stain 
Apoptosis was measured by duel stain immunofluorescence flow cytometry. Briefly, post 
72 hour FA treatments, cell counts were performed and approximately 5 x 10
5
 cells were treated 
in the presence of DMSO, H2O (solvent controls), doxorubicin (1.5μM), vincristine (100nM) or 
fludarabine (40μM) as previously described under sensitivity trials. Cells were washed twice 
with cold 1X PBS and subsequently incubated for 15 minutes in the dark in 100μL of Annexin-V 
binding buffer (0.01 M HEPES, 0.14 M NaCl, 2.5 mM CaCl2), 1μL Annexin-V Alexa Fluor 488-
Conjugate (Invitrogen), and 10 μg/mL propidium iodide (Sigma Aldrich). Cells were analyzed 
using an Accuri Flow Cytometer. „Early‟ Apoptosis was defined as cells positive for Annexin-V-
FITC only. „Late‟ Apoptosis was defined as cells positive for Annexin-V-FITC and Propidium 
Iodide (PI). „Necrotic‟ was defined as cells positive for PI only (Equation 2). Total% cell death 
was defined as the sum population of cells in early apoptosis, late apoptosis and necrosis. 
Annexin-V assays were performed in biological triplicate. 
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Equation 2: Total % Cell Death 
Total % Cell Death = (% Necrotic) + (% Late Apoptosis) + (% Early Apoptosis) 
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Cell Cycle Analysis 
Post 72 hour FA treatments, cells were counted and approximately 1 x 10
6
 cells were 
treated in the presence of DMSO, H2O (solvent controls), doxorubicin (1.5μM), vincristine 
(100nM) or fludarabine (40μM) as previously described under sensitivity trials. Cells were 
subsequently washed twice with cold 1X PBS and resuspended in DNA staining buffer 
containing 0.2% Triton X-100, 0.2% Na3-Citrate, 30 μg/mL RNase and 20 μg/mL propidium 
iodide (Sigma Aldrich) or DNA staining buffer without propidium iodide to serve as negative 
controls. Cells were incubated for 30 minutes in the dark at room temperature and subsequently 
analyzed using an Accuri Flow Cytometer. Cell cycle analyses were performed in biological 
triplicate. Calculation of G1/G2 ratio is described in Equation 3. 
 
 
 
 
 
 
 
 
 
Lipid Peroxidation 
Lipid peroxidation was measured by means of thiobarbituric acid reactive substances 
(TBARS) assay. Briefly, approximately 1 to 1.5 x 10
6
 cells were collected in 600μL 1X PBS 
post 72 hour fatty acid treatments as described under fatty acid treatments and after doxorubicin 
(1.5μM) or vincristine (100nM) or fludarabine (40μM)alone or in combination with 50μM 
vitamin E (doxorubicin only). Cells were sonicated 2X on 10 second intervals at 40 V setting 
E
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Equation 3: G1/G2 Ratio 
G1/G2 Ratio = (# of events in G0 + G1)/ (# of events in G2 + M) 
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over ice using a Fisher Scientific Sonic Dismembrator. TBARS assay (Cayman Chemical), in 
biological triplicate, was performed according to protocol and reported as ng of 
malondialdehyde/μg of protein. 
Intracellular ROS Generation 
Levels of intracellular ROS were determined using 5-(and-6-)chloromethyl-2‟,7‟-
dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen). Briefly, post 
72 hour fatty acid treatments, one hundred thousand (10
5
) live cells were seeded in triplicate into 
a round bottom 96 well plate (CELLSTAR, Greiner Bio One International AG). Cells were 
washed twice with 1X Dulbecco‟s PBS (DPBS) (GIBCO, Invitrogen) and incubated for 60 
minutes in the presence or absence of 10μM CM-H2DCFDA in Dulbecco‟s Modified Eagles 
Medium (DMEM, Thermo Scientific) (SIGMA) without FBS containing 100 units/mL pencillin, 
0.1 mg/mL streptomycin. Post 60 minute incubation, cells were washed 2X with 1X DPBS and 
treated in the presence or absence of DMSO, doxorubicin (1.5μM), or fludarabine (40μM) where 
after cell suspensions were transferred to a 96 well flat bottom black well plate (VWR 
International, LLC). Fluorescence was measured every 10 minutes for 2 hours using SpectraMax 
M2 spectrophotometer (Molecular Devices, Sunnyvale, CA) at 480 nm excitation 530 nm 
emission. Assays for intracellular ROS generation were performed in technical triplicates and 
biological duplicates. 
Statistical Analysis 
Prism
©
 software (Graphpad, Inc., La Jolla, CA) was used for statistical analysis of 
numeric data by Multiple Comparison using appropriate Post-Hoc Test and for linear regression 
analyses. Prism
©
 software (Graphpad, Inc., La Jolla, CA) was used for preparation of graphs. 
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Statistical significance on Annexin-V assays is based on total% cell death as described in 
Equation 2. 
RESULTS 
N-3 and N-6 fatty Acids Induce Cell Death  
 Figures 3.1A-C illustrates the % alive cells ± SEM of EHEB, JVM-2 and MEC-2 
following treatment with vehicle, or increasing concentrations of AA, EPA and DHA. Cell 
viability was assessed by Trypan Blue Exclusion assay following treatment for 72 hours. 
Treatment with AA, EPA or DHA induced dose-responsive reductions in cell viability as 
compared to vehicle in all three cell lines. We wanted to determine the chemo-sensitizing effects 
of FA following treatment with concentrations of FA that alone did not induce significant 
cytotoxicity. Thus, we chose to use concentrations of AA at 25µM, 35µM and 25µM, EPA at 
50µM (all cell lines) and DHA at 75µM, 50µM and 50µM for EHEB, JVM-2 and MEC-2, 
respectively. The chosen FA concentrations used in this study are clinically achievable 
(Fahrmann et al., 2013). Gas chromatography post 72 hour of FA treatment validated FA 
incorporation in all cells (Figure 3.2).  
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Figure 3. 1. Determination of optimal FA concentrations. 
Figures 3.1A-C illustrates the mean % live cells ± SEM of EHEB, JVM-2 and MEC-2 following 72 hour treatment with vehicle, or increasing 
concentrations of AA, EPA or DHA. Percent (%) live cells was determined after 72 hour treatments by trypan blue exclusion assay.  Figure 3.1A illustrates 
the mean % live cells ± SEM of EHEB following treatment with vehicle, or increasing concentrations of AA, EPA or DHA. Significant reductions in % live 
cells were observed at 55µM AA, 75µM and 100µM EPA, and 100µM DHA as compared to vehicle. Although not statistically significant, concentrations of 
AA35µM and AA45µM indicated viabilities of 57% and 54%. FA concentrations of AA25µM, EPA50µM and DHA75µM were chosen for the remainder of 
the study. Figure 3.1B illustrates the mean % live cells ± SEM of JVM-2 following treatment with vehicle, or increasing concentrations of AA, EPA or 
DHA. Significant reductions in % live cells were observed at 45µM and 55µM AA, and 75µM and 100µM EPA as compared to vehicle. Although not 
statistically significant, concentrations of DHA75µM and DHA100µM indicated cell viabilities of 65% and 55%. FA concentrations of AA35µM, 
EPA50µM and DHA50µM were chosen for the remainder of the study. Figure 3.1C illustrates the mean % live cells ± SEM of MEC-2 following treatment 
with vehicle, or increasing concentrations of AA, EPA or DHA. Significant reductions in % live cells were observed at 45µM AA, 75µM and 100µM EPA 
and 75µM and 100µM DHA as compared to vehicle. FA concentrations of AA25µM, EPA50µM and DHA50µM were chosen for the remainder of the 
study. Statistical significant was determined by Multiple Comparison Test using Tukey‟s correction. Abbreviations: AA- arachidonic acid, EPA- 
eicosapentaenoic acid, DHA- docosahexaenoic acid, α= 0.05, * <0.05, **<0.01, ***< 0.001 
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Figure 3. 2. Validation of FA incorporation. 
Figure 3.2 illustrates the percentage (%) ± SEM of analyzed fatty acids in MEC-2 following 72 hour treatments 
with vehicle, 25µM AA, 50µM EPA or 50µM DHA. Ten (10) fatty acids were analyzed, only % of AA, EPA, 
DPA and DHA are shown. B-Leukemic cell lines EHEB and JVM-2 indicated similar results (data not shown). 
Abbreviations: AA-arachidonic acid; EPA- eicosapentaenoic acid; DPA- docosapentaenoic acid; DHA- 
docosahexaenoic acid; (X:Yn-3/6): X denotes number of carbon atoms, Y denotes number of unsaturations, n-3: 
omega 3, n-6: omega 6.  
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EPA and DHA Differentially Sensitize Malignant B-lymphocytes to 
Doxorubicin, Vincristine and Fludarabine In Vitro 
In our study, we wanted to determine whether FA pre-treatment would synergistically 
increase the cytotoxic effects (greater effect than the sum effect due to FA and drug individually) 
of anti-cancer drugs doxorubicin, vincristine or fludarabine on three different B-leukemic cells. 
Thus, all measurements obtained from the MTT assay following treatment with the anti-cancer 
drug in the presence of vehicle, or FA were compared to cells treated with vehicle or FA only. 
Figure 3.3A illustrates the in vitro sensitivity of EHEB to doxorubicin (0–7.5 μM) in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, cell viability was 
significantly reduced in cells pre-treated with either EPA or DHA but not with AA when treated 
with doxorubicin. 
Figure 3.3B illustrates the in vitro sensitivity of EHEB to fludarabine (0-50μM) in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, cell viability was 
significantly reduced in cells pre-treated with EPA when treated with fludarabine (30μM and 
40μM). However, there was no difference in the sensitivity of EHEB to fludarabine when cells 
were pre-treated with either AA or DHA. It is interesting to note that AA pretreatment had a non-
significant slightly protective effect on EHEB cells treated with fludarabine. 
Compared to vehicle, pre-treatment with AA, EPA or DHA did not significantly change 
the sensitivity of EHEB to vincristine (Appendix, Supplementary Figure 3.1). 
In our model, an increase in chemo-sensitivity of cells to the drug by FA can be mediated 
by both enhanced cell death and/or enhanced growth-inhibition. To determine whether the 
decreases in cell viability seen in the MTT assays were a result of enhanced cell death or of 
growth-inhibition we performed an Annexin-V assay. 
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Figure 3.3C illustrates the % dead EHEB cells (± SEM) in the presence or absence of 
vehicle, AA, EPA, or DHA alone and after treatment with doxorubicin (1.5μM) or fludarabine 
(40μM). The concentration of doxorubicin (1.5μM) was chosen as this concentration induced a 
significant difference in cell viability between FA and vehicle pre-treated cells and because this 
concentration is clinically achievable (Muller et al., 1993). The concentration of fludarabine 
(40μM) was chosen as this concentration induced the greatest significant difference in cell 
viability between EPA and vehicle pre-treated cells (Figure 3.3B); however, this concentration is 
~5-10 times greater than the peak plasma concentration of fludarabine (Foran et al., 1999). 
Compared to vehicle, cells pre-treated with DHA, but without drug, had significantly higher cell 
death. The addition of doxorubicin or fludarabine to DHA pre-treated cells significantly 
increased cell death as compared to vehicle and drug treatment. Cell death was mediated 
predominately through apoptosis (Figure 3.3C). In cells treated with doxorubicin or fludarabine, 
pre-treatment with either AA or EPA did not increase cell death as compared to vehicle. Figure 
3.3D displays a graphical 2D representation of Annexin-V/PI plots of EHEB cells pre-treated 
with either vehicle or DHA and following treatment with doxorubicin or fludarabine. 
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  Figure 3. 3. In vitro sensitivity of EHEB following treatment with doxorubicin or fludarabine in the 
presence and absence vehicle, AA, EPA or DHA. 
Figure 3.3A illustrates the % cell viability ± SEM of EHEB to doxorubicin (0-7.5µM) in the presence or 
absence of vehicle, AA25µM, EPA50µM or DHA75µM. Cells pre-treated with either EPA or DHA had 
significantly greater decreases in cell viability as compared to vehicle when treatment with doxorubicin. Figure 
3.3B illustrates the % cell viability ± SEM of EHEB to fludarabine (0-50µM) in the presence or absence of 
vehicle, AA25µM, EPA50µM or DHA75µM. Pre-treatment of cells with EPA had significantly greater 
reductions in cell viability as compared to vehicle when treated with 30µM and 40µM fludarabine. Figure 3.3C 
illustrates the % dead cells ± SEM of EHEB following pre-treatment with vehicle, AA25µM, EPA50µM or 
DHA75µM alone and following treatment with 1.5µM doxorubicin or 40µM fludarabine. The % cell death was 
determined by annexin-V/propidium iodide duel stain with flow cytometry. Pre-treatment with DHA alone 
induced significantly greater cell death as compared to vehicle. Compared to vehicle, cells pre-treated with DHA 
had significantly higher cell death when treated with doxorubicin or fludarabine. Figure 3.3D provides 2D 
graphical representations of Annexin-V/PI Plots. „Early‟ Apoptosis was defined as cells positive for Annexin-V-
FITC only. „Late‟ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. „Necrotic‟ was defined 
as cells positive for PI only. Statistical significance was determined by Multiple Comparison Test with Dunnet‟s 
correction  (Figures 3.3A and B) or Tukey‟s correction (Figure 3.3C). α = 0.05, * <0.05, **<0.01, ***< 0.001.  
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Figure 3.4A illustrates the in vitro sensitivity of JVM-2 to doxorubicin (0–7.5μM) in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, all FA pre-treatment 
significantly decreased cell viability due to doxorubicin treatment. 
Figure 3.4B illustrates the in vitro sensitivity of JVM-2 to vincristine (0-250nM) in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, only DHA pre-
treatment significantly decreased cell viability due to vincristine treatment.  
Pre-treatment with AA, EPA or DHA did not induce any significant differences in the 
sensitivity of JVM-2 cells to fludarabine (Appendix, Supplementary Figure 3.2). 
Figure 3.4C illustrates the % dead JVM-2 cells (± SEM) in the presence or absence of 
vehicle, AA, EPA, or DHA alone and following treatment with doxorubicin (1.5μM) or 
vincristine (100nM). The concentration of vincristine (100nM) was chosen as this concentration 
induced a significant difference in cell viability between DHA and vehicle pre-treated cells and 
because this concentration is clinically achievable (Guilhaumou et al., 2011). Compared to 
vehicle, pre-treatment with DHA alone induced significant cell death. Pre-treatment with DHA 
significantly increased cell death due to either doxorubicin or vincristine treatment. Figure 3.4D 
displays a graphical 2D representation of Annexin-V/PI plots of JVM-2 cells pre-treated with 
either vehicle or DHA and following treatment with doxorubicin or vincristine. 
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  Figure 3. 4.In vitro sensitivity of JVM-2 following treatment with doxorubicin or vincristine in the 
presence and absence vehicle, AA, EPA or DHA. 
 Figure 3.4A illustrates the % cell viability ± SEM of JVM-2 to doxorubicin (0-7.5µM) in the presence or 
absence of vehicle, AA35µM, EPA50µM or DHA50µM. Cells pre-treated with AA, EPA or DHA induced 
significantly greater decreases in cell viability as compared to vehicle when treated with doxorubicin. Figure 
3.4B illustrates the % cell viability ± SEM of JVM-2 to vincristine (0-250nM) in the presence or absence of 
vehicle, AA35µM, EPA50µM or DHA50µM. Compared to vehicle, only cells pre-treated with DHA had 
significantly greater reductions in cell viability when treatment with vincristine. Figure 3.4C illustrates the % 
dead cells ± SEM of JVM-2 following pre-treatment with vehicle, AA35µM, EPA50µM or DHA75µM alone 
and following treatment with 1.5µM doxorubicin or 100nM vincristine. Pre-treatment with DHA alone induced 
significantly greater cell death as compared to vehicle. Compared to vehicle, Cells pre-treated with DHA had 
significantly greater cell death when treated with doxorubicin or vincristine. Figure 3.4D provides 2D graphical 
representations of Annexin-V/PI Plots. „Early‟ Apoptosis was defined as cells positive for Annexin-V-FITC 
only. „Late‟ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. „Necrotic‟ was defined as cells 
positive for PI only. Statistical significance was determined by Multiple Comparison Test with Dunnet‟s 
correction (Figures 3.4A and B) or Tukey‟s correction (Figure 3.4C). α = 0.05, * <0.05, **<0.01, ***< 0.001.  
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Figure 3.5A illustrates the in vitro sensitivity of MEC-2 to doxorubicin (0–7.5μM) in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, pre-treatment with 
either EPA or DHA significantly decreased cell viability due to doxorubicin treatment. 
Figure 3.5B illustrates the in vitro sensitivity of MEC-2 to vincristine (0-250nM) in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, pre-treatment with 
either EPA or DHA significantly decreased viability of cells treated with vincristine. 
Pre-treatment of cells with AA, EPA or DHA did not increase the sensitivity of MEC-2 to 
fludarabine (Appendix, Supplementary Figure 3.3). 
Figure 3.5C illustrates the % dead cells ± SEM of MEC-2 in the presence or absence of 
vehicle, AA, EPA, or DHA alone and following treatment with doxorubicin (1.5μM) or 
vincristine (100nM). Compared to vehicle, cells pre-treated with DHA alone had significantly 
higher cell death; whereas cells pre-treated with either AA or EPA had significantly less cell 
death. The addition of doxorubicin or vincristine to DHA pre-treated cells induced higher cell 
death as compared to vehicle; however, this was only significant when compared to AA pre-
treated cells. Figure 3.5D displays a graphical 2D representation of Annexin-V/PI plots of MEC-
2 cells pre-treated with either vehicle or DHA and following treatment with doxorubicin or 
vincristine. 
  
122 
 
 
MEC-2
Annexin-V/Propidium Iodide Duel Stain
C
on
tr
ol
Ve
hi
cl
e
A
A
25
µM
EP
A
50
µM
D
H
A
50
µM
C
on
tr
ol
Ve
hi
cl
e
A
A
25
µM
EP
A
50
µM
D
H
A
50
µM
C
on
tr
ol
Ve
hi
cl
e
A
A
25
µM
EP
A
50
µM
D
H
A
50
µM
0
20
40
60
80
100
% Early Apoptotic
% Late Apoptotic
% Necrotic
***
***
**
*
*
No Drug
(+) 1.5µM Doxorubicin
(+) 100nM Vincristine
%
 D
e
a
d
 C
e
ll
s
 ±
 S
E
M
A
B
C
P
ro
p
id
iu
m
 I
o
d
id
e
Annexin-V-FITC
Vehicle Vehicle + 1.5µM Dox Vehicle + 100nM Vin
DHA50µM DHA50µM + 1.5µM Dox DHA50µM + 100nM Vin
76.8%
1.2%
Necrotic
13.0%
Late
Apoptosis
Early
Apoptosis
9.0%
61.3%
4.7% 22.9%
11.2%
59.3%
1.0% 16.7%
23.0% 45.4%
10.8% 29.6%
14.2%
34.8%
4.2% 19.2%
41.8% 22.7%
2.5% 50.9%
23.9%
D
MEC-2
Live Cell Fraction (compared to no Doxorubicin)
0 2 4 6 8
0.0
0.2
0.4
0.6
0.8
1.0
1.2 Control
Vehicle
AA-25µM
EPA-50µM
DHA-50µM
**
*
* **
*
Doxorubicin Concentration [µM]
%
 C
e
ll
 V
ia
b
il
it
y
 (
1
=
1
0
0
%
) 
±
 S
E
M
MEC-2
Live Cell Fraction (compared to no Vincristine)
0 100 200 300
0.4
0.6
0.8
1.0
Control
Vehicle
AA25µM
EPA50µM
DHA50µM
**
**
*
** **
**
**
**
Vincristine Concentration [nM]
%
 C
e
ll
 V
ia
b
il
it
y
 (
1
=
1
0
0
%
) 
±
 S
E
M
123 
 
  
Figure 3. 5. In vitro sensitivity of MEC-2 following treatment with doxorubicin or vincristine in the 
presence and absence vehicle, AA, EPA or DHA. 
Figure 3.5A illustrates the % cell viability ± SEM of MEC-2 to doxorubicin (0-7.5µM) in the presence or 
absence of vehicle, AA25µM, EPA50µM or DHA50µM. Cells pre-treated with either EPA or DHA had 
significantly greater decreases in cell viability as compared to vehicle when treated with doxorubicin. Figure 
3.5B illustrates the % cell viability ± SEM of MEC-2 to vincristine (0-250nM) in the presence or absence of 
vehicle, AA25µM, EPA50µM or DHA50µM. Cells pre-treated with either EPA or DHA had significantly 
greater decreases in cell viability as compared to vehicle following treatment with vincristine. Figure 3.5C 
illustrates the % dead cells ± SEM of MEC-2 following pre-treatment with vehicle, AA25µM, EPA50µM or 
DHA50µM alone and following treatment with 1.5µM doxorubicin or 100nM vincristine. Compared to vehicle, 
pre-treatment DHA alone induced significantly greater cell death; whereas pre-treatment with either AA or EPA 
induced significantly lower cell death. Cells pre-treated with DHA had higher cell death, as compared to vehicle, 
when treated with doxorubicin or vincristine; however, this was only significant when compared against AA pre-
treated cells. Figure 3.5D provides 2D graphical representations of Annexin-V/PI Plots. „Early‟ Apoptosis was 
defined as cells positive for Annexin-V-FITC only. „Late‟ Apoptosis was defined as cells positive for Annexin-
V-FITC and PI. „Necrotic‟ was defined as cells positive for PI only. Statistical significance was determined by 
Multiple Comparison Test with Dunnet‟s correction (Figures 3.5A and B) or Tukey‟s correction (Figure 3.5C). 
α = 0.05, * <0.05, **<0.01, ***< 0.001.  
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N-3 Alone and in Combination with Anti-cancer Drugs Induce G2/M Arrest 
We wanted to determine whether increased chemo-sensitivity by FA was also associated 
with enhanced growth-inhibition; thus, we performed a cell-cycle analysis. Inhibition of cell-
cycle progression leads to growth-inhibition (reduced proliferation). 
Table 3.1 illustrates the mean G1/G2 ratio ± SEM of all three cell lines in the presence of 
vehicle, AA, EPA or DHA alone and following treatment with 1.5μM doxorubicin (EHEB, 
JVM-2, MEC-2), 40μM fludarabine (EHEB), or 100nM vincristine (JVM-2, MEC-2). Cell cycle 
analysis was not performed on EHEB following treatment with vincristine or on JVM-2 and 
MEC-2 following treatment with fludarabine as there were no significant differences in the in 
vitro sensitivity of these cell lines to these drugs in the presence AA, EPA or DHA as compared 
to vehicle. 
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Table 3. 1. Cell Cycle Analysis: G1/G2 Ratio 
EHEB          
 Control ± 
SEM 
Vehicle ± 
SEM 
p-value AA25µM ± 
SEM 
p-value EPA50µM ± 
SEM 
p-value DHA75µM ± 
SEM 
p-value 
(-) Drugs 4.1 ± 0.09 4.3 ± 0.04 NS 3.7 ± 0.8 NS 4.0 ± 0.50 NS 4.2 ± 0.20 NS 
(+) 1.5µM Dox 9.2 ± 0.21 9.0 ± 0.27 NS 9.5 ± 0.32 NS 8.9 ± 0.72 NS 5.8 ± 0.77 <0.05 
(+) 40µM Flud 13.3 ± 0.21 15.5 ± 0.04 NS 13.5 ± 0.19 NS 11.6 ± 2.08 NS 4.9 ± 0.22 <0.01 
JVM-2          
 Control ± 
SEM 
Vehicle ± 
SEM 
p-value AA35µM ± 
SEM 
p-value EPA50µM ± 
SEM 
p-value DHA50µM ± 
SEM 
p-value 
(-) Drugs 2.4 ± 0.14 2.4 ± 0.04 NS 2.2 ± 0.06 NS 1.8  ±0.12 NS 1.8  ± 0.09 <0.05 
(+) 1.5µM Dox 2.9 ± 0.16  3.1 ± 0.18 NS 2.6 ±0.00 NS 2.6 ± 0.07 NS 2.18 ± 0.23 <0.05 
(+) 100nM Vin 1.2 ± 0.00 1.2 ± 0.02 NS 0.9 ±0.00 <0.05 0.8 ±0.01 <0.01 0.9 ±0.06 <0.05 
MEC-2          
 Control ± 
SEM 
Vehicle ± 
SEM 
p-value AA25µM ± 
SEM 
p-value EPA50µM ± 
SEM 
p-value DHA50µM ± 
SEM 
p-value 
(-) Drugs 5.2 ± 0.29 4.8 ± 0.10 NS 4.9 ± 0.37 NS 3.6 ± 0.14 <0.05 2.8 ± 0.28 < 0.001 
(+) 1.5µM Dox 3.0 ± 0.11 2.8 ± 0.23 NS 1.5 ± 0.08 <0.001 1.12 ± 0.10 <0.001 1.1 ±0.15 <0.001 
(+) 100nM Vin 1.2 ± 0.07 1.4 ± 0.19 NS 0.7 ± 0.06 <0.05 0.6 ± 0.04 <0.01 0.9 ± 0.18 NS 
Table 3.1. Pre-treatment with FAs alone and following treatment with doxorubicin, vincristine or fludarabine induce G2/M arrest. Table 3.1 
illustrates the G1/G2 ratios ± SEM of EHEB, JVM-2 and MEC-2 following treatment with 1.5µM doxorubicin, 100nM vincristine or 40µM fludarabine in 
the presence or absence of vehicle, AA, EPA or DHA. Treatment with DHA alone indicated significantly lower ratios of G1/G2, indicative of G2/M arrest, as 
compared to vehicle in all three cell lines. Treatment with EPA indicated a significantly lower G1/G2 ratio as compared to vehicle in MEC-2. Pre-treatment 
with AA, EPA or DHA indicated significantly lower G1/G2 ratios as compared to vehicle following treatment with doxorubicin or vincristine. Only pre-
treatment with DHA indicated a significantly lower G1/G2 ratio as compared to vehicle following treatment with fludarabine in EHEB. Statistical 
significance was determined by Multiple Comparison Test using Tukey‟s correction. Abbreviations: Dox: doxorubicin, Vin: Vincristine, Flud: Fludarabine. α 
= 0.05, * <0.05, **<0.01, ***< 0.001.  
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FA treatment alone: A significantly lower G1/G2 ratio indicates G2/M arrest. Treatment 
with EPA alone induced a significantly lower G1/G2 ratio, as compared to vehicle in MEC-2 (p: 
<0.05). Treatment with DHA alone induced a significantly lower G1/G2 ratio as compared to 
vehicle in JVM-2 and MEC-2 (p: <0.05 and <0.001; respectively). Treatment with AA alone did 
not induce any significant differences in the G1/G2 ratio as compared to vehicle in EHEB, JVM-
2 or MEC-2. 
FA plus drug treatment: Cells pre-treated with AA had significantly lower G1/G2 ratios 
as compared to vehicle when treated with doxorubicin (p: <0.001 in MEC-2) or vincristine (p: 
<0.05 and <0.05 in JVM-2 and MEC-2, respectively). 
Cells pre-treated with EPA had significantly lower G1/G2 ratios as compared to vehicle 
when treated with doxorubicin (p:<0.001 in MEC-2) or vincristine (p:<0.01 in JVM-2 and MEC-
2). Cells pre-treated with DHA had significantly lower G1/G2 ratios as compared to vehicle 
when treated with doxorubicin (p: <0.05, <0.05, and <0.001 in EHEB, JVM-2 and MEC-2, 
respectively), fludarabine (p:<0.01 in EHEB), or vincristine (p:<0.05 and <0.001 in JVM-2 and 
MEC-2, respectively). 
N-3 Increases Generation of Intracellular ROS 
To investigate ROS production in response to AA, EPA or DHA alone and following 
treatment with doxorubicin or fludarabine we used a CM-H2DCFDA probe. 
Figure 3.6A illustrates mean relative fluorescence units (RFU) ± SEM across time for 
MEC-2. Of the 3 cell types, ROS were increased only in MEC-2 cells due to pre-treatment with 
either EPA or DHA. Linear regression analysis indicated that the rate of increase in ROS was 
significantly greater in DHA pre-treated MEC-2 cells than in vehicle pre-treated cells (Mean 
slope (RFU)/min: 0.683 versus 0.267, p: <0.01). Similarly, the rate of increase in ROS was 
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greater in the presence of EPA than in vehicle treated MEC-2 cells (Mean slope (RFU)/min: 
0.483 versus 0.267, p: 0.08); however this was not statistically significant. Pre-treatment with 
AA did not induce any differences in the levels of ROS as compared to vehicle. 
N-3 Increases Lipid Peroxidation 
To investigate the formation of lipid peroxides in response to AA, EPA or DHA 
treatment alone and with doxorubicin, fludarabine or vincristine, levels of thiobarbituric acid 
reactive substances (TBARS, byproducts of lipid peroxidation) were evaluated and compared to 
a malondialdehyde (MDA, (a TBARS)) standard curve. Figure 3.6B illustrates the mean ng 
MDA/μg of protein ± SEM of MEC-2 treated in the presence of vehicle, AA, EPA or DHA alone 
and following treatment with 1.5μM doxorubicin or 100nM vincristine. Pre-treatment of MEC-2 
cells with DHA alone induced significantly higher levels of TBARs than did vehicle. Only DHA 
pre-treatment induced significantly higher levels of TBARs in doxorubicin treated cells. Cells 
pre-treated with either EPA or DHA had significantly lower levels of TBARs when treated with 
vincristine as compared to the FA alone. Analysis of TBARs levels following treatment with 
fludarabine were not performed as no statistical differences were found in the in vitro sensitivity 
trials. EHEB and JVM-2 had similar trends in levels of TBARs following n-3 pre-treatment as 
observed in MEC-2; however, the drug treatment did not induce any significant differences as 
compared to vehicle or n-3 alone (Appendix, Supplementary Figure 3.4). 
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Figure 3. 6. Chemo-sensitizing capability of DHA is mediated through generation of intracellular ROS 
and formation of lipid peroxides. 
 Figure 3.6A illustrates mean relative fluorescence units ± SEM of MEC-2 over the course of 2 hours following 
72 hour pre-treatment with vehicle, AA25µM, EPA50µM or DHA50µM. Intracellular ROS was determined 
using 5-(and-6-)chloromethyl-2‟,7‟-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) dye. 
Treatment with either EPA or DHA alone induced significant increases in ROS generation. Linear regression 
analysis indicated a greater slope following treatment with EPA or DHA versus vehicle (0.483 and 0.683 versus 
0.267) indicating an increased generation of ROS across time. The addition of doxorubicin did not significantly 
alter levels of ROS as compared to vehicle or FA alone (Appendix, Supplementary Figure 3.5). Figure 3.6B 
illustrates the mean ng MDA/µg protein ± SEM in the presence or absence of vehicle, AA25µM, EPA50µM or 
DHA50µM alone and following treatment with doxorubicin (1.5µM) or vincristine (100nM). Pre-treatment with 
DHA alone induced significantly higher levels of MDA as compared to vehicle. The addition of doxorubicin to 
DHA pre-treated cells induced significantly higher levels of MDA versus either alone. The addition of 
vincristine to either EPA or DHA pre-treated cells induced significantly lower levels of MDA as compared to n-
3 or drug alone. Figure 3.6C illustrates the % cell viability ± SEM of MEC-2 following treatment with 1.5µM 
doxorubicin and 50µM vitamin E alone and in combination in the presence or absence of vehicle, AA25µM, 
EPA50µM or DHA50µM. Compared to vehicle, cells pre-treated with DHA had significantly greater reductions 
in cell viability when treated with doxorubicin. Co-treatment of DHA pre-treated cells with doxorubicin and 
vitamin E abrogated the enhanced sensitivity of MEC-2 to doxorubicin by DHA. Figure 3.6D illustrates the 
mean ng MDA/µg protein ± SEM of MEC-2 following pre-treatment with DHA alone and after treatment with 
1.5µM doxorubicin alone and in combination with 50µM vitamin E. Co-treatment with doxorubicin and vitamin 
E in DHA pre-treated cells indicated significantly lower levels of MDA versus doxorubicin alone. Statistical 
significance was determined by Multiple Comparison Test with Tukey‟s correction. Abbreviations: MDA: 
malondialdehyde, α = 0.05, * <0.05, **<0.01, ***< 0.001.  
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Vitamin E Abrogates Enhanced Sensitization of MEC-2 to Doxorubicin by 
DHA 
To validate that the ability of n-3 to sensitize malignant B-lymphocytes to doxorubicin is 
dependent on the formation of toxic lipid peroxides, we tested the in vitro sensitivity of MEC-2 
in the presence of vehicle, AA, EPA or DHA alone and following treatment with 1.5μM 
doxorubicin alone or in combination with 50μM vitamin E. Figure 3.6C illustrates the in vitro 
sensitivity of MEC-2 to 1.5μM doxorubicin and 50μM vitamin E alone and in combination in the 
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, DHA pre-treated cells 
had significantly greater reductions in viability when treated with doxorubicin. The addition of 
vitamin E abrogated the enhanced sensitization of MEC-2 to doxorubicin by DHA. In agreement 
with the in vitro sensitivity trial, co-treatment of DHA pre-treated cells with doxorubicin and 
vitamin E induced significant reductions in the levels of TBARs as compared to doxorubicin 
alone (Figure 3.6D). 
DISCUSSION 
Chronic lymphocytic leukemia is the most common form of adult leukemia in the 
western world (Riches et al., 2011). Clinical treatment of CLL is often limited due to drug 
resistance and severe toxicities associated with chemotherapy (Riches et al., 2011; Schriever & 
Huhn, 2003; Silber et al., 1994). A therapeutic intervention that could enhance the sensitivity of 
CLL cells to anti-cancer drugs without causing additional adverse effects would be clinically 
beneficial. 
Omega-3 fatty acids have consistently been shown to enhance the sensitivity of various 
solid tumor cells to chemotherapy in vitro (Germain et al., 1998; Kinsella & Black, 1993) and in 
vivo (Borgeson et al., 1989; Hardman et al., 2001; Shao et al., 1997). However, this has not been 
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shown in CLL. Previous results from our group indicated that consumption of an n-3 supplement 
enhanced the sensitivity of lymphocytes isolated from patients with early stage (Rai 0,1) CLL to 
doxorubicin in an in vitro assay (Fahrmann et al., 2013). These findings prompted us to further 
evaluate the potential use of n-3 as chemo-sensitizing agents for the treatment of CLL. 
The primary purpose of this study was to illustrate that pre-treatment of B-CLL-and B-
PLL-derived cells with n-3 increases the sensitivity of cells to actively used chemotherapeutic 
drugs: doxorubicin and vincristine, components of the CHOP (cyclophosphamide, doxorubicin, 
vincristine and prednisone) regimen (Leporrier et al., 2001; Van der Jagt et al., 2012), or 
fludarabine, a commonly used first-line treatment option for CLL (Riches et al., 2011; Silber et 
al., 1994). Rather than testing combination therapies, we evaluated the ability of n-3 to enhance 
the sensitivity of malignant B-lymphocytes to single-arm treatments. Secondary objectives were 
to elucidate potential mechanism(s) by which n-3 enhanced chemo-sensitivity. 
Although designated as a single disease, CLL is characterized by biological and clinical 
heterogeneity. For these reasons, we particularly wanted to demonstrate that the chemo-
sensitizing effects of n-3 were not limited to one specific cell sub-type (cell line). Rather we 
wanted to demonstrate that the chemo-sensitizing effects of n-3 would be seen in multiple cell-
types. Thus, each cell line could be viewed as a distinct case of CLL. 
For the purposes of this study, we used the highest concentrations FAs that alone did not 
induce significant cytotoxicity (Figures 3.1A-C). Our results indicated that clinically achievable 
concentrations of EPA and DHA generally, but not equally, sensitized the B-leukemic cells to 
the drugs. Only JVM-2 cells were sensitized to doxorubicin (1.5μM) when cells were pre-treated 
with AA (Figure 3.4A), indicating that the chemo-sensitizing capabilities of FAs are more likely 
to be found amongst n-3 fatty acids than n-6 fatty acids. This is an important consideration. The 
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western diet is heavily favored towards n-6 FA with little to no n-3 FA intake (Simopoulos, 
2000, 2002). Omega-3 and n-6 FAs compete with each other for incorporation into the cell 
(Simopoulos, 2000, 2002). The addition of n-3 as an augment to therapy may, therefore, provide 
clinical benefit to the patient receiving therapy. We are currently conducting a clinical trial to 
determine if we will see the same chemo-sensitizing capabilities of n-3 on lymphocytes isolated 
from patients with CLL. 
 We have illustrated that pre-treatment with n-3 increased the sensitivity of B-CLL- and 
B-PLL-derived cells to three actively used chemo-therapeutic drugs. While doxorubicin, 
vincristine and fludarabine have different mechanisms by which they exert their cytotoxic 
effects, all three drugs can induce cell death and/or growth-inhibition. Thus, increasing the 
sensitivity of cells to the drug is not a function limited to increased cell death, but can also be 
mediated through increased growth-inhibition (reduced proliferation). Both cell death and/or 
growth-inhibition leads to a decrease in numbers of viable cells in culture. For these reasons, we 
performed Annexin-V assays, as a measure of cellular death, and cell cycle analyses, as an 
indirect measure of growth (proliferation). Increased cell death and/or increased growth-
inhibition are clinically relevant and would provide benefit to the patient. 
Collectively, our results indicated that pre-treatment with DHA, as compared to vehicle, 
enhanced cell death due to doxorubicin in all three cell lines, vincristine in two (JVM-2 and 
MEC-2) of the three cell lines, and fludarabine in one (EHEB) of the three cell lines. Increased 
cell death is clinically beneficial and would improve the outcome of the patient receiving 
therapy. 
Noteworthy, MEC-2, which harbors a p53 mutation, showed enhanced cell death due to 
vincristine or doxorubicin when pre-treated with DHA as compared to vehicle. This is an 
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important observation. The loss of short arm p13 of chromosome 17, which disrupts the p53 
tumor suppressor gene, is found in approximately 5-10% of all CLL patients and is associated 
with particularly poor prognosis and chemorefractoriness (Gaidano, Foa, & Dalla-Favera, 2012). 
N-3 may provide a beneficial augment to the treatment of chemorefractory CLL patients. 
We performed cell-cycle analyses to determine whether increased chemo-sensitivity by 
FA was associated with enhanced growth-inhibition. Previous studies have demonstrated that n-3 
treatment alone can induce cell cycle arrest at the G2/M phase (Dekoj et al., 2007). Vincristine is 
a mitotic inhibitor known to induce cell cycle arrest at the M phase (Casado et al., 2009). 
Similarly, studies have indicated that malignant cells in G2/M arrest are more sensitive to 
doxorubicin than normal cells (Ling, el-Naggar, Priebe, & Perez-Soler, 1996; Tyagi, Singh, 
Agarwal, Chan, & Agarwal, 2002). For these reasons, we were particularly interested in the ratio 
of cells in G1 (G0 + G1) and G2 (G2 + M) phases. An increase in the population of cells in the 
G2 (G2 + M) phase is indicative of G2/M arrest. Thus, an increase in G2 (G2 + M) would result 
in a lower population of cells in G1 (G0 + G1) and a lower G1/G2 ratio. A decrease in the G1/G2 
ratio (indicative of G2/M arrest) would be expected to result in growth-inhibition (reduced 
proliferation). 
Our results illustrate that cells pre-treated with n-3, but without drug, had significantly 
greater G2/M arrest, indicated by a lower G1/G2 ratio, as compared to vehicle pre-treated cells 
(Table 3.1). This demonstrates that n-3 by themselves can potentially slow the growth of 
malignant B-lymphocytes. This is of considerable interest as we had previously shown that 
consumption of n-3 decreased the activity of nuclear factor kappa B (NFκB) in isolated 
lymphocytes of patients with early stage CLL and would be expected to slow the progression of 
the disease (Fahrmann et al., 2013). Studies have shown that inhibition of NFκB activation leads 
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to cell cycle arrest at the G2/M phase aiding to both growth-inhibition and cell death (Zhang, 
Ruan, et al., 2012; Zhang, Tao, et al., 2012). Future studies will be aimed in determining if n-3 
can slow the progression and growth of CLL and whether growth-inhibition is mediated through 
suppression of NFκB activation and G2/M arrest. Slowing the progression of CLL by n-3 FAs 
could be a therapeutic choice in patients for whom standard chemotherapy is not an option. 
The addition of doxorubicin to FA pre-treated cells induced significantly greater G2/M 
arrest than when cells were not treated with n-3 prior to doxorubicin (Table 3.1). It is interesting 
to note that cells pre-treated with either EPA (MEC-2) or DHA (EHEB, JVM-2 and MEC-2) 
which had significantly greater G2/M arrest due to doxorubicin also showed increased chemo-
sensitivity to doxorubicin than did cells pre-treated with vehicle (Figures 3.3A, 3.4A and 3.5A). 
This suggests that n-3 plus doxorubicin induced greater growth-inhibition than doxorubicin 
alone. This notion is supported by other investigators who have shown that cells in G2/M arrest 
are more sensitive to doxorubicin as compared to normal cells (Ling et al., 1996; Tyagi et al., 
2002) and, importantly, that enhanced sensitivity of cells in G2/M arrest to doxorubicin was 
mediated through both growth-inhibition and apoptosis (Tyagi et al., 2002). 
Similarly, the addition of vincristine (JVM-2 and MEC-2) or fludarabine (EHEB) to cells 
pre-treated with certain FAs (all FAs in JVM-2, AA and EPA in MEC-2, DHA in EHEB) had 
significantly greater G2/M arrest as compared to vehicle pre-treated cells (Table 3.1). However, 
there was no association between the increase in chemo-sensitivity of cells to vincristine (JVM-2 
and MEC-2) or fludarabine (EHEB) by FA and the increase in G2/M arrest. 
Numerous pre-clinical studies have demonstrated that enhanced chemo-sensitization by 
n-3, particularly DHA, was dependent on the formation of toxic lipid peroxides and generation of 
ROS  (Begin, Ells, Das, & Horrobin, 1986; Begin, Ells, & Horrobin, 1988; Das & Madhavi, 
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2011; Germain et al., 1998; Hardman et al., 2001; Kang et al., 2010). We wanted to determine 
whether the increase in chemo-sensitivity of cells to the anti-cancer drugs by FA was dependent 
on the induction of oxidative stress. Our results illustrate that n-3 induced significantly higher 
levels of intracellular ROS than did vehicle in MEC-2 cells (Figure 3.6A). Linear regression 
analysis indicated an increased rate of ROS generation in the presence of either EPA or DHA as 
compared to vehicle. However, this effect was not enhanced by the addition of any of the anti-
cancer drugs. Results also illustrate that treatment with n-3 alone induced higher levels of 
TBARS, (products of lipid peroxidation), as compared to vehicle in all three cell lines (only 
MEC-2 is shown, Figure 3.6B). Only MEC-2 had significantly higher levels of TBARs following 
treatment with doxorubicin in cells pre-treated with DHA as compared to cells treated with DHA 
or doxorubicin alone (Figure 3.6B). The addition of vitamin E, a fat soluble anti-oxidant, 
abrogated the enhanced sensitivity of MEC-2 to doxorubicin by DHA (Figure 3.6C) and 
decreased the levels of TBARS (Figure 3.6D). The fact that enhanced sensitivity of MEC-2 to 
doxorubicin by DHA and increased formation of TBARs was abrogated by vitamin E supports 
the notion that enhanced chemo-sensitivity by DHA is, in part, dependent on the formation of 
lipid peroxides. 
In conclusion, EPA and DHA differentially sensitized B-leukemic cell lines EHEB, 
JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro. Enhanced chemo-
sensitivity is likely mediated through both increased cellular death as well as growth-inhibition. 
Our results have shown that enhanced sensitivity is also, in part, dependent on the formation of 
toxic lipid peroxides. Additional work should be done to elucidate the mechanisms by which n-3 
increase chemo-sensitivity. Supplementation of the diet with n-3 fatty acids provides a promising 
non-toxic approach to not only sensitize CLL cells to anti-cancer drugs but may have 
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independent therapeutic benefit. Importantly, the chemo-sensitizing effects of n-3 do not appear 
to be limited to a specific cell-type or a specific drug. Increased chemo-sensitivity is clinically 
beneficial and would be expected to increase drug efficacy, and potentially reduce drug dosage 
resulting in decreased drug-induced toxicities. 
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APPENDIX 
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Supplementary Figure 3. 1. In Vitro sensitivity of EHEB following treatment with vincristine in the presence or 
absence of vehicle, AA, EPA or DHA. 
The % cell viability ± SEM of EHEB to vincristine (0-250nM) in the presence or absence of vehicle, AA25µM, 
EPA50µM or DHA75µM is shown. Pre-treatment with AA, EPA or DHA did not induce any significant differences 
in the sensitivity of EHEB cells to vincristine. 
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Supplementary Figure 3. 2. In Vitro sensitivity of JVM-2 following treatment with fludarabine in the presence 
or absence of vehicle, AA, EPA or DHA. 
The % cell viability ± SEM of JVM-2 to fludarabine (0-40µM) in the presence or absence of vehicle, AA35µM, 
EPA50µM or DHA50µM is shown. Pre-treatment with AA, EPA or DHA did not induce any significant differences 
in the sensitivity of JVM-2 cells to fludarabine. 
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Supplementary Figure 3. 3. In Vitro sensitivity of MEC-2 following treatment with fludarabine in the presence or 
absence of vehicle, AA, EPA or DHA. 
The % cell viability ± SEM of MEC-2 to fludarabine (0-40µM) in the presence or absence of vehicle, AA25µM, 
EPA50µM or DHA50µM is shown. Pre-treatment with AA, EPA or DHA did not induce any significant differences in the 
sensitivity of MEC-2 cells to fludarabine. 
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Supplementary Figure 3. 4. Effects of FA pre-treatment alone and follwed by treatment with anti-cancer drugs on the 
formation of lipid peroxides and generation of ROS in EHEB and JVM-2. 
Supplementary Figure 3.4A illustrates mean relative fluorescence units ± SEM of EHEB over the course of 2 hours 
following 72 hour pre-treatment with vehicle, AA25µM, EPA50µM or DHA75µM. Intracellular ROS was determined using 
5-(and-6-)chloromethyl-2‟,7‟-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) dye. Compared to vehicle, 
pre-treatment with FA did not induce any significant changes in the levels or generation of ROS. Supplementary Figure 
3.4B illustrates the mean ng MDA/µg protein ± SEM of EHEB in the presence or absence of vehicle, AA25µM, EPA50µM or 
DHA75µM alone and following treatment with doxorubicin (1.5µM) or fludarabine (40µM). Pre-treatment with either EPA 
or DHA alone induced significantly higher levels of MDA as compared to vehicle. The addition of doxorubicin to FA pre-
treated cells did not induced any significantly changes in the levels of MDA versus either alone. The addition of fludarabine 
to DHA pre-treated cells induced significantly lower levels of MDA as compared to DHA or drug alone. Supplementary 
Figure 3.4C illustrates mean relative fluorescence units ± SEM of JVM-2 over the course of 2 hours following 72 hour pre-
treatment with vehicle, AA35µM, EPA50µM or DHA50µM. Compared to vehicle, pre-treatment with FA did not induce any 
significant changes in the levels or generation of ROS. Supplementary Figure 3.4D illustrates the mean ng MDA/µg protein 
± SEM of JVM-2 in the presence or absence of vehicle, AA35µM, EPA50µM or DHA50µM alone and following treatment 
with doxorubicin (1.5µM) or vincristine (100nM). Pre-treatment with DHA alone induced significantly higher levels of MDA 
as compared to vehicle. The addition of either doxorubicin or vincristine to FA pre-treated cells did not induce any significant 
differences in levels of MDA as compared to FA alone. Statistical significance was determined by Multiple Comparison Test 
with Dunnet‟s correction. Abbreviations: MDA: malondialdehyde, α = 0.05, * <0.05, **<0.01, ***< 0.001.; N.D.: no detect.  
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Supplementary Figure 3. 5. The addition of doxorubicin to FA pre-treated MEC-2 cells does not increase 
the generation of ROS versus either alone. 
Mean relative fluorescence units ± SEM of MEC-2 in the presence or absence of AA25µM, EPA50µM or 
DHA50µM alone and following treatment with 1.5µM doxorubicin is shown. The addition of doxorubicin to FA 
pre-treated cells did not increase the levels or generation of ROS versus FA alone. Abbrev. Dox: doxorubicin.  
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CHAPTER 4: DISCUSSIONS AND CONCLUSIONS 
The body of work performed and compiled in the previous chapters highlights the 
potential applications of n-3 as therapeutic options (both as adjuvants and individual treatments) 
for the treatment of CLL. In this context, it is important to remember the over-arching goal of 
these projects. It should be recalled that CLL is the most common form of adult leukemia in the 
western world (Gaidano, Foa, & Dalla-Favera, 2012). CLL is a disease of the elderly with a 
median age range of 60-68 years (Shanafelt & Call, 2004). CLL is typically diagnosed in the 
asymptomatic stages where “watchful waiting” remains the primary course of treatment 
(Shanafelt & Call, 2004). However, approximately 50% of these patients will progress to 
symptomatic stage and require therapy (Shanafelt & Call, 2004). Although numerous therapies 
exist for CLL, most are undermined due to progressive drug resistance which can manifest 
during the course of treatment and severe drug-induced toxicities which are often too toxic for 
the elderly or those with co-morbidities (Shanafelt & Call, 2004). Therefore, a non-toxic 
therapeutic intervention which could slow the progression of the disease or enhance the chemo-
sensitivity of malignant cells to chemotherapy would be clinically beneficial. Slowing 
progression of the early stages of the disease would provide improved quality of life and clinical 
benefit. Increased chemo-sensitivity for individuals who require therapy would increase drug 
efficacy and potentially reduce drug dosage, thereby reducing drug-induced toxicities. Similarly, 
increased tolerability of therapy regimens may also increase the number of chemotherapy cycles 
a patient can tolerate, thereby increasing the likelihood of receiving a response.   
Several studies have demonstrated that NF B can promote oncogenesis by virtue of its 
ability to regulate the expression of a wide array of genes that modulate apoptosis, proliferation, 
inflammation, tumor metastasis, and angiogenesis (Clevers, 2004). Constitutively active NF B 
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has been observed in various solid tumors as well as hematological malignancies (Braun et al., 
2006; Darnell, 2002; Ditsworth & Zong, 2004) and has been linked to aggressive tumor growth 
and resistance to both chemotherapy and radiotherapy (Li & Sethi, 2010). Consistent with these 
thoughts, NF B has been found to be constitutively active in CLL cells (Hewamana, Alghazal, et 
al., 2008; Hewamana, Lin, et al., 2008; Hewamana et al., 2009). Studies by Hewamana et al. 
indicated that increased binding of Rel A, a subunit of NF B which contains the transactivation 
domain, was positively correlated with WBC counts, a measure of tumor burden, and 
lymphocyte doubling time, a measure of tumor kinetics (Hewamana, Alghazal, et al., 2008). 
Furthermore, Hewamana et al. also demonstrated that Rel A DNA binding was strongly 
associated with Binet staging, predictive of time to initial treatment and subsequent treatment, 
and predictive of overall survival (Hewamana et al., 2009). Similarly, we found that NF B 
activation was positively correlated with WBC counts (Appendix, Supplementary Figure 2.2). 
Additionally, we found that patients who displayed „lower initial NF B activation‟ had 
significantly lower absolute lymphocyte counts (Mean ± SEM: 11.9 ± 3.2 x 10
3
 lymphocytes/µl 
vs 28.8 ± 4.0 x 10
3
 lymphocytes/µl; p: 0.009; Table 2.2) and tended to be at lower Rai stage 
(stage 0, 84% vs 58%, not statistically different by Fisher exact test) than patients exhibiting 
„higher initial NF B activation‟ at baseline. Collectively, our results support the observations of 
Hewamana et al. and indicate the prognostic value of NF B activity.  
Rel A DNA binding has also been shown to be negatively correlated with induction of 
spontaneous apoptosis in vitro suggesting that NF B is an important mediator of survival 
(Hewamana, Alghazal, et al., 2008). This is supported by the fact that inhibition of NF B 
activation, through the use of an irreversible-IKK inhibitor (LC-1), induced dose-responsive 
increases in apoptosis (Hewamana, Lin, et al., 2008). The addition of LC-1 was also able to 
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overcome the cytoprotective effects of CD40L and IL-4, upstream agonists of NF B activation, 
providing further support of the importance of NF B in CLL (Hewamana, Lin, et al., 2008). 
Inhibition of NF B activation by LC-1 was also shown to exhibit strong synergy with 
fludarabine, a commonly used first-line treatment in CLL (Riches, Ramsay, & Gribben, 2011; 
Silber et al., 1994), in both good prognostic CLL patients who were fludarabine-sensitive and 
poor prognostic CLL patients who displayed chemorefractoriness toward fludarabine 
(Hewamana, Lin, et al., 2008). Given the ability of NF B to promote survival of CLL cells in 
vitro and aid in various biological processes such as proliferation, migration, inhibition of 
apoptosis and chemo-resistance, a therapeutic interventions which target NF B would be of 
considerable interest and clinically relevant. 
In our initial study, we demonstrated that consumption of an n-3 supplement, 
predominately composed of EPA and DHA, suppressed activation of NF B in lymphocytes 
isolated from patients in the early stages of CLL (Figures 2.2. and 2.3). Gene expression profiles 
indicated that consumption of n-3 decreased the expression of 31 genes including genes known 
to be regulated by NF B (JMJD1C, ZNF644 and PTGS2; Table 2.4). Suppression of genes 
known to be regulated by NF B supports our findings that n-3 suppressed NF B activation. We 
also found that, in patients who were unwilling to take 7.2 g of n-3 per day, over time either 4.8 g 
or 2.4 g of n-3 per day also suppressed NF B to nearly normal levels. This provides an important 
piece of information as it indicates that a lower consumption of n-3 can provide equal benefit as 
a higher dose over a period of time. A lower dose would aid in study design allowing for 
increased compliancy rates and a decreased likelihood of adverse effects associated with n-3 
consumption.  
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In line with this thought, despite plasma concentrations of EPA and DHA being highest 
following consumption of 7.2 g of n-3/per day for a month of more, these concentration did not 
differ statistically from that following consumption of 4.8 g (6 capsules; composition: 2.4 g of 
EPA, 1.8 g of DHA, 0.6 g of other n-3) of n-3/day (Table 2.3). This suggests that plasma 
concentrations of EPA and DHA reached a state of saturation and that saturated concentrations 
of EPA or DHA can be achieved at lower concentrations. Our findings are supported by Yee et 
al. who indicated that a dose of ~2.5g/day EPA+DHA achieved the maximum possible elevation 
of concentrations in mammary tissue and blood in a supplementation study (Yee et al., 2010). 
Similarly, Arterburn et al. indicated that supplementation with 2g/day DHA resulted in plasma 
saturation (Arterburn, Hall, & Oken, 2006). Thus, consumption of a lower concentration of n-3 
over time could achieve similar effects as those observed at higher concentrations supporting our 
findings that either 2.4 g or 4.8 g of n-3 per day can also suppressed NF B activation. 
Evidence by our group and others (Hewamana, Alghazal, et al., 2008; Hewamana, Lin, et 
al., 2008; Hewamana et al., 2009) suggest that activated NF B correlates with disease 
progression. Therefore, inhibition of NF B activation would be expected to slow the progression 
of CLL.  Our results justify expansion into a definitive randomized clinical trial aimed to 
determine whether consumption of n-3 will slow the progression of early stage CLL to 
symptomatic CLL and whether clinical benefit is correlated with suppression of NF B 
activation. Given that CLL is a heterogeneous disease with a highly variable course of 
progression (Eichhorst, Dreyling, Robak, Montserrat, & Hallek, 2011; Gaidano et al., 2012); aim 
should be taken to target patients who are at risk of progressing quickly. This would allow for 
identification of potential clinical benefit in a short period of time, thereby preventing the use of 
long multi-year studies.  
149 
 
Although we have demonstrated that n-3 suppressed NF B activation in lymphocytes 
from our patient population, potential benefit from n-3 is likely multi-factorial, a trait provided 
by the diversity of the various n-3 metabolites. In this sense, the application of metabolomics 
coupled with lipidomics and genomic studies should be explored. The application of these types 
of profiling studies may provide key insight into the functionality and potential benefits of n-3 
consumption.  
Increasing evidence suggests that leukaemogenesis can be explained by epigenetic 
alterations (Chen, Odenike, & Rowley, 2010; Galm, Herman, & Baylin, 2006). Epigenetic 
changes, which include DNA methylation, histone modifications and microRNAs, alter gene 
expression without changing DNA sequences. Histone modifications alter gene expression 
through changes in chromatin composition and conformation. Our results indicated that 
consumption of n-3 reduced mRNA abundance of multiple genes associated with chromatin 
remodeling (Table 2.3). These genes are JMJD1C (JmjC domain-containing histone 
demthylation protein 2C) (Katoh & Katoh, 2007), CHD9 (a chromatin remodeling transcription 
regulator) (Marom, Shur, Hager, & Benayahu, 2006; Shur, Socher, & Benayahu, 2006), ASH1L 
(a histone methyltransferase) (An, Yeo, Jeon, & Song, 2011) and PKN2 (a histone deacetylase 5 
interacting protein) (Harrison et al., 2010). Current studies are underway to determine whether n-
3, EPA, induces changes in histone post-translational modifications (PTMs) in lymphocytes 
isolated from patients with CLL and how changes in PTMs correlate to changes in mRNA levels. 
The intent of this study is to provide novel insight into specific epigenetic changes induced by n-
3 consumption and the genes that are influences by those changes. Future studies will be aimed 
at determining whether epigenetic changes induced by n-3 in CLL cells will correlate with 
increased clinical benefit. 
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Our results also indicated that consumption of n-3 increased the sensitivity of 
lymphocytes from patients with early stage CLL to doxorubicin in an in vitro assay. These 
findings prompted us to further explore the chemo-sensitizing capabilities of n-3. In our second 
study, we evaluated whether n-3, EPA and/or DHA, would enhance the chemo-sensitivity of 
CLL-derived cell lines EHEB and MEC-2 and PLL-derived cell line JVM-2 to actively used 
chemo-therapeutic drugs doxorubicin, vincristine and/or fludarabine in vitro.  
Results from these studies indicated that EPA and DHA generally, but not equally, 
sensitized B-leukemic cells to actively used chemotherapeutic drugs: doxorubicin and 
vincristine, components of the CHOP regime (Leporrier et al., 2001; Van der Jagt et al., 2012), 
or fludarabine, a commonly used first-line treatment option for CLL (Riches et al., 2011; Silber 
et al., 1994). Importantly, we demonstrated that the chemo-sensitizing capabilities of n-3 were 
not specific towards one specific cell sub-type, but rather, multiple sub-types. This is a desirable 
trait given the vast heterogeneity that exists amongst CLL patients (Gaidano et al., 2012; Riches 
et al., 2011). Similarly, the fact that n-3 enhanced the chemo-sensitivity of B-leukemic cells to 
three different anti-cancer drugs, whose cytotoxic effects are mediated through different 
mechanisms of action, highlights the versatility and potential applicability of n-3 as adjuvant 
therapies.  
Even though n-3 generally increased the chemo-sensitivity of B-leukemic cells to anti-
cancer drugs, cells pre-treated with AA generally indicated no difference in chemo-sensitivity as 
compared to vehicle. Inversely, in EHEB, pre-treatment with AA appeared to protect against the 
cytotoxic effects of fludarabine; however, this was not statistically significant (Figure 3.3B).  
Collectively, this indicates that the sensitizing capacities of FAs are more likely to be found 
amongst the n-3 FA rather than the n-6 FA. This is an important consideration as the western diet 
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is heavily favored towards n-6 with little to no n-3 consumption (Simopoulos, 2008). N-3 and n-
6 compete with each other for incorporation and metabolism, often times having antagonistic 
actions (Simopoulos, 2002). The addition of n-3 as an adjuvant to therapy may, therefore, 
provide clinical benefit to patients receiving therapy.  
Results from our second study also indicated that enhanced chemo-sensitivity of B-
leukemic cells to anti-cancer drugs by n-3, particularly DHA, was associated with an increase in 
G2/M arrest (indicative of growth-inhibition) (Table 3.1) and increased cell death (Figures 3.3C, 
3.4C and 3.5C). Slowing the growth and/or increasing cell death of malignant cells is highly 
desirable and would provide clinical benefit.  
Notably, MEC-2, which harbors a p53 mutation, showed enhanced cell death due to 
vincristine or doxorubicin when pre-treated with DHA as compared to vehicle. The loss of short 
arm p13 of chromosome 17, which disrupts the p53 tumor suppressor gene, is found in 
approximately 5-10% of all CLL patients and is associated with particularly poor prognosis and 
chemo-refractoriness (Gaidano et al., 2012). N-3 may provide a beneficial augment to the 
treatment of chemo-refractory CLL patients. 
We have also demonstrated that enhanced chemo-sensitivity of MEC-2 cells to 
doxorubicin by DHA was, in part, mediated through generation of ROS and formation of lipid 
peroxides (Figure 3.6). Selective enhancement of chemo-sensitivity of EHEB, MEC-2 and JVM-
2 to anti-cancer drugs by n-3 that was not dependent on increased lipid peroxidation and 
generation of ROS indicates alternative mechanism(s) through which n-3 enhance chemo-
sensitivity.  
Collectively, results from our initial study and subsequent study highlight the potential 
application of n-3 as therapeutic options for the treatment of CLL and provided key data to 
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support expansion into our current clinical trial. The primary aim of our current study is to 
determine whether n-3 EPA and/or DHA increase the chemo-sensitivity of lymphocytes isolated 
from patients with CLL who 1) have a WBC count ≥ 17 (103/µL) or have progressed to the point 
of requiring therapy but have not received therapy or 2) have relapsed post standard first line 
therapy and require second-line therapy but have not received second-line therapy to anti-cancer 
drugs fludarabine, vincristine or chlorambucil in vitro. Secondary objectives of this study are to 
1) evaluate whether increased chemo-sensitivity of cells to anti-cancer drugs by n-3 is mediate, 
in part, through suppression of NF B activation and 2) demonstrate that increased chemo-
sensitivity is selective against the malignant cells and not healthy cells. While the data obtained 
thus far is limited, the results are encouraging. The primary goal of this study is to provide the 
final data necessary for expansion into a definitive clinical trial aimed to determine whether 
consumption of n-3 will improve the efficacy of chemo-therapy in CLL patients who require 
treatment. Future studies will also be aimed at evaluating the safety of n-3 as an adjuvant 
therapy.  
Whereas transitions to clinical studies are the primary focus of the studies highlighted in 
this thesis, further studies evaluating the mechanism(s) of actions through which n-3 induce 
growth-inhibitory effects, increased cell death and/or enhanced chemo-sensitivity are also areas 
of importance. Mechanistic studies will provide a further understanding of how n-3 function as 
therapeutic options. In this sense the following areas of research are of particular interest: 
Studies have indicated that malignant cells in G2/M arrest are more sensitive to 
doxorubicin than normal cells (Ling, el-Naggar, Priebe, & Perez-Soler, 1996; Tyagi, Singh, 
Agarwal, Chan, & Agarwal, 2002). Similarly, vincristine is a mitotic inhibitor known to induce 
cell cycle arrest at the M phase (Casado et al., 2009). Studies have demonstrated that inhibition 
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of NFκB activation leads to cell cycle arrest at the G2/M phase aiding to both growth-inhibition 
and cell death (Zhang, Ruan, et al., 2012; Zhang, Tao, et al., 2012). Our initial study 
demonstrated that consumption of n-3 reduced activation of NF B in lymphocytes of early stage 
CLL patients. In our second study, we demonstrated that n-3, particularly DHA, induced G2/M 
arrest alone and indicated greater G2/M arrest when used with anti-cancer drugs versus anti-
cancer drugs alone. Future studies should be conducted to determine whether the ability of n-3 to 
induce arrest at G2/M is mediated through suppression of NF B activation and how this 
proposed mechanism influences the chemo-sensitizing capabilities of n-3.  
Multi-drug resistance remains one of the primary causes of suboptimal outcomes in 
cancer therapy and is a major target of intervention (Gottesman, Fojo, & Bates, 2002). P-
glycoprotein (Pgp), encoded by MDR1 (ABCB1) gene, is an ABC transporter shown to confer 
resistance to certain chemotherapeutic drugs including anthracyclines and alkaloids (Gottesman 
et al., 2002; Leonard, Fojo, & Bates, 2003; Sonneveld et al., 1992). MDR1 has been shown to be 
overexpressed in CLL and correlate with increased Pgp activity (Consoli et al., 2002; Hoellein et 
al., 2010; Sparrow, Hall, Siregar, & Van der Weyden, 1993; Szendrei et al., 2008). Additionally, 
MDR1 was particularly found to be elevated in patients with advanced stages of the disease and 
correlated with clinical drug resistance (Hoellein et al., 2010; Sparrow et al., 1993; Szendrei et 
al., 2008). Similarly, multidrug-resistance-associated protein 1 (MRP1), another type of ABC 
transporter, has been shown to be increased in CLL (Hoellein et al., 2010) and confer drug 
resistance in vitro (Gottesman et al., 2002). MRP1 (ABCC1) expression, like MDR1, has also 
been negatively correlated with response to therapy and survival in clinical settings (Gottesman 
et al., 2002). MRP1‟s mode of action is primarily by transporting glutathione and glutathione-
conjugated anti-cancer drugs (Gottesman et al., 2002; Keppler, 1999). MDR1 expression is 
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known to be regulated through COX-2 (Liu, Qu, & Tao, 2010; Sorokin, 2004) and NF B (Wang, 
Liu, Zhang, Yu, & Wang, 2007; Zatelli et al., 2009). MRP1 expression has also been shown to 
be strongly correlated with COX-2 expression (Szczuraszek et al., 2009). Studies have illustrated 
that inhibition of COX-2 and NF B lead to decreased expression of MDR1 mRNA and Pgp 
resulting in increased sensitivity of solid tumors and hematologic malignancies to 
chemotherapeutic drugs in vitro (Wang et al., 2007; Zatelli et al., 2009). Similarly, studies 
utilizing COX-2 inhibitors indicated decreased expression of MRP1 and enhanced cytotoxicity 
of anticancer drugs in vitro
 
(Liu et al., 2010). We have demonstrated that consumption of n-3 
suppressed activation of NF B and reduced mRNA abundance of COX-2 in lymphocytes 
isolated from early stage CLL patients (Table 2.4). Future studies evaluating whether n-3 can 
suppress the expression and/or the efflux capabilities of MDR1/MRP1 and whether this is 
through suppression of NF B activation and/or COX-2 are of considerable interest. Additionally, 
studies have demonstrated that n-3 can deplete glutathione pools (Merendino et al., 2003). 
Glutathione is a key component for the functional activity of MRP-mediated efflux (Gottesman 
et al., 2002; Keppler, 1999). Therefore, depletion of glutathione pools by n-3 may inhibit the 
efflux capabilities of MRPs, thereby increasing the efficacy of certain anti-cancer drugs. Future 
studies should be performed to explore whether n-3 can deplete glutathione pools and whether 
this will reduce the functional capabilities of MRPs and aid to increased anti-cancer drug 
efficacy. The potential application of n-3 to combat multi-drug resistance remains of 
considerable importance and warrants investigation. 
In conclusion, the application of n-3 as therapeutic options for the treatment of CLL is 
very promising and presents several advantages over conventional therapy. N-3 are non-toxic 
(dose-dependent) and have the potential of slowing the growth of cancer, increasing the chemo-
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sensitivity of malignant cells to chemo- and radio-therapy and reducing toxicities. Slowing the 
growth of cancer would prolong the time before treatment is required and improve the quality of 
life for the individual. Increased chemo-sensitivity would lead to increased drug efficacy and 
potential decreases in drug dosage thereby leading to reduced drug-induced toxicities. Similarly, 
reducing therapy-induced toxicities by n-3 can lead to potential increases in the amount of cycles 
a patient can tolerate, thereby increasing the likelihood of receiving a response. Therefore, the 
use of n-3 as therapeutic options for CLL warrants further attention and presents a novel 
therapeutic approach. 
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